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ABSTRACT 
 
 
Infantile exposure to xenobiotics, e.g. from breastfeeding, poses a serious toxicity 
risk.  Since the toxicokinetic mechanisms that principally determine exposure 
outcomes undergo a significant developmental maturation, infants may respond to 
exposures in a different way than adults.  Hence, suitable model systems are required 
to provide risk relevant information in pediatric populations.  This dissertation’s 
primary goal was to provide a critical evaluation of two such model systems; first, a 
pharmacokinetic model that may predict an infant’s capacity to eliminate toxicants by 
cytochrome P-450 (CYP) mechanisms and second, the developing rat as a model of 
human CYP2E1 and CYP1A2 ontogeny. 
The first objective was to evaluate underlying assumptions of a pharmacokinetic 
model that describes the ontogeny of hepatic CYP activity using the rat.  The study 
recognized some discrepancies with the stated assumptions.  The impact of these 
discrepancies on the potential applicability of the model is discussed.  As proof-of-
concept, the observed data were fit to a model describing rat CYP2E1 and CYP1A2 
ontogeny.  A reasonable correlation (r = 0.75) was observed between observed and 
predicted oral clearance values of a CYP2E1 substrate indicating the potential 
applicability of such a model in risk assessment.   
The second objective was to conduct an extensive characterization of rat hepatic 
CYP2E1 and CYP1A2 ontogeny at mRNA, protein, activity and intrahepatic 
expression levels.  The results were compared to available human data to determine 
the appropriateness of the rat for assessment of toxicokinetic mechanisms underlying 
age-dependent differences in susceptibility to toxicity.  Similarities in age-dependent 
changes in mRNA, activity and zonal hepatic expression patterns were noted between 
the rat and human prior to weaning.  Unlike human data, rats show good correlation 
between changes in CYP2E1 and CYP1A2 activity and transcript levels, but not with 
the immunoquantifiable protein.  Recognizing such similarities and differences 
between rats and human regarding onset, rate and pattern of CYP ontogeny will 
 iii
improve the accuracy of rat-to-human extrapolation of developmental toxicokinetic 
data.  
Overall, the dissertation research provides mounting and supportive evidence for the 
use of such model systems in providing risk-relevant information in pediatric 
populations and to identify toxicokinetic mechanisms underlying age-dependent 
differences in susceptibility to toxicity. 
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1. LITERATURE REVIEW 
 
I. INTRODUCTION 
 
Epidemiological research provides convincing evidence that breastfeeding is 
advantageous to the breast-fed infant, lactating mother and society.  However, the ability 
of most drugs and chemicals to transfer from maternal plasma to breast milk puts the 
suckling infant under an uncertain exposure risk to harmful xenobiotics and raises 
concerns about breastfeeding safety.  When a nursing mother is exposed to a 
xenobiotic(s), either from the environment or through drug therapy, a decision to 
discontinue the exposure (e.g. stop medication) or discontinue breast feeding is largely 
based on data regarding the ability of the drug to appear in breast milk, the amount 
transferred to the suckling infant and, more importantly, the ability of the suckling infant 
to handle such an exposure.  Despite the growing information about the ability of 
chemicals to transfer into breast milk and the numerous methods developed to estimate 
the amount exposed to the suckling infant, very little is known regarding the ability of 
the infant to deal with the exposed dose.  Following an external exposure dose, 
pharmacokinetic processes determine the concentration of a xenobiotic in the biophase. 
In many instances it is the capacity of the detoxification mechanisms to eliminate a 
xenobiotic that poses as the major underlying cause for a toxic outcome following an 
exposure.   
Detoxification systems undergo significant maturation during postnatal 
development. In human paediatric populations, such age-related differences in 
elimination mechanisms are generally poorly understood.  However, for a given dose, 
the rate and pattern of the ontogeny of elimination processes will alter the toxicological 
significance of a xenobiotic in an age-dependent manner and such developmental 
maturation will confound the extrapolation of toxicity data obtained in adults to the 
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developing infant.  Although the recent establishment of the Children’s PK Database 
(available at http://www2.clarku.edu/faculty/dhattis), a database presently under 
construction to identify differences in pharmacokinetics during development, facilitates 
extrapolation of risks between adults and infants, this database still falls short of 
providing sufficient information for the adequate extrapolation of toxicity data, 
particularly for environmental toxicants. 
Interspecies extrapolation of toxicity studies performed with the developing animal 
is one potential approach proposed to elucidate the impact of the maturation of 
toxicokinetic processes on age-dependent differences in susceptibility to toxicity and to 
allow inclusion of risk-relevant information on the developing animal into risk 
assessment models.  An animal model that can, at the very least, identify an underlying 
toxicokinetic mechanism for age-dependent differences in susceptibility to toxicity has 
great value in risk assessment.  However, because of the interrelationship between 
genetic and environmental factors that influence the pattern and rate of xenobiotic 
elimination, a perfect animal model is unlikely to be found.  Relevant differences will 
always exist between human and animal models and these differences will pose serious 
challenges for qualitative and quantitative predictions of human toxicological outcomes. 
Translating animal data to humans requires an understanding of how and where these 
systems are similar and different to evaluate their impact on extrapolation to human 
exposure risks.  
This dissertation takes a systems level approach (i.e. evaluation of mRNA, protein 
and function) in the evaluation of two detoxification mechanisms, Cytochrome P450 
(CYP) 2E1 and CYP1A2.  This evaluation will provide critical descriptive information 
necessary to known information on human CYP ontogeny and to draw comparisons that 
determine the appropriateness of the developmental animal model system for assessment 
of toxicokinetic mechanisms underlying age-dependent differences in susceptibility to 
toxicity.  Furthermore, this dissertation evaluates critical assumptions of a 
pharmacokinetic model that describes the ontogeny of CYP enzymes for its application 
as a risk assessment tool when infants are exposed to xenobiotics present in breast milk.  
Literature to date indicates that CYP enzymes in humans are regulated in a similar 
manner to rodents1.  Therefore rodents are frequently used to provide initial information 
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about xenobiotic elimination in humans.  Accordingly, a rat model system was used to 
evaluate the underlying assumptions of a pharmacokinetic ontogeny model of CYP 
enzyme-mediated clearance.  Furthermore, rat and human CYP2E1 and CYP1A2 
enzymes exhibit high homology and similar substrate profiles2-4.  This could allow use 
of the rat as an appropriate model to study the developmental expression and function of 
human CYP2E1 and CYP1A2.  
For the purpose of this literature review, the term infant encompasses ages from birth 
to 2 years and children from 2 years to 12 years of age in humans.  However, the term 
neonate includes birth to postnatal day 21, weanling indicates postnatal days 21 to 28/35 
and juvenile encompasses age from postnatal days 28/35 to 49/70 days for rat.  
 
II. BACKGROUND 
 
1. Breastfeeding and Infant Exposure to Chemicals 
 
1.1 Breastfeeding and its Benefits 
 
Extensive epidemiological research has identified diverse and compelling 
advantages of breastfeeding for infants, mothers, families, and societies and the use of 
human milk for infant feeding5.  These advantages include health, social, environmental, 
and economic benefits5.  Thus, current guidelines set out by international (i.e. World 
Health Organization and United Nations Children’s Fund) and national (i.e. Canadian 
Pediatric Society, Health Canada and Dietitians of Canada) organizations recommended 
that infants be exclusively breastfed for at least the first six months of life, and continue 
breastfeeding with complementary foods for up to two years of age and beyond6-8.  
Surveys in Canada and United States report that approximately 70% of women initiate 
breastfeeding and 30% continue to breastfeed their infants to 6 months of age5. 
The unique components of human milk make it superior for infant feeding, and 
differs markedly from all substitute feeding preparations9.  The nutrients, enzymes, 
growth factors, hormones and immunological and anti-inflammatory properties of 
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human milk contribute to  reductions in the incidence and severity of acute infectious 
diseases such as sepsis/meningitis10, otitis media11, respiratory tract infections12, 
gastroenteritis11 and necrotizing enterocolitis13.  As well, studies correlate breastfeeding 
with reduced incidences of sudden infant death syndrome14,15, Crohn’s disease, insulin-
dependent diabetes, lymphoma and allergic diseases13,15,16 and reduced prevalence of 
childhood obesity17,18.  Furthermore, breastfeeding may enhance performance on tests of 
cognitive developments and achievement of better academic scores19,20.  Such health 
benefits may increase with duration and exclusivity of breastfeeding21.           
Breastfeeding and lactation have many important benefits for nursing women.  These 
benefits include decreased postpartum bleeding and more rapid uterine involution22, 
reduced risk of epithelial ovarian cancer23 and breast cancer24,25,  reduced risk of hip 
fracture in old age26,27 and faster return to the pre-pregnancy weight 28.  The act of 
breastfeeding delays resumption of ovulation and increases child spacing29.  Finally, 
breastfeeding is associated with increased maternal-infant bonding and maternal sense of 
worth5.                                                                                      
Breastfeeding has important social, economic and environmental benefits.  These 
benefits include reduced health care costs due to reduced risk of infant illness and 
duration of hospitalization11,13.  Also breastfeeding is associated with increased family 
saving due to the greater cost of formula feeding compared to breastfeeding cost11 in 
addition to lower parental absence from work, and reduced environmental load for 
disposing formula cans and  bottles5.  Some countries, including Canada, have 
recognized the potential economical savings from breastfeeding and provide a subsidy to 
low income mothers for each month of breastfeeding11.   
 
1.2 Infant Exposure to Drugs and Chemicals in Breast Milk 
 
Almost all maternally administered drugs and environmental chemicals appear in 
breast milk and find their way into the breast-fed infant30-33.  Consequently, breast milk 
constitutes a major exposure route to chemicals for nursing infants.  Governmental and 
regulatory agencies have become gravely concerned about the presence of chemicals in 
breast milk, particularly in light of recent surveys that suggest approximately 90% of 
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women take at least one medication, more than 20% take at least two or more 
medications in the first week after delivery and more than 5% of nursing mothers 
receive long-term drug therapy30,34 (Table 1.1).   
 
Table 1.1- Example of maternally-administered medications that my have possible 
effects on the nursing infant. Adapted from references (37-39) 
Drug Reported or possible Effects on the Nursing Infant 
  
1. Cytotoxic Drugs  
Cyclosporine Possible immune suppression, carcinogenesis 
Doxorubicin Possible immune suppression, carcinogenesis 
Methotrexatae Possible immune suppression, carcinogenesis 
  
2. Drugs of Abuse  
Amphetamine Irritability, poor sleeping pattern 
Cocaine Intoxication, irritability, seizures, diarrhea 
Heroin Tremors, restlessness, poor feeding 
  
3. Cardiovascular Drugs 
Acebutolol Hypotension, bradycardia, tachypnea 
Atenolol Cyanosis, bradycardia 
Amiodarone Possible hypothyroidism 
  
4. Antipsychotics  
Chlorpromazine Drowsiness, decline in developmental scores, lethargy  
Haloperidol decline in developmental scores 
  
5. Antibiotics  
Amoxicillin None 
Nalidixic acid Hemolysis in infants with glucose-6-phosphate-  
 dehydrogenase (G-6-PD)deficicncy. 
Nitrofurantoin Hemolysis in infants with (G-6-PD)deficicncy. 
Tetracycline  Negligible absorption by infant 
  
6. Others  
Phenobarbital Sedation, infantile spasms 
Sulfasalazine Bloody diarrhea 
Caffeine Irritability, poor sleeping pattern, slower elimination 
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This table shows examples of these drugs that are usually taken by the nursing 
mother and could result in adverse effects to the developing infant. 
These concerns have translated into recommendations to pharmaceutical companies 
to provide data about drug excretion in breast milk as a part of drug development and 
labeling35.  Adherence to such recommendations will provide necessary and critical 
information about compounds newly introduced to the market.  Nevertheless, the 
distribution of most other chemicals into breast milk and their actual milk levels remain 
largely unknown. Additionally, a recent FDA Task Force identified a need to advance 
research into mechanisms governing transfer of chemicals into milk and the factors 
influencing their milk levels36. Identification of such factors is critical in the 
determination of potential exposure doses and risk to the nursing infant16,31. 
When maternal medication is necessary during lactation, breastfeeding parents and 
healthcare professionals are mainly concerned about infant exposure to the drug and 
how this may affect infant health in the long and short term16.  Although many 
medications are considered compatible with breastfeeding37-39, recommendations are 
usually made to either discontinue breastfeeding or stop maternal therapy for fear of 
exposing an infant to drugs in mother’s milk40.  The American Academy of Pediatrics in 
its 2001 policy statement37 reported  lists of  agents that transfer into breast milk and 
described their possible adverse effects on infants or on lactation.  These lists should 
assist the physician in counseling a nursing mother regarding breastfeeding when the 
mother has a condition for which a drug is medically indicated.                                       
Risk/benefit analyses facilitate decisions regarding breastfeeding during maternal 
medication.  Such analyses must weigh the benefits (breastfeeding to infant and 
treatment of maternal illness) against the potential risks (infant exposure and 
withholding medication to the mother) to both the mother and the infant.  Researchers 
have defined a number of different indices of exposure to provide assessments of risk 
(see section 13).  Until recently, such exposure risk indices were based principally upon 
estimates of the amount of drug presented to the infant from breast milk41-43.  Normally, 
drug dose presented to the infant from breast milk is compared to the normal paediatric 
dose rate, or to the maternal dose (relative to body weight) to assess the potential risk of 
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exposure to the infant43.  However, even low level exposures may result in potential 
adverse effects when a nursing infant lacks the capacity to efficiently eliminate the 
exposed dose.  Exposure risk indices, then, must make provision for an infant’s capacity 
to eliminate compounds, i.e. these indices must incorporate infant systemic clearance as 
a critical factor defining exposure risk.  This requirement presents a serious problem in 
risk assessment because we have limited knowledge of infant systemic clearance44-46.   
 
1.3 Assessment of Infant Exposure Risk                                                                       
 
The literature reports numerous exposure indices used to predict and assess the 
potential risk of toxicity to the suckling infant following exposure to drugs from breast 
milk16,43,47-49.  These indices consider duration of exposure (acute versus chronic) and 
include milk to serum ratio ( )SM , infant dose relative to maternal dose, infant steady 
state serum concentration ( )Inf Css, , exposure index related to maternal dose ( (Dose)EI ) 
and exposure index related to maternal serum concentration ( (Conc)EI ).   
Maternal dose and maternal systemic clearance determine the maternal plasma 
steady-state concentration which, in turn, acts as the driving force for drug concentration 
in mammary epithelial cells and ultimately, drug concentration in milk.  The infant 
ingests a dose while nursing and the resulting serum concentration is a function of the 
pharmacokinetic processes absorption, distribution, biotransformation and elimination16.  
These processes undergo developmental changes as the infant grows50.  A better risk 
assessment index will take into consideration all maternal and neonatal factors affecting 
the amount of drug presented to the suckling infant via milk and can predict the potential 
risk posed to the infant following exposure to this amount.                            
 
1.3.1 Duration of Exposure (Acute versus Chronic) 
 
Infant exposure risk to drugs present in the breast milk depends upon factors 
associated with the maternal dosage situation such as maternal dose, dosing frequency, 
duration of therapy and interval between dose administration and breastfeeding.  Many 
literature reports suggest that adverse effects, if any, of acute and short term maternal 
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dosage regimens are mild and pose little risk to infants51-53.  In such cases, times of 
breastfeeding and medication administration can be manipulated to minimize any 
possible adverse effect on the nursing infant according to the half life of the 
administered drug47.  For drugs with short half lives, nursing mothers are usually advised 
to breastfeed immediately before taking medication.  Breastfeeding while on 
medications with long half lives requires careful consideration of the relationship 
between the nursing time and when maternal concentrations are greatest.  In such cases 
breastfeeding could be interrupted, or even suspended, for a short period of time so that 
the infant is not exposed to milk during times of peak maternal plasma levels.  The 
chronic or long-term drug exposure to nursing infants via breast milk poses the greatest 
concern37.  For example, adverse effects have been observed in nursing infants following 
administration of cardiac glycosides drugs to nursing mothers54.  As well, opiates that 
are commonly used as postoperative analgesics adversely affect nursing infants after 
maternal administration in the first week after birth55,56.   
As noted above, most recommendations are based on the amount of drug transferred 
to the infant and duration of exposure.  Even with short term exposure, the immature 
elimination mechanisms in the developing infant could result in drug accumulation and 
an increased risk of toxicity.  On the other hand, with chronic exposure of the nursing 
infant to certain chemicals in breast milk, their detoxification mechanisms can handle 
the dose and consequently, it would be safe to continue both breastfeeding and maternal 
medication without any discontinuation or interruption. 
                                                                             
1.3.2 Milk to Serum ( )SM Ratio  
 
The ratio between drug concentration in milk and maternal serum is called the milk-
to-serum ratio ( )SM .  This ratio is used in several exposure indices to estimate the 
maternal dose transferred to the infant via breast milk41,53,56,57.   On its own, ( )SM  ratio 
indicates the extent of drug distribution into milk and was frequently used as an index of 
exposure such that drugs with ( )SM  ratios greater than one were avoided or used with 
caution during breastfeeding32,33,42.  Accurate and useful assessments of ( )SM  ratio are 
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made by assaying milk and serum concentrations following maternal drug 
administration to steady state or assaying the area under milk and serum concentration 
versus time curve after a single intravenous injection33,42.  This value can be affected by 
many factors such as maternal pharmacokinetics, mammary physiology, 
physicochemical properties of the drug, variations in milk composition and pH, lactation 
period and maternal illness16,48.  The value of ( )SM  ratio only provides a measure of 
“input” without considering the multitude of additional factors that contribute to infant 
exposure risk (sections 1.3.3, 1.3.4 and 1.3.5)47. 
                                                                                         
1.3.3 Infant Dose as a Percentage of Absolute Maternal Dose 
 
Drug dose given to the infant during a nursing interval ( InfDose ) via breast milk may 
be calculated using ( )SM  ratio using Equation 1.1. 
          
 Dose rateInf = Css, Mat (M/S)(VMilk/τ)                (1.1)     
Where Css, Mat  is the average concentration at steady state in maternal serum, τ is the 
infant nursing interval and τ/VMilk  is the volume of milk ingested by an infant per 
nursing interval, approximately 150 mL/kg/day42,48.  The dose of drug ingested by the 
infant can then be compared with the maternal dose as a body weight adjusted dose 
(mg/kg) as depicted in Equation 1.2. 
 
% Maternal dose = 
DoseInf
DoseMat
⎛
⎝⎜
⎞
⎠⎟ ×100           (1.2) 
This index normalizes the infant dose received via the breast milk to maternal dose 
and considers an average dosing rate with chronic exposure.  An arbitrary cut-off level 
of predicted infant exposure of less than 10% of the weight adjusted maternal dose has 
been recommended43.  This arbitrary level is applied to drugs that have no known 
inherent toxicity and taken by a mother at a normal therapeutic dose.  Levels higher than 
10% indicate a higher exposure risk43.                        
At steady state, the minimum maternal concentration occurs just before the next oral 
dose.  Assuming milk concentration parallels serum levels, nursing the infant just before 
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the next dose will minimize the relative infant exposure58.  While this method 
incorporates more variables involved in infant exposure to drugs via breast milk, the 
index still does not accurately assess the amount of drug which actually enters the 
infant's bloodstream (i.e. the bioavailable dose), nor does it predict the capacity of the 
infant to handle such amount. 
Another way to express infant dose to maternal dose is by evaluating an (Dose)EI  (an 
exposure index related to maternal dose).  This exposure index views infant dose as a 
percentage of maternal dose.  Its relative value is inversely related to the maternal 
systemic clearance but proportional to maternal bioavailability (FMat), ( )SM  ratio and 
milk consumption rate, Equation 1.3.  
 
EI(Dose)  = 
DoseInf
DoseMat
 = FMat
ClS,Mat
M
S
⎛
⎝⎜
⎞
⎠⎟
VMilk
τ
⎛
⎝⎜
⎞
⎠⎟           (1.3) 
 
As shown in Equation 1.3, estimation of (Dose)EI would require estimation of maternal 
bioavailability and systemic clearance in addition to ( )SM  ratio and milk consumption 
rate.  Mean values for all of these parameters can be obtained from the literature. 
 
1.3.4  Infant Steady State Serum Concentration (Css, Inf) 
 
M/S values and infant dose as a percent of absolute maternal dose may incorrectly 
estimate the infant exposure risk as they do not take into consideration the contribution 
of infant pharmacokinetic (PK) factors in the infant response to a drug exposure.  These 
PK parameters undergo continuous changes in the developing infant44,50.  Therefore a 
particular dose (normalized to body weight) might result in different steady state 
concentrations (Css, Inf) in the developing infant depending on the age.  Pharmacological 
or toxicological effects in the infant, in most of the cases, correlate with drug 
concentration at the site of action47,50,59.  Because of the difficulty in measuring drug 
concentration at the site of action, a proportional relationship between drug 
concentrations in the bloodstream and at the site of action is assumed, such that serum 
concentration can be used as a surrogate measure to concentration at the site of action.  
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Steady state serum concentration in an infant following any route of drug administration 
can be described by Equation 1.4 in which (Css, Inf) is a function of infant bioavailability 
( )InfF , infant systemic clearance (Cls, Inf ) and dose (Doseinf).                                                                     
    
  ⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛=
InfS,
Inf
 InfInfss,
Cl
rate, DoseFC            (1.4) 
 
When the infant is exposed to a drug in breast milk, Equation 1.4 is rewritten as: 
 
 
CSS,Inf  = 
FInf
ClS,Inf
CSS,Mat  M S( ) VMilk τ( )⎡⎣ ⎤⎦           (1.5) 
 
Assuming linear pharmacokinetics in the mother, Css, Mat can be described as a function 
of maternal bioavailability (FMat), maternal dose (DoseMat) and maternal systemic 
clearance (Cls, Mat) as indicated in Equation 1.6. 
 
  ⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛=
MatS,
Mat
Mat Matss,
Cl
 rate, DoseFC          (1.6) 
 
Finally, by substituting the value of Css, Mat into Equation 1.5, Equation 1.7 can be 
derived. 
 
CSS,Inf  = 
FInf
ClS,Inf
FMatDoseMat
ClS,Mat
M S( ) VMilk τ( )⎡⎣⎢
⎤
⎦⎥
          (1.7) 
 
Equation 1.7 provides insight into the factors that determine infant steady state 
serum concentration.  Those factors can be divided into maternal factors (dose, 
bioavailability, systemic clearance and M/S ratio), infant factors (bioavailability and 
systemic clearance) and milk consumption rate (volume of milk and nursing interval).  
Figure 1.1 summarizes these factors resulting in the final infant response to a chemical 
present in breast milk.   
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Figure 1.1- Interrelationship between factors affecting infant exposure to drugs in breast 
milk and the resulting pharmacological/toxicological response. 
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Population estimates for maternal factors (FMat, DoseMat, ClS,Mat) as well as milk 
consumption rate (VMilk and τ) can be obtained from the literature42,48.  (M/S) ratio can 
be predicted from various in vitro or in vivo models42,48,58.  Consequently, infant 
bioavailability and infant systemic clearance remain the unknown determinants of Css, 
Inf.   If a hundred percent infant bioavailability is assumed (the worst case-scenario for 
infant exposure), ClS,Inf remains the principal unknown determinant of Css, Inf.   If the 
assumption that both the qualitative and quantitative nature of the pharmacodynamic 
response in the infant is the same as in adult holds true, then the resulting Css, Inf will 
produce the same pharmacological/toxicological outcome as observed in adults.  
Consequently, Css, Inf becomes an informative index of infant exposure.     
 
1.3.5  Exposure Index Related to Maternal Concentration (EI(Conc))  
 
A more recently elaborated exposure index relates the relevant exposure term CSS,Inf 
to maternal steady state levels to give rise to (EI(Conc))49.  Rearrangement of Equation 1.5 
derives Equation 1.8, which presents the determinants of this exposure index.  
According to Equation 1.8, determinants of infant exposure risk are largely a function of 
infant PK (bioavailability and systemic clearance), the ( )SM  value, and milk 
consumption rates. 
 
EI(Conc)  = 
CSS,Inf
CSS,Mat
 = 
FInf
ClS,Inf
M
S
⎛
⎝⎜
⎞
⎠⎟
VMilk
τ
⎛
⎝⎜
⎞
⎠⎟           (1.8) 
Although difficult to estimate, this exposure index is considered as the best estimate 
of infant exposure to chemicals present in breast milk16,47.  As shown in Equation 1.8, 
estimation of (EI(Conc)) would require estimation of infant bioavailability and infant 
systemic clearance in addition to M/S ratio and milk consumption rate.  Mean values for 
M/S and milk consumption rate can be obtained from the literature.  Very little 
information is available regarding systemic clearance in infants due to logistic and 
ethical concerns60.  Hence, understanding the mechanisms governing drug distribution 
into milk and developmental changes in infant PK, particularly systemic clearance, is 
very important for appropriate estimates of exposure level and the toxicological impact 
of this exposure.  
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2.  Infant systemic Clearance as a Determinant of Css, Inf 
 
The pharmacological/toxicological response to a drug often correlates well with the 
steady state serum concentration (Css) of the drug.  Because systemic clearance is a 
principal determinant of Css (see Equation 1.4), infant systemic clearance constitutes a 
critical PK parameter in the determination of the pharmacological/toxicological response 
to a drug from breast milk or from the environment44,47.  Systemic clearance (ClS) 
describes the efficiency of the elimination pathways to irreversibly remove drugs from 
the body.  Although many elimination pathways contribute to the determination of ClS, 
infants eliminate drugs principally through hepatic (ClH) and renal (ClR) clearance 
mechanisms (Equation 1.9).  This dissertation is concerned more about hepatic clearance 
and the role of developmental maturation of hepatic drug metabolizing enzymes in 
determining the capacity of the developing infant to eliminate drugs or chemicals 
following exposure from breast milk.  
 
 ClS,Inf  = ClH  + ClR                         (1.9) 
 
2.1 Hepatic Clearance (ClH) 
 
Hepatic clearance is of critical importance due to the abundance of drug 
metabolizing enzymes (DME) in the liver.   The liver has a unique anatomical position, 
as it is located between the gastrointestinal tract (GIT) and the general circulation and 
receives the majority of blood supply perfusing the GIT61.  Due to these unique 
physiological and anatomical characteristics, the liver can reduce the fraction of the 
orally administered drug that reaches the systemic circulation.  This phenomenon is 
commonly referred to as “first pass effect”. 
Hepatic clearance of a drug is governed by three principal physiological parameters: 
hepatic blood flow, the extent of drug binding to plasma proteins or other blood 
constituents, and the inherent ability of hepatic metabolic enzymes to eliminate the drug 
(i.e. the hepatic intrinsic clearance)59.  These parameters undergo rapid changes during 
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early infant life62,63.  Such changes can cause dramatic influences on infant hepatic 
elimination capacity44,64.  Several models have been developed to describe the 
interrelationship between those parameters and to predict the changes in hepatic 
clearance following changes in the above mentioned physiological determinants65.  One 
of the most commonly used models is the ‘Well Stirred Model”, (Equation 1.10).   This 
model is simple and can make qualitative predictions of the impact of changes in the 
determinants of hepatic clearance on various PK parameters65.      
 
 
 
ClH  = 
QHfuClint
QH  + fuClint
           (1.10) 
 
Where, QH is the hepatic blood flow, fu is the fraction of the drug unbound in plasma, 
and Clint is the hepatic intrinsic clearance.  According to this model, hepatic clearance of 
drugs that are highly extracted by the liver (>80%) will be governed only by the rate of 
drug delivery to the liver (i.e. QH), while changes in hepatic intrinsic clearance and the 
extent of drug binding have a little or no effect on HCl .  Examples of such drugs are 
lidocaine66, propranolol67,68 and propoxyphen65.  On the other hand, drugs that have low 
hepatic extraction (EH) (<20%), hepatic clearance is limited by the degree of drug 
binding (hepatic uptake) and the intrinsic ability of the hepatic enzymes to metabolize 
the drug.  Examples of these drugs are antipyrine69 and warfarin65.  Following oral 
administration of a high or low EH drug, the apparent oral clearance is determined only 
by the extent of plasma protein binding and intrinsic clearance of the drug59. 
 
2.1.1 Hepatic Blood Flow 
 
Fetal liver receives its blood supply from three vessels; the umbilical vein (73%), 
portal vein (18%) and hepatic artery (9%)61,70-72.  Birth results in a discontinuation of the 
supply of highly oxygenated blood from the umbilical vein and the liver becomes 
primarily dependent on poorly oxygenated blood from the portal vein (95%) and hepatic 
artery (5%)61,73,74.  Studies in newborn lambs (at 2 hours and 10 hours after birth) and  
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neonatal lambs (7-10 days) showed that blood flow and oxygen delivery to the liver are 
significantly lower than those to the fetal liver73,74, but comparable to the adult liver75. 
These dramatic changes in hepatic blood flow and the degree of oxygenation with 
birth may affect hepatic clearance of many drugs that show high hepatic extraction, 
where their clearance is hepatic blood flow-dependent.  Using propranolol and lidocaine 
as high clearance drugs, their systemic clearance in neonatal sheep livers was greater in 
infants than fetuses, but not significantly lower than the adult clearance value67,68,76.  
Given the similar systemic clearance values of these high EH drugs, comparable hepatic 
blood flow in neonates and adults could be expected.  The problem of not having good 
data on developmental changes in QH in human is alleviated by the fact that immature or 
low metabolic capacity of the liver enzymes in neonates and developing infants 
decreases the hepatic extraction of drugs and make total clearance less hepatic blood 
flow-limited77,78.  Accordingly, the immature hepatic drug metabolizing enzymes, not 
the hepatic blood flow, plays the major role in determining the capacity of infants to 
eliminate drugs by the liver.  As mentioned above, changes in hepatic blood flow have 
no effect in the apparent clearance of orally administered drugs whether they have a low 
or high EH values59. 
 
2.1.2 Plasma Protein Binding 
 
Several studies have reported age-dependent differences in binding of drugs in 
human newborn and adult plasma79-81.  These reports show significantly less binding to 
infant plasma compared to adult plasma.  This may result in higher unbound drug 
fractions in the infant, which can affect drug distribution and elimination.  Given that 
pharmacological and toxicological effects of many drugs are highly correlated to the 
unbound concentration59, less binding capacity in infants compared to adults, can 
increase their risk of toxicity following exposure to drugs from breast milk or from the 
environment. 
Several factors may contribute to this age-related difference in plasma protein 
binding.  These include differences in plasma protein concentration between infants and 
adults, differences in binding properties, and presence of endogenous compounds that 
 17
can compete with and displace the drug from the protein binding sites.  Albumin and 
alpha1-acid glycoprotein (AAG) are the major plasma proteins responsible for binding of 
various acidic and basic drugs and endogenous compounds80,82,83.  Concentration of 
plasma albumin and AAG are significantly lower at birth and increase progressively to 
reach the adult values at 6 months of age84.  
Rather than differences in plasma protein concentrations, lower binding affinities of 
some acidic and basic drugs to albumin and AAG in newborn plasma compared to adult 
plasma80,81,85 may account for the differences in drug binding79.  Endogenous 
compounds such as bilirubin and free fatty acids (FFA) can compete with and displace 
drugs from plasma protein binding sites86-88.  Higher circulating levels of bilirubin and 
FFA in infant plasma account for greater displacement of compounds relative to the 
adult79,82,84,86.  
For high clearance drugs, their hepatic uptake and removal from blood is an efficient 
process and independent on the extent of drug binding.  On the other hand, for low 
clearance drugs, only the unbound fraction becomes accessible to the elimination site.  
Hepatic clearance of those drugs will change in proportion to the unbound drug 
concentration.  Since most compounds are low clearance compounds, McNamara and 
Alcorn89 developed a model to predict the extent of protein binding in the infant in the 
absence of direct measurement of plasma protein binding based upon known binding 
characteristics in adults89.  
 
2.1.3 Hepatic Biotransformation 
 
Many studies have reported the capacity of fetal and infant livers to metabolize 
xenobiotics90-94.  Other studies demonstrate a prolonged half life in infants and children 
for drugs whose elimination is directly related to their rate of hepatic 
biotransformation64,95,96.  This could result in drug accumulation and potential risk of 
toxicity in the exposed infants.  While hepatic blood flow and other physiological 
determinants may affect the rate of drug elimination, the immature hepatic drug 
metabolizing enzymes is probably the predominant factor accounting for drug 
accumulation in infants.  Understanding the ontogeny of enzyme(s) involved in the 
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biotransformation pathway(s) could allow a more accurate risk assessment and precise 
prediction of the toxicological outcome following exposure of the developing infant to 
foreign chemicals. 
Hepatic drug biotransformation and elimination usually takes place in a two-step 
process and usually the two pathways, phase I and phase II metabolism, function in a 
sequential manner for drug elimination45,97.  The first step, phase I, is principally 
mediated by cytochrome P450 (CYP) enzymes.  These enzymes are located on the 
smooth endoplasmic reticulum and catalyze the biotransformation of both endogenous 
compounds and xenobiotics to more water-soluble derivatives98-100.  Although CYP 
enzymes normally generate metabolites with diminished biological activity, there are 
numerous examples where these enzymes mediate the formation of reactive 
intermediates from chemically inert agents101-103.  These reactive metabolites play a key 
step in initiating cytotoxicity and carcinogenicity98,104.  The second step, phase II 
reactions, mediate the conjugation of exogenous and endogenous compounds (or 
reactive metabolites produced during phase I metabolism) with water-soluble 
endogenous molecules like uridine 5’diphospahte (UDP)-glucouronic acid, glutathione 
or sulfate46,105.  The conjugated product is usually pharmacologically inactive and easily 
eliminated from the body via the bile or urine46. 
When phase I reactions result in the production of reactive metabolites, the balance 
between phase I-induced bioactivation and phase II-mediated detoxification is a critical 
factor in determining the toxicological consequences of exposure to such an agent106,107.  
If the formation of reactive metabolite during phase I reaction exceeds the conjugation 
capacity of phase II enzymes, reactive metabolites accumulate in the cell and can bind to 
endogenous biomolecules like DNA and protein, inducing cellular damage105.  Thus, the 
postnatal development of drug metabolizing enzymes (DME) activities, which catalyze 
the formation or detoxification of reactive intermediates, could have a profound effect 
on the ultimate toxicological outcome of exposure to xenobiotics. 
 
 
 
 
 19
2.1.3.1 Ontogeny of Hepatic CYP Enzymes 
 
The cytochrome P450 enzymes (CYP) are a group of heme-thiolate proteins that 
comprise a superfamily of related enzymes grouped into families and subfamilies based 
upon similarities in amino acid sequences2.  These enzymes catalyze the oxidative 
metabolism of endogenous compounds such as steroids, fatty acids, vitamins, and 
prostaglandins as well as exogenous chemicals such as drugs, carcinogens and 
environmental toxins98,99,108.  In addition, CYP enzymes play a major role in maintaining 
steady state levels of endogenous ligands involved in modulating gene transcription 
affecting homeostasis, growth and differentiation109.  Xenobiotics are mainly 
metabolized by families CYP1, CYP2, CYP3 and CYP4100.  To date, at least 57 CYP 
forms are responsible for the metabolism of substrates in human, and most of these are 
primarily expressed in the liver100.   
 
2.1.3.1.1 Human CYP Enzymes 
 
CYP enzymes activity is very low during early stages of gestation and remains low 
until birth.  After parturition many CYP enzymes undergo significant postnatal 
maturation110-113.  The total CYP content in the human fetal liver is about one-third of 
the adult value, and increases after birth to reach the adult value during the first 10 years 
of life95,111.  Cresteil105 categorized CYP enzymes into three groups according to the 
onset of their activities:  
(a) Enzymes expressed in fetal livers (CYP3A7 and CYP4A1): These enzymes 
are mostly active on endogenous and some exogenous molecules.  Their 
activities decline with postnatal maturation. 
(b) Enzymes expressed during the early neonatal period (CYP2E1 and CYP2D6): 
The activity of these enzymes are undetectable during gestation but surge 
immediately after birth. 
(c) Enzymes expressed later in neonatal development (CYP1A2, CYP2B, 
CYP2C and CYP3A4): The activity of these enzymes tend to surge a few 
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weeks after birth and have slower rates of development than early neonatal 
enzymes. 
 In adult human livers, CYP1A2, CYP2A6, CYP2C, CYP2D6, CYP2E1, and 3A 
protein account for approximately 70 % of the total hepatic CYP enzymes, with the 
CYP2C and CYP3A subfamilies being the major forms99,108,111.  Reasonable levels of 
CYP1A2 (13%) and CYP2E1 (7%) are present, while CYP2A6, CYP2D6 and CYP2B6 
represent less than 4%, 2% and 1%, respectively108,111.  Figure 1.2 presents the levels of 
immunoquantifiable CYP proteins in adult human livers (expressed as a percentage of 
total CYP protein) and the percentage contribution of each CYP enzyme in the 
metabolism of drugs available in the market. 
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Figure 1.2- Average level of cytochrome P450 (CYP) enzyme content of adult human 
liver microsomes (recalculated from reference 108) and the estimation of the 
contribution of individual CYP enzymes in the metabolism of drugs currently available 
on the market (adapted from reference 100). 
 
 
 21
 
2.1.3.1.2 Rat CYP Enzymes 
 
Few studies are reported regarding the ontogeny of CYP enzymes in rats.  Total CYP 
content does not change much with age in male and female rats114, but when the results 
were expressed on a gram liver weight basis, 4- and 6- fold increase in the CYP content 
was detected at postnatal days 7 and 14, respectively, compared with day 1 of birth115.  
With the exception of CYP1A1, which is expressed during the early gestation, 
detectable expression of most of the other CYP enzymes occur at or near birth (CYP2B, 
CYP2C23, CYP3A) or immediately after birth (CYP2E1)1.  The metabolism of marker 
substrates for CYP2B1 and CYP2E1 could not be measured in rat livers during early or 
late gestation115.  After birth, CYP2B1 catalytic activity increased significantly to 
achieve activity level at postnatal day (PD) 4 comparable to the level observed in adult 
livers115.  In contrast, postnatal activity of CYP2E1 increased linearly with age and 
comparable activity to that estimated in adult liver was measured at PD371,115.   
Rat hepatic CYP2C23 and CYP3A exhibit similar pattern of ontogenesis as CYP2E1 
with expression reached its maximal value in early neonates and remained quite 
stable62,115.  Other CYP enzymes are expressed after the first week of birth (CYP1A2, 
CYP2C6, 2C11, 2C12 and 4A10)1,114-116.  While the catalytic activity of rat hepatic 
CYP1A2 was not detected in fetal livers, metabolism of its marker substrates increased 
at approximately linear rate during postnatal development with maximum levels 
achieved at PD351,115.  In contrast, the developmental profiles of CYP2C11 and 
CYP2C12 exhibit a characteristic rise at puberty (PD28)1. 
An interesting study by Imaoka et al has shown sex-related differences in the 
developmental maturation of CYP expression in rats114.  Activity of the male-specific 
form, CYP2C11 was induced developmentally and levels reached a plateau at 14-52 
weeks of age followed by a marked decline at 104 weeks114.  CYP2C11-mediated 
activities were not detected at any age in female rats.  On the other hand, activity of the 
female-specific form, CYP2C12 increased with age in female rats114.  However, this 
activity was very low or undetectable in male rats until juvenile age, but increased to a 
level similar to that of female rats at 104 weeks of age114.   
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Extensive studies have investigated the sex-related differences in drug metabolism in 
rats, a phenomenon commonly known as sexual dimorphism.  Majority of these studies 
found out that growth hormone (GH) is the only endogenous factor known to maintain 
the expression of gender-specific or gender-dominant isoforms of CYP enzymes117.  The 
sexually-dimorphic expression of CYP isoforms appear to be dictated mainly by the 
gender-dependent profiles of the circulating GH118,119.  In male rats, GH secretion shows 
a strongly pulsatile pattern with episodic peak every 3-4 hours with generally 
undetectable levels between peaks117,118.  In female rats, GH is continuously released 
with a pattern that is more frequent, irregular and with lower magnitude than 
males117,118. 
The strongly pulsatile or episodic rhythm of GH secretion in male rats is responsible 
for the expression of male-specific (e.g. CYP2C11, CYP2C13, CYP2C22, CYP3A2) 
and male-dominant (e.g. CYP2B1, CYP2B2, CYP3A1) isoforms119.  However, the 
continuous feminine pattern of GH secretion in female rats is responsible for expression 
of female-specific (e.g. CYP2C12) and female-dominant (e.g. CYP2C7, CYP2A1, 
CYP2E1)118.  
Many studies have reported sexually dimorphic GH profiles in human120,121 which 
results in sex differences in drug metabolism122.  However, these sexually dimorphic 
effects of GH on human CYP expression are not as significant as those observed in rats 
and could be subtle and easily hidden by the extensive interindividual variations in 
human population108,122. 
 
Due to their toxicological significance and major roles in detoxification of many 
important environmental chemicals and widely used pharmaceutical agents and their 
role in mediating cellular damage and carcinogenesis, the ontogeny of CYP2E1 and 
CYP1A2 in human and rats will be discussed in greater detail.  
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2.1.3.1.3 CYP2E1 Enzyme 
 
The ethanol-oxidizing enzyme123,  CYP2E1, is constitutively expressed in the liver 
and many other extrahepatic tissues including lung, brain and kidney100,124,125.  CYP2E1 
is highly inducible by treatment with ethanol, acetone, imidazole and other compounds, 
most of them being CYP2E1-substrates126-130.  CYP2E1 is moderately abundant in adult 
human liver, where it constitutes approximately 7% of the total hepatic CYP enzymes108.  
Despite the relatively few drugs that are metabolized by CYP2E1, e.g. acetaminophen, 
chlorzoxazone and halogenated anaesthetics, this enzyme is involved in the bioactivation 
of many toxicologically important chemicals including ethanol, organic solvents and 
procarcinogens present in tobacco smoke to reactive intermediates that lead to 
hepatotoxicity and carcinogenicity (Table 1.2).  Therefore, the postnatal development of 
CYP2E1, that mediates bioactivation or detoxification of toxicants, could significantly 
affect the toxicological outcome of xenobiotic exposure during development.  
As shown in Table 1.2, CYP2E1 substrate profile includes endogenous compounds, 
which indicates an important physiological role for this enzyme.  Studies have shown 
active utilization of acetone as a precursor by CYP2E1 in a gluconeogenic pathway 
during starvation and diabetic ketoacidosis123,126,131,132.  Immediately after birth, the 
newborn experiences a temporary fasting situation that causes increases in plasma 
ketone bodies concentrations.  This could explain the rapid surge of CYP2E1 protein 
following parturition133,134.   
Ethanol and imidazole were found to induce rat CYP2E1 protein without affecting 
levels of mRNA.  This suggests a posttranscriptional mechanism involving protein 
stabilization against degradation through ligand binding130.  CYP2E1 is also induced 
through a transcriptional regulation mechanism under conditions of starvation and 
diabetic ketosis135-138.    
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Table 1.2- Examples of substrates metabolized/bioactivated by CYP2E1. 
 
 
CYP2E1 substrates 
 
Toxicological effect 
 
References 
1. Halogenated anesthetics                  
1.1. Halothane Hepatotoxicity 139,140 
1.2. Isoflurane Hepatotoxicity 140 
1.3. Enflurane Hepatotoxicity 140 
2. Alcohols   
  2.1. Ethanol Hepatotoxicity 141-143 
  2.2. Methanol Hepatotoxicity 144 
  2.3. Glycerol** Hepatotoxicity 145,146 
3. Organic solvents   
  3.1. Styrene Carcinogenicity  102,147 
  3.2. Benzene Hepatotoxicity 148 
  3.3. Carbon tetrachloride Hepatotoxicity 149 
  3.4. Chloroform Hepatotoxicity 150 
  3.5. Trichloroethylene Nephrotoxicity and lung cancer 151,152 
4. Nitrosamines   
  4.1. N,N dimethynitrosamine Hepatotoxicity and carcinogenicity 153 
  4.2. N,N diethynitrosamine Hepatotoxicity and carcinogenicity 144 
5. Drugs   
  5.1. Acetaminophen Hepatotoxicity and nephrotoxicity 101,154 
  5.2. Chlorzoxazone* N/A 155 
  5.3. Isoniazide Hepatotoxicity 144 
6. Miscellaneous   
  6.1. Lauric acid** N/A 100 
  6.2. Acetone** N/A 132 
  6.3. ρ-nitrophenol* N/A 156 
 
N/A – No reported toxicity data 
*Probe substrates for CYP2E1 
**Endogenous substrates 
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Contradictory data are reported regarding the expression of CYP2E1 in human fetal 
liver.  Several studies have failed to detect CYP2E1 mRNA by reverse transcription 
polymerase chain reaction (RT-PCR), protein using immunoblotting, or activity using ρ-
nitrophenol oxidation in fetal liver111,133,157.  Other studies reported very low levels of 
CYP2E1 mRNA, protein and activity in fetal liver samples at late gestational 
stages134,158,159.  Postnatally, CYP2E1 protein and activity levels increase rapidly during 
the first 24 hours after birth without significant elevation of mRNA level133.  At the age 
of one month, mRNA level rises gradually and in correlation with protein and activity 
levels.  Adult CYP2E1 protein and activity levels are achieved at 1-10 years133.   
As mentioned above, two mechanisms, transcriptional and posttranscriptional, have 
been proposed for the regulation of human hepatic CYP2E1160.  The transcriptional 
mechanism primarily regulates CYP2E1 expression during the early postnatal period. 
Interestingly, transcriptional activation of CYP2E1 gene after birth correlated with the 
demethylation of certain cytosine residues at the 5’end of the gene resulting in 
accumulation of RNA after one month of age133,134,160.  CYP2E1 is also regulated by 
posttranscriptional mechanism through substrate-dependent stabilization as indicated 
above.   
In rats, Carpenter et al161 reported detectable levels of CYP2E1 protein and 
chlorzoxazone hydroxylase activity in fetal livers during late gestation.  These levels 
were much less (16- fold) than levels from adult livers116.  CYP2E1 mRNA is very low 
or undetectable in fetal livers during late gestation, but increase markedly within a few 
hours after birth1,114,115.  Neonatal rats express small quantities of CYP2E1 protein 
despite larger quantities of mRNA114,115.  Maximum CYP2E1 content and activity are 
observed at weaning (2-fold the adult value), followed by a gradual decline to reach the 
adult value at 14 weeks of age114. 
 
 
2.1.3.1.4 CYP1A2 Enzyme 
 
CYP1A2 is a constitutive enzyme that is expressed principally in the liver108,111.  
Extrahepatic tissues such as lung and colon express low levels of CYP1A2162.  In adult 
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human liver, CYP1A2 constitutes approximately 13 % of the total hepatic CYP 
content108.  This enzyme catalyzes the metabolism of a wide variety of chemicals, some 
of which are potential inducers for CYP1A2 (Table 1.3).  The list of substrates includes 
a variety of polycyclic aromatic hydrocarbons (PAHs), nitrosamines, and heterocyclic 
aromatic amine (HAAs).  Several of these substrates are potential or suspected human 
and/or animal carcinogens.  Several clinically used drugs such as phenacetin and 
endogenous compounds such as17 ß-estradiol are also CYP1A2 substrates163.  
Therefore, and as CYP2E1, the ontogeny pattern of CYP1A2 could have a profound and 
age-dependent effect on the toxicological outcome of xenobiotic exposure. 
While one study reported detectable levels of CYP1A2 mRNA in human fetal livers 
few days prior to parturition1, many studies failed to detect any fetal CYP1A2 mRNA at 
any gestational age157,164.  Most reports indicate the absence of CYP1A2 protein 
expression in human fetal livers.  Very low protein levels are detected during the early 
postnatal period, but undergo a gradual increase in expression in infants’ ages 1-3 
months.  The protein level attains about 50 % of the adult value at age 1-10 
years108,111,158,165.  The development of CYP1A2 activity parallels the increase in protein 
expression111,165,166,91.  Generally, CYP1A2 shows delayed ontogeny compared with 
other CYP enzymes165. 
Studies have shown that the constitutive expression of human CYP1A2 is regulated 
by a liver-enriched transcription factor, HNF-1167 and an upstream stimulatory factor168.  
Expression of CYP1A2 in extrahepatic tissues, e.g. olfactory tissues is regulated by 
nuclear factor, NF-1169.  Treatment of rodents with high concentrations of the inducer 
2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) or 3-methylcholanthrene (MC) increases 
hepatic mRNA expression and detection of low mRNA levels in lung, kidney and 
intestine170.  This increase in mRNA level is partially due to transcriptional activation 
and mainly due to posttranscriptional mRNA stabilization98.   Several studies have 
confirmed the role of Aryl hydrocarbon (Ah) receptors in governing induction of 
CYP1A2 gene expression170,171. 
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Table 1.3- Examples of substrates metabolized/bioactivated by CYP1A2. 
 
    
CYP1A2 Substrates  
 
Toxicological effect 
 
References 
1. Polycyclic aromatic hydrocarbons  
  1.1. Benzo[a]Pyrene** Carcinogenicity 172 
  1.2. 3-Nitrobenzanthrene Genotoxicity 173 
1.3. Benzo[a]phenanthrene Carcinogenicity                         103 
2. Heterocyclic amines   
  2.1. 2-Acetylaminofluorene Carcinogenicity and genotoxicity 174 
  2.2. MeIQx¶ Hepatocarcinogenesis 175 
3. Nitrosamines   
  3.1. N,N dimethynitrosamine  Carcinogenicity 155 
  3.2. N,N diethynitrosamine Carcinogenicity 155 
  3.3. N-nitrosodibutylamine Carcinogenicity 155 
4. Drugs   
4.1. Phenacetin* Hepatotoxicity and carcinogenicity 176,177 
4.2. Acetaminophen Hepatotoxicity and carcinogenicity 154,174 
 4.3. Propranolol N/A§ 178 
4.4. Caffeine N/A 91 
 4.5. Imipramine N/A 165 
5. Endogenous compounds   
  5.1. 17 ß-estradiol N/A 163 
  5.2. Retinol N/A 179 
  5.3. Arachidonic acid N/A 179 
  5.4. Estrogen N/A 163 
6. Miscellaneous   
  6.1. Methoxyresorufin* N/A 180 
  6.2. Ethoxyresorufin† N/A 181,182 
  6.3. Benzyoxyresorufin N/A 180 
 
¶MeIQx – 2-amino-3, 8-dimethylimidazole [4.5] quinoxaline 
§ N/A - No reported toxicity data 
* Probe substrates for CYP1A2 in rats 
** Inducer for CYP1A2 
† Probe substrate for CYP1A2 in human 
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In rats, the constitutive levels of CYP1A2 throughout fetal development could not be 
detected at protein or activity levels1,114,115.  CYP1A2 mRNA is detected as early as a 
few days prior to parturition114,115.  The protein and activity levels are very low in 
neonatal rats but a marked surge occurs immediately before weaning (5-fold the adult 
values) followed by a sharp decline to reach the adult value at 12 weeks of age183. 
 
2.1.3.2 Ontogeny of Phase II Enzymes 
 
Phase II drug metabolizing enzymes play an important role in metabolic inactivation 
or detoxification.  These enzymes are capable of converting phase I metabolites or the 
parent substrates into a more polar and water-soluble product.  Phase II metabolizing 
enzymes accomplish this role by catalyzing the conjugation of their substrate to a small 
molecular weight and polar endogenous molecule, like UDP-glucouronic acid, inorganic 
sulfate, glutathione, or acetyl coenzyme A97.  The resulting conjugation product is 
usually more water-soluble and can be readily excreted in urine or bile.  As well, the 
conjugation product is inactive and non-toxic, with few exceptions184.  Therefore, phase 
II conjugation reactions are considered, in most cases, as effective detoxification 
pathways.  Some endogenous molecules, e.g. bilirubin, steroids and catecholamines, are 
also substrates for Phase II enzymes97.  This could reflect the physiological and 
biochemical roles of these enzymes in affecting cellular growth and differentiation.  
Generally, Phase II enzymes expression undergoes tremendous developmental changes.   
 
2.1.3.2.1 Glucuronide conjugation 
Glucuronide conjugation reactions are mediated by UDP glucuronosyl-transferases 
(UGTs).  These enzymes catalyze the conjugation of glucuronic acid to several 
endogenous and exogenous substrates185.  Endogenous substrates include bilirubin, fatty 
acids, estradiols and thyroxine186, while exogenous compounds include numerous 
clinically used drugs, e.g. acetaminophen, NSAIDs and opioids.  In general, 
glucuronidation capacity is low in infants, which can result in drug accumulation and 
higher risk of toxicity185.  An example of this is the gray baby syndrome associated with 
markedly reduced capacity for chloramphenicol glucuronidation in infants187.  The 
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catalytic activity of UGTs towards bilirubin was found to be less than 1% of the adult 
values during fetal and early postnatal periods, and the activity increases to reach adult 
values by 3 months of age, after which it remains constant188.  Morphine, a UGT enzyme 
substrate189 exhibits very low plasma clearance in infants when compared with older 
children190,191.  Immunoreactivity studies with polyclonal antibodies indicate that 
enzyme activity develops in parallel with the immunodetectable protein levels189,192.   In 
rats, conjugation reactions catalyzed by UGTs are measurable during the first 10 days of 
gestation but remain low during fetal and perinatal period115,193.  After birth, activity 
increases to reach a maximum value at three weeks followed by a decline to 50% the 
maximum value at four weeks115. 
 
2.1.3.2.2 Sulfate conjugation 
Sulfate conjugation is a major pathway in metabolism and elimination of 
endogenous and exogenous compounds194.  Sulfation is catalyzed by a family of 
cytosolic proteins called sulfotransferases (SULT).  These enzymes catalyze the 
conjugation of inorganic sulfate derived from the active donor molecule 3’-
phosphoadenosine-5’-sulphophosphate, with a hydroxyl or phenolic functional 
groups194,195.  Sulfation normally results in the reduction of biological activity and 
increase in water solubility relative to parent molecule.  Therefore, a sulfate conjugate 
may be excreted from the body in urine and/or bile, or undergoes bioactivation by 
sulfatase enzymes196.  The ontogeny of SULT enzymes is inadequately described as 
most of the studies were done using substrates that may or may not be specific to SULT 
isozymes46.  A study by Richard et al 197 demonstrates high expression of SULT protein 
and activity in fetal and neonatal livers.  The activity and protein levels increased with 
age so that the level measured in adult livers wer approximately 5-fold that observed in 
fetal livers198.  Generally, sulfate conjugation is an efficient pathway in fetus, newborn, 
and infant compared with other phase II reactions46,199. 
 
2.1.3.2.3 N-acetylation 
N-acetyl transferases (NAT) catalyze the addition of  an acetyl moiety to xenobiotics 
or endogenous compounds that carry a primary aromatic amino or hydrazine functional 
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group200,201.  Acetylation of ρ-amino benzoic acid, a selective substrate for NAT, is 
detected in fetal hepatic and extrahepatic tissues202.  The acetylation activity in adult 
liver tissues is more than 3-fold the fetal activity202.  Studies in infants and children 
show the capacity of NAT enzymes to acetylate several NAT substrates.  This activity 
was almost half the activity detected in adult203,204.  A study in mice showed expression 
of NAT mRNA in fetal liver that increases with age after birth in a non-linear fashion205.  
Infant livers were able to acetylate several NAT’s substrates with activity that increases 
with age205.  
 
2.1.3.2.4 Glutathione-S-Transferases 
The glutathione-S-transferases (GST) represent a group of detoxification enzymes 
that are expressed in most tissues, particularly the liver and kidney206.  These enzymes 
catalyze the conjugation of reduced glutathione (GSH) with an electrophilic center in a 
wide variety of xenobiotics184,207,208.  Therefore, GST enzymes protect vital cellular 
nucleophilic constituents against electrophilic reactive species and prevent cellular 
damage 209.  In addition, GST enzymes act as an intracellular carrier protein for the 
transport of a wide variety of endogenous hydrophobic molecules, including bilirubin, 
heme and hormones208.  Due to their toxicological significance and critical role in 
providing protection against cellular damage, genotoxicity and carcinogenesis, 
glutathione-S-transferases (GST) will be discussed in detail in this dissertation. 
 
Given their important detoxification role in protecting against cellular damage and 
carcinogenesis, changes in the developmental expression of GST enzymes could have a 
profound toxicological impact on developing infants exposed to xenobiotics.  Extensive 
studies in human and rodents livers have shown that GST enzymes are homodimers or 
heterodimers of subunits that have been grouped into seven classes based upon primary 
structure, catalytic properties and N-terminal amino acid sequences, namely alpha, mu, 
pi, sigma, theta, zeta and omega207.  Dimerization of the subunit members of the same 
class gives rise to a significant number of isozymes (some examples are shown in Table 
1.4).  These isozymes show different, and sometimes, overlapping substrate specificity. 
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   Table 1.4- Human GST isozymes (adapted from reference 207). 
 
Class/family Isozymes (examples) 
Alpha GSTA1-1, GSTA1-2, GSTA2-2, GSTA3-3, GSTA4-4 
Mu 
 
GSTM1-1, GSTM1-2, GSTM2-2, GSTM2-3, GSTM3-3, 
GSTM4-4, GSTM5-5 
Pi GSTP1-1 
Sigma GSTS1-1 
Theta GSTT1-1, GSTT2-2 
Zeta GSTZ1-1 
Omega GSTO1-1, GSTO 2-2                      
 
The expression of GST enzymes is complex and exhibits tissue, sex and age 
dependent patterns208.  Studies for measuring the ontogeny of GST activity in humans 
were done using 1-chloro-2,4 dinitrochlorobenzen (CDNB) as a general electrophilic 
substrate210-215.  These results indicate the ability of the fetus to detoxify possible 
reactive molecules that are generated intracellularly or cross the placenta.  Although 
these studies suffer from a lack of specificity for GST isozymes, they demonstrate GST 
activity in the fetal livers at early gestational ages.  Recently, with the utilization of 
highly specific antibodies, data regarding the developmental expression and cellular 
distribution of some GST isozymes have become available.  The expression of Mu 
isozymes was detected as early as 10 weeks of gestation and did not change significantly 
until birth216.  After birth, the expression level increased to reach the adult value at infant 
age of 42-85 weeks216,217.  The expression of Pi isozymes was detected in the fetal liver 
at 8 week gestational age and undergoes downregulation until birth, where the 
expression is either very weak or undetected211,216,218.  After 6 months of life, this 
isozyme is completely undetected in infant and adult livers217,219.  The expression of 
alpha class isozymes was detected in fetal livers after 10 weeks of gestation216,220.  The 
expression levels increase by age after birth, where they become the predominant 
isozymes in infant and adult liver220.  Adult levels of expression were achieved at about 
50 weeks of postnatal age211,216. 
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In rats, the activity of GST enzymes is detected as early as 10 days of gestation and 
increases up to 5-fold during the fetal hepatoorganogenesis period115,193.  After birth, the 
activity increases more than 2-fold, followed by a linear increase with age115,200,210.  
After 10 months of age, GST activity remains constant115. 
 
3. Relevance of CYP Enzyme Ontogeny to Developmental Toxicity 
 
Physiological and biochemical processes that govern pharmacokinetics 
(absorption, distribution, metabolism and elimination) of administered/exposed dose 
undergo significant and dynamic changes during developmental maturation50,221. 
These pharmacokinetic (PK) differences between developmental ages result in 
differences in therapeutic/toxic outcomes that can not be expected by simple adult-to-
infant extrapolation based on body weight or body surface area adjustment factors222-
224.  To remove uncertainties in such extrapolations, the internal dosimetry in various 
developmental ages of childhood has to be considered in relation to adults.  
Since metabolism (mediated mainly by hepatic CYP enzymes) is a principal 
determinant of plasma concentration of chemicals, a thorough understanding of the 
ontogeny of these hepatic enzymes is required for establishing accurate and potential 
exposure risk assessment measures, especially in pediatric populations.  For example, 
knowing that CYP1A2 enzyme is immature in full-term neonate may suggest that this 
population is under low risk of cancer due to CYP1A2-mediated bioactivation 
compared to adult.  However, chemicals that are eliminated by CYP1A2 pathway may 
accumulate in neonates and enhance risk of toxicity compared to adults. 
Given these significant bioactivation and detoxification roles of CYP enzymes, the 
susceptibility of the developing infant to a toxicant can be critically influenced, both 
qualitatively and quantitatively, by the developmental maturation (ontogeny) of CYP 
enzymes222.  However, most of the available information regarding CYP bioactivation 
potential, induction and inhibition properties, effect of xenobiotics and 
pathophysiological states on their regulation and expression are based on in vitro and 
in vivo studies performed in adult life stage225-227. 
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Developmental toxicology studies suggest that exposure to xenobiotics can affect 
the developing child in ways often different than adults and can lead to profound and 
permanent effects if the insult occurs during a sensitive developmental period (critical 
window)222.  However, due to several logistic and ethical issues, very few 
toxicological studies are available in pediatric populations228.  Also, the few studies 
conducted in animal models (mostly rodents) do not assess toxicity at the most critical 
developmental ages.  Furthermore, assessments are solely based on the maternal 
exposures without consideration of the knowledge of the developmental window of 
susceptibility (i.e. the onset of pharmacodynamic processes that lead to toxicity) and 
the internal dosimetry in the neonate during that developmental window229. 
To overcome the ethical considerations that preclude the use of children in 
toxicological assessments, suitable animal models should be used to define a 
toxicokinetic basis for age-dependent differences in toxicity228.  The appropriate 
animal model of developmental toxicology should exhibit sufficient similarities to 
human to ensure appropriate risk assessments.  To relate susceptibility to injury by 
CYP enzyme-mediated xenobiotic metabolism to the time course of maturational 
changes in the xenobiotics metabolism, however, requires a detailed understanding of 
hepatic CYP enzyme ontogeny in an appropriate animal model.  
 
 
4.  Methods Used to Study the Ontogeny of Hepatic Drug Metabolizing 
Enzymes (DME) 
 
The ontogeny of hepatic DME is generally studied by two principal approaches.  The 
first approach is an in vivo study of the age-related changes in the elimination of a probe 
substrate for the enzyme being investigated.  The second approach is an in vitro 
description of the age-related changes in expression of mRNA levels (using specific 
nucleic acid probes), protein contents (using specific monoclonal or polyclonal 
antibodies), and enzyme activity (using specific probe substrates). 
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4.1 In Vivo Approach 
 
In this approach, the ontogeny of enzyme activity is assessed in vivo by monitoring 
the systemic clearance of an in vivo metabolic probe substrate.  For example, diazepam 
and midazolam have been frequently used to determine the ontogeny of CYP2C and 
CYP3A activities, respectively93,94.  Some methods depend on monitoring the metabolic 
changes in some endogenous probe substrate.  For example, age-related changes in 
urinary 6ß hydroxyl cortisol/cortisol ratio can be used to assess the ontogeny of CYP3A 
in human90,92.  The in vivo approach has many limitations: 
1. The ethical, moral and technical boundaries of drug research in pediatrics60.  
Regulatory agencies have started to encourage the pharmaceutical industry 
to establish safety in children. 
2. Most of the in vivo methods are invasive and require multiple blood and /or 
urine collections.  However, non-invasive techniques are becoming 
available.  For example, breath tests using erythromycin or caffeine to 
assess the ontogeny of CYP3A or CYP1A2, respectively230,231. 
3. In many situations, the elimination of the in vivo probe substrate is mediated 
by elimination pathways other than hepatic mechanisms.  For example, 
diazepam and caffeine undergo renal elimination in addition to hepatic 
biotransformation91,93.  Therefore, specificity of the probe substrates have to 
be considered carefully before interpretation of ontogeny studies using an in 
vivo approach. 
4. This approach can not be used to assess the hepatic expression of DME 
during the gestational stage. 
 
4.2   In Vitro Approach 
 
This approach depends on the use of human liver tissues obtained immediately after 
death.  Rapid collection of these tissues after death and their storage at -80 °C without 
frequent freeze-thaw cycles are very critical to decrease the rate of enzymatic 
degradation and mRNA loss232.  Liver tissues are used to prepare hepatic microsomes, 
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cytosols or hepatocytes, which are used to assess the ontogeny of various phase I and 
phase II metabolic enzymes on the three systems biology levels.  Taking into 
consideration the ontogeny of hepatic DME at mRNA, protein and activity levels can 
help in identifying the consequences of exposure to endogenous and exogenous factors 
on the normal ontogeny pattern.  Such exposures during critical periods of development 
could induce permanent alterations in enzyme activity (i.e. genetic imprinting) that tend 
to be irreversible223,233.  As well, activity levels of hepatic DME determine the 
bioactivation potential and the elimination kinetics of numerous toxicants. 
Characterization of the maturation profiles of these enzymes can facilitate predictions of 
xenobiotic disposition and toxicological impact during development77,234,235.  Finally, 
incorporating molecular techniques into traditional toxicity studies can provide potential 
markers for the early detection of toxicity236. 
 
4.2.1   mRNA Expression Level 
 
This approach involves estimation of the corresponding mRNA using specific 
nucleic acid probes.  There are four methods commonly used to assess mRNA 
expression; northern blotting, RNase protection assay, in situ hybridization and real time 
reverse transcription polymerase chain reaction (RT-PCR).  The latter is the most 
sensitive and flexible for mRNA quantitation237-240.  Improved detection sensitivity 
allows the characterization of tissue and cell-specific distribution of genes where 
expression is limited, e.g. in fetal and neonatal livers. 
 
 
4.2.2   Protein Expression Level 
 
Due to the increased availability of monoclonal and polyclonal antibodies, 
immunoblotting (western blotting) became widely used to determine age-related changes 
in expression of different hepatic phase I and phase II enzyme94,105,108,111,157,241,242.  
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4.2.3   Catalytic Enzyme Activity 
 
This approach depends on incubating a probe substrate with age-dependent hepatic 
microsomes or cytosols under appropriate conditions, followed by monitoring 
metabolite formation rates that corresponds to the metabolic pathway under 
investigation.  With such approach, the probe substrate should be specifically 
metabolized by the enzyme of interest.  As well, the analytical method has to be 
sensitive enough to detect low metabolite levels in cases of low enzyme activity. 
 
5.  Developmental Changes in Zonal Expression of CYP Enzymes 
 
Hepatic DME exhibit a prominent zonation across the hepatic acinus, the functional 
unit of the liver243.  The zonal expression and induction of DME are related to the 
vascular architecture of the liver244.  In the adult, CYP enzymes exhibit high expression 
and inducibility in hepatocytes of the perivenous region243,245,246 which increases the 
vulnerability of this zone to toxicity due to accumulation of CYP-mediated generation of 
reactive intermediates.  Phase II conjugation enzymes, in particular GST and UGT, also 
exhibit  high expression levels in the perivenous region247,248.  However, the gradient of 
expression from periportal to perivenous hepatocytes is less steep when compared to 
CYP enzymes245,249.  Therefore, cells in the perivenous region may not have the 
detoxification capacity to compensate for the high rate of reactive intermediates 
formation, especially after exposure to CYP inducers.  Another factor increasing the 
susceptibility of this region to toxicity is the minimal expression of glutathione 
peroxidase.  This enzyme is responsible for the elimination of peroxides and its 
expression is focally concentrated in the periportal zone247. 
Ratanasavanh et al243 showed age-dependent changes in the hepatic zonal expression 
pattern of several CYP enzymes.  In the fetal and perinatal period, the liver exhibits a 
homogenous distribution of CYP enzymes, with some preference towards the perivenous 
zone for several enzymes.  During postnatal development, a progressive heterogenous 
distribution of CYP enzymes is observed with more expression in the perivenous cells, 
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and for some CYP enzymes the expression becomes completely absent in the periportal 
hepatocytes243. 
In rat livers, distribution of some CYP enzymes remains homogeneous from birth to 5 
days after birth1.  However, by 15 days of age, CYP expression becomes localized in the 
perivenous hepatocytes.  
 
6.  Approaches to Predict Hepatic Clearance  
 
Several approaches have been applied for the prediction of hepatic drug clearance in 
humans.  These approaches are based upon in vitro data in human and animals, and/or in 
vivo pre-clinical data.  In vitro metabolism studies provide estimates of the Michaelis-
Menten kinetic parameters and, hence, an estimate of in vitro intrinsic clearance (Clint). 
This Clint estimate, then, is extrapolated to the whole body by the use of hepatic scaling 
factors, which is subsequently incorporated into a model of hepatic clearance (ClH)  (i.e. 
the Well-Stirred Model)225.  Predictions based on in vivo pre-clinical data can be 
performed by using allometric scaling techniques250.  An alternative approach is the use 
of physiologically-based pharmacokinetic (PBPK) models that have been developed 
based upon physiological principles and measured physiological parameters234. 
 
6.1 Prediction from In Vitro Data 
 
The basis of the extrapolation from in vitro data to in vivo situations involves the 
parameter, intrinsic clearance (Clint), which is a pure measure of inherent capacity of 
hepatic enzymes to eliminate a drug in absence of other physiological determinants of 
hepatic clearance such as hepatic blood flow and drug binding within blood matrix225.  
In vitro Clint can be obtained from metabolic studies using hepatocytes, liver slices, and 
hepatic microsomes251,252.  The strategy of in vitro-in vivo extrapolation has been fully 
explained225,227,253 and is illustrated in Figure 1.3. 
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Figure 1.3- Strategy for extrapolation of in vitro intrinsic clearance to in vivo hepatic 
metabolic clearance (modified from reference 225). 
 
The first stage of the strategy is to calculate in vitro Clint from the ratio of the 
maximum velocity of the metabolic reaction (Vmax) to the Michaelis-Menten constant 
(KM) determined from  the initial rate of metabolic formation or drug loss as a function 
of substrate concentration250. The second stage involves scaling of the in vitro intrinsic 
clearance estimate to an in vivo Clint.  The hepatic scaling factor will depend on the in 
vitro system initially used. The last stage of the strategy includes the application of a 
liver model that allows the use of Clint to estimate the hepatic clearance of a specific 
pathway(s).  The use of a liver model accounts for the influence of non-enzymatic 
factors (e.g. hepatic blood flow and plasma/blood protein binding of a drug) in 
determining the in vivo clearance process. 
 
6.2 Allometric Scaling 
 
Allometric scaling is based upon an observable relationship between body weight 
and a physiological parameter, e.g. hepatic or renal blood flow254.  A similar approach 
can be applied to pharmacokinetic processes where the allometric scaling method 
considers the relationship between a physiological parameter and a PK parameter, e.g. 
 39
body weight and volume of distribution (Vd). Allometric scaling can be applied to 
correlate human pharmacokinetics with pharmacokinetics in other species227. 
Numerous physical and physiological functions vary according to some 
mathematical function of body weight (BW), and appear reasonably uniform across a 
wide range of animal species.  This can allow prediction of PK parameters in one 
species based on values from other mammalian species250,255.  In addition to cross-
species scaling, allometric scaling can be used to extrapolate within humans, which can 
be beneficial in adjusting drug dosages in infants and predicting their susceptibility to 
drug toxicity256.   
The allometric equation allows prediction of PK parameters from the product of an 
allometric coefficient and the body weight to a power function represented by Equation 
1.11. 
Y = a.(BW)b             (1.11) 
                                                                                                                                                  
where Y is the biological characteristic to be predicted (e.g. clearance), BW is the body 
weight, a is the allometric coefficient and b is the allometric exponent. 
Although some success has been achieved using this empirical equation256, many 
predictions are rather poor especially for compounds that undergo hepatic 
metabolism250,255.  Boxenbaum231,255 suggested the incorporation of  empirical correction 
factors such as maximum lifespan potential (MLP) and brain weight (BrW), as 
correction factors to predict systemic clearance for compounds that undergo oxidative 
metabolism, Equations 1.12 and 1.13.  
Cl. MLP = a. (BW) b            (1.12) 
Cl. BrW = a. (BW) b              (1.13) 
Although these correction factors improve predictions, allometric scaling generally 
fails to provide accurate quantitative predictions of metabolic clearance in adult or 
pediatric patients255.  This is largely due to species difference in rates of drug 
metabolism and differences in drug metabolism pattern (phase I and phase II).   
For high clearance compounds, ClH is limited by QH, which scales allometrically 
across different species254.  Typically, allometric models provide reasonable predictions 
for high clearance drugs.  For drugs with low or intermediate clearance values, a more 
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accurate prediction of ClH could be achieved using allometric scaling that combines in 
vitro hepatocytes and in vivo clearance data in animal species with in vitro hepatocytes 
data in humans250 according to Equation 1.14. 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛=
es)(hepatocyt animal
es)(hepatocythuman 
(in vivo) animalH Cl
Cl
 ClCl            (1.14) 
 
Many factors contribute to the uncertainty associated with allometric predictions of 
hepatic clearance in humans.  Such factors include inter-individual variability, 
extrahepatic metabolism, involvement of an active transport process and inactivation of 
the metabolic enzymes during processing or storage of the liver samples235,250,255. 
 
6.3 Physiologically-Based Pharmacokinetic (PBPK) Models 
 
PBPK modeling provides a more scientifically credible extrapolation across species 
and across different routes and classes of exposure and, therefore, can provide more 
accurate risk assessments78,234.  Pharmacokinetic approaches that are used to describe the 
relationship between the exposure and concentration-time profile are, in many cases, 
limited and provide little relationship to the physiological processes involved.  PBPK, 
being based on physiological and physicochemical properties of a chemical, provides a 
more meaningful approach to understand the consequences of an exposure to such a 
chemical234 and facilitates prediction of events in humans from animal data78.  
Physiological parameters used to build a PBPK model include, organ size, structure, 
blood flow and functions.  Chemical parameters include binding with blood constituents, 
binding to tissues, membrane permeability and sensitivity to enzymatic reactions251. 
However, generation and validation of a PBPK model is resource and time intensive, 
and it would be neither possible nor practical to generate PBPK models for all 
chemicals78,257. 
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7. Development of a Pharmacokinetic Model of Hepatic CYP-Mediated 
Elimination 
A novel mathematical pharmacokinetic model that describes the postnatal maturation 
of hepatic human CYP-mediated elimination has been described77(See Appendix I for 
details of the model).  This model was developed based on an in vitro/in vivo 
extrapolation of CYP enzyme activity data for CYP-specific probe substrates in age-
dependent human fetal and pediatric hepatic microsomes225,227,251.  The model can be 
used to predict age- and enzyme-specific infant scaling factors (ISF) that directly 
correlates adult clearance values with the ability of the infant to eliminate drugs by the 
same metabolic pathway (j), as shown in Equations 1.15 and 1.16. 
 
            adultsystemict)H(j,
infant
t)H(j, ClISFCl =                           (1.15)  
    )1(ISFISFISF D(j,0)t)(j,
kte −−+=           (1.16)     
Where ISF(j,t) is the predicted hepatic CYP enzyme-specific infant scaling activity in 
vivo at age, t (day); ISF(j,0) is the scaled in vivo CYP enzyme activity present at birth; 
ISFD is a fitted parameter; and k is the first-order rate constant describing the rate of 
increase in CYP enzyme pathway efficiency (day-1).  Comparing the predicted values of 
clearance by the model with those published in the literature demonstrated that the 
model gave reasonable predictions for clearance mediated by some CYP pathways; 
however, poor predictions were shown for other pathways77. 
Development of a robust and predictive model of CYP-mediated clearance will 
require extensive hepatic microsomal activity data and an evaluation of the underlying 
model assumptions.  The critical assumptions that were used to build the general model 
of CYP enzyme ontogeny include77:  
1. Hepatic microsomal protein (MP) content (mg per g liver weight) is constant 
throughout postnatal developmental.  Therefore an adult MP value (52.5 mg per 
g liver)258 was assumed for all infants age groups. 
2. Substrate affinity of the CYP enzyme (expressed as the Michaelis-Menten 
constant, KM) is constant and not a function of developmental age. 
3. Age-dependent differences in metabolic clearances reflect exclusively the 
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differences in the amount of functional enzymes (Vmax). 
4. Catalytic CYP activity is proportional to the functional CYP protein level. 
5. The drug has a low hepatic extraction ratio value. 
6. Different substrates for the same CYP enzyme should exhibit similar pattern of 
age-dependent changes in Vmax values. 
7. No significant contribution from uptake and/or efflux transporters in the intrinsic 
clearance. 
8. The elimination pathway is known and similar between infants and adults. 
If these assumptions are valid then the observed differences in Clint between infants and 
adults are due to the degree of functional maturation of the particular CYP enzyme or 
the amount of functional CYP enzyme (i.e. Vmax). 
 
8. Use of Rats as an Animal Model in Studying CYP Ontogeny 
 
As mentioned above, hepatic drug metabolizing enzymes (DME) undergo a 
significant and dynamic maturation during development.  Therefore, simple 
extrapolation of adult ontogeny data to infants could result in under-or over-
predictions of the exposure risk.  Development of an accurate toxicological risk 
assessment tool to predict the potential risk of toxicity in the developing infant 
following exposure to xenobiotics requires a full understanding of the developmental 
maturation and factors affecting activities of the DME (e.g. CYP enzymes) that are 
involved in bioactivation of xenobiotics.  Ethical and technical limitations restrict the 
use of human fetal and infant tissues in drug metabolism studies60.  Therefore, a 
suitable animal model system has to be used followed by appropriate extrapolation to 
human. 
Due to the sufficient similarities between rats and human regarding developmental 
physiology (e.g. liver development), enzymology and molecular mechanisms affecting 
drug metabolism1,259, the rat model system has been used frequently to provide initial 
information about drug metabolism in human1,116,260-262.  Many CYP genes, 
particularly CYP1A and CYP2E1 subfamilies show remarkable conservation between 
human and rats2.  These genes are regulated in diverse ways including transcriptional 
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and posttranscriptional mechanisms160.  Most of the hepatic CYP genes are under 
control of liver-enriched transcriptional factors, which themselves undergo certain 
developmental changes160,167,169.  Comparison of DNA sequences of both human and 
rat CYP2E1 gene revealed a high degree of nucleotide similarities (80-94%) within 
150 bp of the RNA polymerase start point4,263,264.  This could indicate the presence of a 
well-conserved regulatory region that might bind transcription factors.  As well, 
Hepatocyte Nuclear Factor-1α (HNF-1 α) is the primary factor responsible for hepatic 
expression of CYP1A2 and CYP2E1 genes in both rat and human160,169.  
Developmental activation of the genes encoding liver-enriched transcriptional factors 
determines when a particular CYP enzyme will be expressed.  Physiological/hormonal 
or developmentally-programmed factors that control these genes are still not fully 
understood both in human and rat160.  
Expression of CYP genes in human is regulated in a similar manner to 
rodents1,160,259.  For example, the induction of CYP1A gene in human and rats occurs 
via the aryl hydrocarbon receptor (AhR), which associates with the AhR nuclear 
translocator (ARNT) in response to many polycyclic aromatic hydrocarbons (PAHs) 
such as Benzo[a]Pyrene and 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD)170.  
Similarly, the constitutive androstane receptor (CAR) and pregnane-X-receptor (PXR), 
both heterodimerize with the retinoid X receptor (RXR)265-267.  This complex binds to 
a cis-acting sequence in the promoter region of CYP2B or CYP3A genes leading to 
induction of the gene expression by xenobiotics such as phenobarbital-like compounds 
(CYP2B) or dexamethasone/ rifampin-type compounds (CYP3A) in both human and 
rats265,267. 
Due to such close similarity between human and rats regarding CYP basic 
enzymology, biochemistry and regulation, rat will be used as an animal model to 
evaluate the underlying assumptions of the PK model of hepatic CYP-mediated 
clearance (section 8).  As well, rat is a commonly used model for toxicological and 
nutrition studies, in human disease states and in pre-clinical studies.  Consequently, the 
ontogeny of hepatic CYP2E1 and CYP1A2 will be characterized at the hepatic 
mRNA, protein, activity level and immunolocalization in the liver. The significance of 
these studies will be twofold: the first is to assess the appropriateness of the rat as a 
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potential model system.  Second, studying the ontogeny on a systems level can provide 
insight into enzyme regulation and potential sites of perturbation due to various 
endogenous and exogenous factors during development. 
 
9. Relevance of the Project to Paediatric Health and Developmental 
Toxicology 
The developing infant is exposed to xenobiotics through breastfeeding, drug therapy 
and from the surrounding environment233. The available information regarding the 
developmental maturation of physiological and biochemical determinants of drug 
pharmacokinetics (PK) or toxicokinetics (TK) is very limited250. Consequently, most of 
the approaches used to design dosage regimens or assess risk of toxicity following 
exposures of pediatric populations to xenobiotics are based upon dosages or toxicity 
information from adult populations221,233.  
Accurate estimation of the exposure outcome in infants necessitates a full 
characterization of the developmental maturation (ontogeny) of physiological processes 
that determine the potential ability of the developing child to handle such exposures. 
One of the most critical determinants of an exposure outcome is the activity of the 
xenobiotic elimination mechanisms, especially cytochrome P450 (CYP) enzymes222. 
These enzymes catalyze xenobiotic elimination, but may also bioactiavte xenobiotics 
leading to the generation of reactive intermediates that can induce cellular damage and 
cancer98,100.  Because these enzymes undergo significant and dynamic maturation during 
fetal and postnatal maturation110,268, the developing infant is expected to respond in a 
different way than the adult to the same exposure dose (normalized to body 
weight)229,233.  Accordingly, simple adult-to-infant extrapolation of toxicity data can lead 
to an underestimation (or sometimes overestimation) of the toxicological risk to 
xenobiotic exposure221,224.  The consequences of this inaccurate risk assessment can 
sometimes be very serious, e.g. infant toxicity from drugs in breast milk or 
discontinuation of either breastfeeding or nursing maternal therapy.  
Being critical in determining the internal dosimetry of the exposure dose, the degree 
of maturation of these CYP enzymes at a particular developmental stage will determine 
the pharmacological/toxicological outcome to this exposure at that particular 
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developmental stage224.  Unfortunately, limited information is available regarding the 
ontogeny of CYP enzymes in pediatric populations. 
As an initial step towards improving risk assessment in paediatric populations, a 
general ontogeny model was developed to predict age-specific CYP enzyme activity77. 
This model could be a promising risk assessment tool if it has the ability to predict the 
capacity of an infant to eliminate specific CYP substrates.  One of the purposes of this 
dissertation is to evaluate the underlying assumptions of this model and identify all 
model parameters needed to account for the developmental patterns of the various CYP 
enzymes.  Furthermore, as a proof-of-concept, the potential ability of the model to 
predict in vivo clearance of CYP substrates will be assessed in a rat model.  
Another important purpose of this dissertation is to extensively characterize the 
ontogeny of CYP enzymes in a rat animal model at the mRNA, protein, activity and 
intrahepatic expression levels.  Although interspecies differences exist in the rate and 
pattern of CYP enzyme maturation, characterization of CYP ontogeny in rats and a 
comparison with known human CYP ontogeny may identify a model system to 
investigate underlying toxicokinetic mechanisms for age-dependent differences in 
susceptibility to toxicity.  The outcome of this study will have a significant impact in 
risk assessment in paediatric populations as it will allow risk estimation during critical 
developmental windows where the toxic effects would not be observable in adults229,233.  
A third objective of this study was to characterize the ontogeny pattern of the 
important phase II enzymes, glutathione-S-transferases (GST)207,268.  GST enzymes play 
a key role in the detoxification of reactive metabolites generated by CYP-mediated 
reactions207.  A parallel characterization of CYP and phase II enzyme activity during 
maturation is very significant in estimating the developmental changes in the 
bioactivation/detoxification balance and the exposure outcome to the developing infant. 
Overall the main aim of this research project is to improve exposure risk assessment 
in paediatric populations through the potential identification of an animal model for 
extrapolation of developmental toxicological data to humans and the development of a 
PK model that describes CYP enzyme ontogeny to provide a predictive model for risk 
assessment. 
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2. PURPOSE OF PROJECT 
 
The overall purpose of this dissertation research is to characterize the developmental 
maturation of two toxicologically relevant CYP enzymes, CYP2E1 and CYP1A2, and 
general GST activity in the rat and to evaluate the assumptions of a pharmacokinetic model 
that describes the postnatal maturation of these CYPs and the model’s ability to predict in 
vivo elimination capacity. To achieve this purpose, the research addresses the following 
objectives and hypotheses: 
 
Objective 1 
To evaluate the underlying assumptions of the general PK model describing the postnatal 
maturation of hepatic cytochrome P450 enzyme activity using a male Sprague-Dawley rat 
model system.  
Hypothesis: Age-dependent increases in intrinsic clearance are attributed only to 
changes in Vmax (the Michaelis-Menten parameter that is proportional to the quantity of 
metabolically active enzyme/mg microsomal protein). 
Specific aims 
a. Development and validation of HPLC assays for probe substrates and metabolites of 
CYP2E1 and CYP1A2 to serve as markers for the maturation of CYP enzyme 
activity. 
b. Assessment of the age-dependent changes in microsomal protein content, liver 
weight and body weight from late gestation to adulthood in rats. 
c. Characterization of the Michaelis-Menten parameters (KM and Vmax) of CYP-specific 
substrates in age-dependent rat hepatic microsomes. This will allow the assessment 
of the age-dependent changes in intrinsic clearance of specific CYP2E1 and 
CYP1A2 probe substrates.  
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d. Characterization of the developmental changes in Vmax using a second probe 
substrate to test whether enzyme activity assessed from one substrate will accurately 
predict the level of activity for all substrates of the same enzyme. 
e. Determination of age-dependent changes in CYP2E1 and CYP1A2 protein levels 
using immunoblotting technique followed by comparison with the developmental 
changes in enzyme activity (Vmax). This will test if there is proportional relationship 
between enzyme activity and protein level during development. 
 
Objective 2: To develop a PK model describing the ontogeny of hepatic CYP2E1 and 
CYP1A2 activity in a rat model system. 
Specific aims:  
a. Estimation of the age-dependent changes in infant scaling factors (ISF) using the 
calculated values of HSF and Vmax at postnatal and adult ages in rats. 
b. Use of a PK modeling software to model age-dependent changes in ISF. 
c. Assessment of the ability of CYP2E1 model to predict the oral clearance of 
chlorzoxazone, a CYP2E1 probe substrate, in rats. 
 
Objective 3: To characterize the ontogeny of rat hepatic CYP2E1 and CYP1A2 at 
mRNA, protein, activity and intrahepatic expression levels.  Comparison of the 
expression data with known information about the ontogeny of these enzymes in human 
livers would provide evidence for the use of the rat as a model for developmental 
toxicokinetic studies.  
Hypothesis: Age-dependent changes in mRNA, protein expression, activity and 
hepatic zonal expression patterns in rat are similar to developmental patterns in human 
livers reported in the literature.  
Specific aims 
a. Evaluation of developmental changes in rat hepatic CYP2E1 and CYP1A2 mRNA 
expression using real-time RT-PCR. 
b. Evaluation of rat hepatic CYP2E1 and CYP1A2 protein expression in age-dependent 
rat hepatic microsomes using specific antibodies and immunoblotting techniques. 
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c. Evaluation of rat hepatic CYP2E1 and CYP1A2 maximum enzyme activity (Vmax) in 
age-dependent rat hepatic microsomes using saturating concentrations of specific 
probe substrates. 
d. Characterization of the age-dependent changes in hepatic zonal expression of 
CYP2E1 and CYP1A2 enzymes in frozen liver sections using immunohistochemical 
analysis. 
 
 
Objective 4: To evaluate the metabolic balance between hepatic CYP2E1 or CYP1A2 and 
GST during development.  
Hypothesis: The ontogeny of hepatic GST activity parallels the activity of hepatic 
CYP2E1 and CYP1A2 enzymes. 
Specific aims 
a. Assessment of the ontogeny of GST activity in age-dependent rat hepatic cytosols 
using a general probe substrate. 
b. Comparison of the ontogeny of hepatic CYP2E1 and CYP1A2 with GST activity. 
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Animals 
Sprague-Dawley rats were obtained from Charles River Canada (St. Constant, PQ). 
Eight pregnant rats were received at day 14 of pregnancy and were allowed to 
acclimatize for one week.  At day 21 of pregnancy, four pregnant rats were anesthetized 
under isoflurane and the fetuses were collected.  The remaining pregnant rats were 
allowed to give birth and one male pup from each dam was collected at postnatal ages 1, 
3, 5, 7 and 10 days.  Male Sprague-Dawley rats at ages 1, 2, 3, 5, 8, 11 and 15 weeks (n 
= 4) were obtained from Charles River Canada (St. Constant, Quebec) and allowed an 
acclimatization period of one week.  Rats were housed under controlled temperature (22 
± 2°C), and were maintained on a 12 hour light:dark cycle (0700 to 1900 hours).  All 
rats received standard laboratory rat chow and water ad libitum throughout the 
acclimatization period.  At the appropriate age, total body weights were recorded. 
Subsequently, rats were lightly anaesthetized (isoflurane), killed by guillotine, and their 
livers rapidly removed and rinsed in ice-cold 0.9% NaCl.  Wet liver weights were 
recorded and the liver tissues were divided so that mRNA and protein expression levels, 
enzyme activity, and immunohistochemistry (IHC) could be simultaneously studied. 
Liver tissues to be used for microsomal preparation and IHC were flash frozen in liquid 
nitrogen and stored at –80°C until use.  Liver samples for mRNA expression analysis 
were stored in RNAlater™ (Sigma-Aldrich, Oakville, ON) solution at –20°C until RNA 
extraction.  
All procedures were conducted in accordance with the Canadian Council of Animal 
Care guidelines for the care and use of laboratory animals and were approved by the Animal 
Care and Supply Committee of the University of Saskatchewan. 
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3.1.2 Chemicals and Reagents 
 
Chlorzoxazone (CZX), 6-hydroxychlorzoxazone (6-OH CZX), umbelliferone 
(UMB), ρ-nitrophenol (PNP), ρ-nitrocatechol (4NC), salicylamide, phenacetin, 
acetaminophen, caffeine, resorufin, methoxyresorufin (MR) and all chemicals used for 
microsomal preparation, determination of microsomal protein content and enzyme 
assays were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada).   
Acetonitrile and methanol were high pressure liquid chromatography (HPLC) grade 
obtained from EMD chemicals (Durham, NC).  Rat CYP2E1 and CYP1A2 supersomes 
were obtained from BD Bioscience (Woburn, MA, USA).  Prestained SDS-PAGE 
standards, peroxidase-conjugated antibody (Goat anti-rabbit IgG HRP conjugate), 
Immun-Star HRP kit, Bio-Rad Trans-Blot cell and polyvinylidene difluoride (PVDF) 
membranes (0.2 µm) were purchased from Bio-Rad Laboratories (Hercules, CA).  
Rabbit anti-Human/Rat CYP2E1 and sheep anti-rat CYP1A2 polyclonal antibodies and 
rabbit anti-sheep IgG HRP conjugate antibody were obtained from Chemicon 
International (Temecula, CA).  RNeasy Midi columns for RNA extraction and 
QuantiTect RT-PCR kit were obtained from Qiagen (Mississauga, ON).  Biotinylated 
goat anti-rabbit IgG H&L was purchased from Abcam (Hornaby, ON).  All other 
chemicals used were analytical grade. 
 
3.2 Methods 
3.2.1 Preparation of Hepatic Microsomes and Cytosols 
Hepatic microsomes were prepared as described previously269.  Briefly, 0.5 g liver 
samples were accurately weighed and homogenized in 2 mL ice-cold homogenization 
buffer (50 mM Tris buffer, 150 mM KCl, 0.1 mM dithiothreitol, 1 mM Ethylenediamine 
tetraaceate (EDTA), 20% glycerol and 0.1 mM phenylmethylsulfonylfluoride) using a 
Polytron homogenizer.  The homogenate was centrifuged at 9000 × g for 30 min at 4°C 
in a Beckman L8-55 Ultracentrifuge (Palo Alto, CA).  The supernatant was carefully 
transferred to clean ultracentrifuge tubes and centrifuged at 100 000 × g for 30 min at 
4°C.  The supernatant (the cytosol) was removed and transferred to labeled tubes and 
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stored at -80ºC until use.  The pellet was washed in 2 mL of ice-cold 150 mM KCl and 
centrifuged again at 100 000 × g for 30 min at 4°C.  The pellet was resuspended in 2 mL 
of ice-cold 0.25 M sucrose solution and aliquots were stored in cryogenic 
microcentrifuge tubes (400 μL) at -80°C until use.  
 
3.2.2 Determination of Microsomal and Cytosolic Protein Content 
 
Protein concentrations of microsomal and cytosolic fractions were determined in 
triplicate by the method of Lowry et al270 using bovine serum albumin as a calibration 
standard. Absorbance was measured at 750 nm on an Agilent 8453E UV-visible 
spectrophotometer using Chemstation software (Palo Alto, CA).  Cytochrome P450 
content was estimated by absorbance differences between 450 and 490 nm based on the 
method of Omura and Sato271.  
 
3.2.3 Microsomal Incubations with CYP2E1 and CYP1A2 Probe Substrates 
 
Preliminary experiments in 50-day old male rat hepatic microsomes were conducted 
to determine the optimum incubation conditions (incubation time and microsomal 
protein content) to give linear metabolite formation kinetics for CYP2E1-mediated 
hydroxylation of CZX and PNP and CYP1A2-mediated methoxyresorufin-O-
dealkylation (MROD) and phenacetin-O-dealkylation (POD) activities. Michaelis-
Menten parameters, KM and Vmax, for CYP2E1 and CYP1A2 were determined by 
measuring formation velocities of 6 OH-CZX and resorufin at substrate concentrations 
of 0 to 1000 µM and 0 to 1000 nM, respectively.  Metabolite formation velocities for 
PNP and phenacetin were measured at saturating probe substrate concentrations of 500 
and 150 μM respectively, in age-specific rat hepatic microsomes to provide estimates of 
Vmax.  Table 3.1 demonstrates enzymatic reactions mediated by CYP2E1 and CYP1A2 
enzymes, their substrates and the major metabolites formed by these reactions. 
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Table 3.1 – Selected enzymatic reactions mediated by CYP2E1 and CYP1A2, their 
selective substrates, formed metabolites and analytical methods used for measuring 
enzyme activity. 
 
CYP2E1 Hydroxylation
chlorzoxazone 6-hydroxychlorzoxazone HPLC-UV detection
ρ-nitrophenol 4-nitrocatechol HPLC-UV detection
CYP1A2 Dealkylation
methoxyresorufin resorufin HPLC-fluorescence detection
phenacetin acetaminophen HPLC-UV detection
Method of quantitationEnzyme Reaction Substrate Metabolite
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3.2.3.1 CZX hydroxylation activity 
 
Microsomal incubation mixtures consisted of CZX (0-1000 µM), 0.4 mg/mL liver 
microsomal protein, 2 mM MgCl2, 1 mM NADPH, and 50 mM phosphate buffer, pH 
7.4, in a final volume of 0.5 mL.  Incubations were carried out at 37°C in uncapped 
12×75 mm glass culture tubes in a shaking water bath.  The reaction was terminated by 
addition of 50 μL ice-cold phosphoric acid (50 %, v/v in water) followed by the addition 
of 50 µL of the internal standard solution (0.078 mM umbelliferone).  The mixtures 
were vortex mixed for 20 s.  After centrifugation at 12 000 ×g in an Eppendorf 
microcentrifuge (Model 5417 C, Brinkman instruments, Westbury, NY) for 20 min, 30 
µL of the supernatant was injected directly onto the analytical column for immediate 
HPLC analysis of 6-OH CZX. 
 
 
3.2.3.2 PNP hydroxylation activity 
 
Microsomal incubation mixtures consisted of PNP (500 µM), 0.4 mg/mL liver 
microsomal protein, 1 mM ascorbic acid, 2 mM MgCl2, 1 mM NADPH, and 50 mM 
phosphate buffer, pH 6.8, in a final volume of 0.5 mL.  After a preincubation period of 1 
min at 37°C, the reaction was started by addition of NADPH and incubated at 37°C in 
glass culture tubes for 30 min in a shaking water bath.  The reaction was terminated by 
addition of 50 μL ice-cold phosphoric acid (50 %, v/v in water) then 50 µL of the 
internal standard solution (salicylamide, 6µg/mL) was added.  The mixtures were vortex 
mixed for 20 s.  After centrifugation at 12 000 × g for 20 min, 20 µL of the supernatant 
was injected directly onto the analytical column for immediate HPLC analysis of 4NC. 
 
 
3.2.3.3 Methoxyresorufin-O-dealkylation (MROD) activity 
 
 Incubation mixtures contained 50 mM potassium phosphate buffer (pH 7.4), 2 mM 
MgCl2, 0.08 mg/mL liver microsomal protein, methoxyresorufin (0-1000 nM) and 1 mM 
NADPH in a final volume of 0.5 mL.  Methoxyresorufin was dissolved in methanol 
 54
(final concentration <1%).  After pre-incubation for 1 minute, the reaction was started by 
the addition of NADPH.  The mixture was incubated at 25°C for 8 minutes with 
shaking.  The reaction was stopped by placing the tubes on ice and adding 0.5 mL ice-
cold methanol with vortexing.  After cooling on ice for 15 minutes, the mixture was 
centrifuged at 6000 × g for 20 minutes.  The supernatant was filtered with a membrane 
filter of 0.45 μm pore size.  Fifty μL of the filtrate was analyzed by HPLC for resorufin. 
 
3.2.3.4 Phenacetin-O-dealkylation (POD) activity 
 
Incubation mixtures contained 50 mM potassium phosphate buffer (pH 7.4), 4 mM 
MgCl2, 0.4 mg/mL rat liver microsomal protein, phenacetin (150 μM) and 1 mM 
NADPH in a final volume of 0.5 mL.  Phenacetin, dissolved in methanol, was added to 
the incubation tubes and evaporated at 45°C with the vacuum concentrator.  The 
incubation mixture, except for microsomes and NADPH was redissolved by sonication 
for 1 minute.  The mixture, including microsomes and NADPH, was incubated at 37°C 
for 60 minutes with shaking.  The reaction was stopped by placing the tubes on ice and 
adding 100 μL cold acetonitrile followed by the addition of 50 μL internal standard 
solution (Caffeine, 5 μg/mL in methanol).  The mixture was centrifuged at 10 000 × g 
for 5 minutes, and the supernatant was evaporated at 45°C for 15 minutes with a vacuum 
concentrator.  Fifty μL of the remaining sample was analyzed by HPLC for 
acetaminophen. 
 
3.2.4 HPLC Analyses 
 
Metabolite formation velocities in rat hepatic microsomal preparations were 
monitored using validated HPLC methods.  The HPLC system consisted of Waters 
Model 600 solvent delivery system, Model 486 variable UV-VIS detector or a model 
2475 multiwavelength fluorescence detector, Model 717 Plus autosampler and a 
Millennium data module (Millipore-Waters, Milford, MA, USA).  All chromatographic 
separations were carried out on a reversed phase C18 column (Supelcosil® 150 × 4.6 mm 
I.D., 5 μm particle size) maintained at 25°C.  
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HPLC method validation procedures were performed according to FDA guidelines 
to evaluate the suitability of the method for the quantitative determination of the 
analyte(s) of interest in age-specific rat hepatic microsomes.  Specificity was tested by 
analysis of four different rat hepatic microsomal preparations supplemented only with 
internal standard to ensure the absence of endogenous compounds with the same 
retention times as the metabolite of interest.  The linearity of the method was evaluated 
by processing a 5-10 point calibration standards spiked into blank hepatic microsomal 
suspensions on different days.  The peak height ratios between metabolite and the 
internal standard were plotted against the nominal concentration of the metabolite.  A 
linear least-squares regression analysis was conducted to determine slope, intercept and 
coefficient of determination (r2) to demonstrate linearity of the method.  The accuracy 
and precision of the proposed method were determined by analysis of the quality control 
(QC) samples.  The intra-day accuracy and precision were assessed from the results of 
six replicate analyses of QC samples (low, medium and high) on a single assay day.  The 
inter-day accuracy and precision were determined from the same QC samples analyzed 
on 3-6 consecutive days.  Precision is expressed as % relative standard deviation (RSD), 
while accuracy (%) is expressed as [(calculated amount/predicted amount) x100].  The 
limit of detection (LOD) was defined as the lowest detectable concentration, taking into 
consideration a signal-to-noise ratio of 3.  Limit of quantification (LOQ) was determined 
at the lowest concentration at which the precision, expressed as % RSD, is less than 20% 
and accuracy, expressed as relative difference between the measured and true value, is 
less than 20%. 
 
3.2.4.1 CZX hydroxylation activity 
 
Chlorzoxazone 6-hydroxlation to 6 hydroxychlorzoxazone (6-OH CZX) was 
assayed by a modification of a previously reported method272.  UV absorbance was 
monitored at 295 nm (λmax for 6-OH CZX).  CZX, 6-OH CZX, and umbelliferone 
(internal standard) were eluted under isocratic conditions using a mobile phase 
composed of acetonitrile and 0.25% acetic acid (20:80) delivered at 1.0 mL/min.   
Calibration curves were constructed from known concentrations of 6-OH CZX working 
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solutions and 50 µL of the internal standard solution (0.078 mM umbelliferone) added to 
heat-inactivated (55°C for 5 min) rat hepatic microsomes and diluted with 50 mM 
phosphate buffer (pH 7.4) to achieve calibration standards of 0.31-40 µM 6-OH CZX in 
a total volume of 0.5 mL.  Three quality control (QC) samples at 0.625 μM (low), 1.25 
μM (medium), and 5 μM (high) were prepared independent of those used for the 
calibration curves.  The mixtures were vortex mixed for 20 s.  After centrifugation at 12 
000 × g in an Eppendorf microcentrifuge (Model 5417 C, Brinkmann instruments, 
Westbury, NY, USA) for 20 min, 30 µL of the supernatant was injected directly onto the 
analytical column for immediate HPLC analysis.  Concentration of the metabolite was 
calculated by interpolation from the linear calibration curve using measured metabolite 
to internal standard peak height ratios.  The metabolite formation rates were calculated 
in units of nmol 6-OH CZX formed per minute per mg microsomal protein. 
 
3.2.4.2 PNP hydroxylation activity 
 
 ρ-Nitrophenol (PNP) hydroxylation to ρ-nitrocatechol (4NC) was assayed as 
reported previously273.  UV absorbance was monitored at 250 nm (λmax for 4NC). PNP, 
4NC, and salicylamide (internal standard) were eluted under isocratic conditions using a 
mobile phase composed of 22% acetonitrile, 0.1% trifluoroacetic acid and 0.5% 
triethylamine delivered at 1.0 mL/min.  Known amounts of 4NC working solutions were 
added to heat-inactivated (55°C for 5 min) rat hepatic microsomes and diluted with 50 
mM phosphate buffer (pH 6.8) to achieve calibration standards of 0.1-40 µM 4NC in a 
total volume of 0.5 mL.  Three quality control (QC) samples at 0.5 μM (low), 5 μM 
(medium), and 20 μM (high) were prepared independent of those used for the calibration 
curves.  These QC samples were prepared on the day of analysis in the same way as 
calibration standards.  To 500 µL calibration standards, QC samples, or microsomal 
incubation mixtures, 50 µL ice-cold phosphoric acid (50 %, v/v in water) and 50 µL of 
salicylamide solution (6 μg/mL in methanol) were added. The mixtures were vortex 
mixed for 20 s.  After centrifugation at 12 000 × g in an Eppendorf microcentrifuge 
(Model 5417 C, Brinkmann instruments, Westbury, NY, USA) for 20 min, 20 µL of the 
supernatant was injected directly onto the analytical column for immediate HPLC 
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analysis of 4NC.  The metabolite formation rates were calculated in units of nmol 4NC 
formed per minute per mg microsomal protein. 
 
3.2.4.3 Methoxyresorufin-O-dealkylation (MROD) activity 
 
 MROD activity was assayed by an HPLC method with fluorescence detection as 
reported previously274.  The excitation and emission wavelengths were fixed at 560 and 
585 nm, respectively.  The mobile phase consisted of 20 mM phosphate buffer (pH 6.8), 
methanol and acetonitrile at a ratio of 50:45:5, delivered at 0.8 mL/min.  Known 
amounts of resorufin working solutions were added to heat-inactivated (55°C for 5 min) 
rat hepatic microsomes and diluted with 50 mM phosphate buffer (pH 7.4)-methanol 
(50:50) to achieve calibration standards of 0.04-2 nM.  Three quality control (QC) 
samples at 0.10 nM (low), 0.40 nM (medium), and 1.0 nM (high) were prepared 
independent of those used for the calibration curves.  These QC samples were prepared 
on the day of analysis in the same way as calibration standards.  To 500 µL calibration 
standards, QC samples, or microsomal incubation mixtures, 50 µL ice-cold methanol 
was added.  The mixtures were vortex mixed for 20 s.  After centrifugation at 6 000 × g 
in an Eppendorf microcentrifuge (Model 5417 C, Brinkmann instruments, Westbury, 
NY, USA) for 20 min, the supernatant was filtered with a membrane filter of 0.45 μm 
pore size.  Fifty μL of the filtrate was analyzed by HPLC for resorufin.  The metabolite 
formation rates were calculated in units of pmol resorufin formed per minute per mg 
microsomal protein. 
 
3.2.4.4 Phenacetin-O-dealkylation (POD) activity 
 
Phenacetin-O-dealkylation (POD) to acetaminophen activity was monitored by an 
HPLC method as reported before177 using caffeine as an internal standard. UV 
absorbance was monitored at 254 nm (λmax for acetaminophen).  The mobile phase 
consisted of 50 mM potassium dihydrogen phosphate and acetonitrile at a ratio of 85:15 
(v/v (%)) and delivered at 1.0 mL/min.  Acetaminophen was quantified based on 
calibration curves constructed from a series of standards containing varying known 
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amounts of acetaminophen (0.2-20 μM) and the internal standard (caffeine 5 μg/mL) in 
heat-inactivated rat hepatic microsomes and 50 mM phosphate buffer (pH 7.4).  Three 
quality control (QC) samples at 0.5 μM (low), 2 μM (medium), and 10 μM (high) were 
prepared independent of those used for the calibration curves.  These QC samples were 
prepared on the day of analysis in the same way as calibration standards.  The rate 
velocities were calculated in units of nmol acetaminophen formed per minute per mg 
microsomal protein. 
 
3.2.5 Measurement of General Glutathione-S-Transferases (GST) Activity 
 
Ontogeny of GST activity was monitored by spectrophotometric analysis of 
glutathione conjugation of 1-chloro-2,4-dinitrobenzene (CDNB), a general GST probe 
substrate275 as illustrated in Figure 3.1.  This method determines the activity of 
numerous GST isoforms with the exception of GST-τ276.   A complete assay mixture 
without the enzyme was used as a control.  Assays were conducted in a thermostated cell 
compartment at 25°C containing 0.1 M phosphate buffer at pH 6.5, GSH (2.5 mM), 1-
chloro-2, 4-dinitrochlorobenzene (1.6 mM), and cytosol from different age groups.  The 
reaction was initiated by the addition of age-dependent cytosolic fraction and the GST 
activity was determined by monitoring the change in absorbance at 340 nm for both 
control and sample over a 5-minute period. GST activity was calculated according to 
equations 3.1 and 3.2.   
DF
9.6
(control)Abs/min -(sample)Abs/min 
(nmol/min)activity  GST ×ΔΔ=   (3.1) 
 
protein mg 
activity  GST
  mg)(nmol/min/activity  GST Cytosolic =        (3.2) 
 
Where, 9.6 (nmol/cm) is the molar extinction of CDNB and DF is the dilution factor for 
rat liver cytosol. 
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Figure 3.1- Glutathione-S-Transferases (GST)-mediated conjugation of 1-chloro-2,4-
dinitrobenzene (CDNB) with glutathione (GSH) 
 
 
 
3.2.6 Age-Dependent Scaling Factors and Model Development 
 
 
Hepatic scaling factors for a particular age (HSF(t)) were estimated from the product 
of microsomal protein yield (MP(t)) (mg microsomal protein per gram liver) and liver 
weight (g) (LW(t)) normalized to body weight (g) (BW(t)) as a function of developmental 
age, t, according to Equation 3.3. 
     
     
 
HSF t( ) = MP t( ) ×
LW t( )
BW t( )
  (3.3) 
  
Normalization of HSF of a particular developmental age to HSF in adult produced age-
specific relative hepatic scaling factor (RHSF(t)) that relates the abundance of 
microsomal protein content per body weight in infant to the adult, Equation 3.4.   
 
(adult)HSF
HSF
RHSF (t)(t) =                   (3.4) 
   
 
As well, age-specific ontogeny scaling factor (OSF(t)) were determined by 
normalizing functional enzyme activity (Vmax (t)) observed at a particular age (t) to that 
GSH/GST
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observed in adult, Equation 3.5.  Accordingly, OSF represents the elimination capacity 
of a specific enzyme in the infant relative to the adult.   
 
     
(adult)max 
(t)max 
(t) V
V
OSF =                 (3.5) 
 
The product of these scaling factors, RHSF(t) and OSF(t), is the age-specific infant 
scaling factor (ISF(t)) that represents the ontogeny of an individual functional enzyme 
normalized to a body size, Equation 3.6, and correlates adult in vivo clearance due to an 
individual CYP enzyme to the capacity of the infant at age (t) to eliminate drugs by the 
same metabolic pathway, Equation 1.15. 
          
(t)(t)(t) OSFRHSFISF =          (3.6) 
adult
t)H(j,t)(j,
infant
t)H(j, ClISFCl =            (1.15) 
 
3.2.7 Protein Expression Analyses 
 
Microsomal proteins were separated on a sodium dodecyl sulfate gel containing 
10% polyacrylamide (SDS-PAGE) by the method of Laemmli et al277.  Heat denatured 
microsomes (10.5 µg for CYP2E1 and 0.4 µg for CYP1A2), rat CYP2E1 purified 
protein (20, 50 & 100 pmol) or rat CYP1A2 purified protein (20, 80, 200 and 500 
pmol) were loaded onto the gel and the electrophoresis was carried out at 125 volts for 
1.5 to 2 hr.  Proteins were transferred onto a PVDF membrane with a Bio-Rad Trans-
Blot cell at 25 volts for 50 minutes.  The membrane was blocked with phosphate-
buffered saline (PBS) containing 0.05% tween 20 (PBSt).  Subsequently, the 
membrane was blocked with PBSt containing 5% milk incubated overnight at 4°C.   
Membrane was then incubated with Rabbit anti-Human/Rat CYP2E1 polyclonal 
antibody prepared in the blocking solution (1:750) for 3 hr at 20°C or incubated with 
sheep anti-rat CYP1A2 polyclonal antibody prepared in PBS solution (1:1000 
dilution) overnight at 4°C.  After washing 3 times with PBSt and once with PBS, the 
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membrane was incubated with peroxidase-conjugated antibody prepared in the 
blocking solution (1:3000) for 2 hr at 20°C.  After 3 washes with PBSt and one wash 
with PBS, the peroxide conjugate was detected with the Immun-Star HRP kit. The blot 
was scanned with an LKB laser densitometer (Amersham Pharmacia Biotech, 
Piscataway, NJ) to estimate the amount of reacting protein.  Reference samples were 
used to calibrate determinations and results were expressed as absorbance unit/µg 
sample protein. 
 
3.2.8 mRNA Expression Analyses 
 
3.2.8.1 RNA isolation 
RNeasy Midi RNA isolation kits (Qiagen) were used to isolate total RNA 
following the manufacturer’s protocol.  Liver tissue (250 mg) was homogenized in 
buffer RLT and centrifuged (4500 × g) to remove cellular debris.  Following 
centrifugation, the lipid layer was removed and the supernatant transferred to a clean 
15 mL polypropylene tube and one volume of 70% ethanol was added. The sample 
was mixed vigorously and then applied to the Midi column.  The column was 
washed with a series of buffers following the manufacturer’s protocol.  Total RNA 
was eluted from the Midi column with 250 μL RNase-free water.  Total RNA 
concentration was determined by the measurement of absorbance at 260 nm with a 
UV/VIS spectrophotometer (#8453E, Agilent Technologies, Palo Alto, CA) 
(Equation 3.7).  Total RNA purity was verified by measuring the ratio of A260/A280 
of a 1:100 dilutions (RNA: 10mM TrisCl pH 7.5).  Ratio between 1.9 and 2.1 
indicates good purity.  
 
RNA[ ] = 40 μg/ml × A260 × Dilution factor                (3.7) 
 
 
3.2.8.2 Primer design 
 
Gene sequences used for primer design were obtained from NCBI Genebank 
(www.ncbi.nih.gov).  Primer sequences (Table 3.2) were generated with assistance from 
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the Primer3 software (www.broad.mit.edu/cgi-bin/primer/primer3) to determine the 
expression levels of CYP2E1 and CYP1A2 genes.  
 
Table 3.2 – Primer sequences and amplicon sizes for real-time RT-PCR analysis. 
 
 
Gene Sequence ID Left Primer (Sense) 
Right Primer 
(Antisense) 
Amplicon 
Size (bp) 
CYP2E1 NM 031543 tccaacctaccccatgaagc ccaacacacacacgctttcc 221 
CYP1A2 NM 012541 gggtgttgagaggcacaagg cactagggcctgcttgatgg 221 
β-actin NM 031144 agcgtggctacagcttcacc tgccacaggattccataccc 237 
 
 
3.2.8.3 Real-Time RT-PCR 
Real time RT-PCR was carried out with the SmartCycler® (Cepheid, Sunnyvale, 
CA) in one step using Qiagen QuantiTect RT-PCR kit according to the 
manufacturer’s protocol with slight modifications.  Briefly, reactions were 
performed in a final volume of 25 µL containing aliquots of 40 ng of total RNA and 
primers at a final concentration of 1 μM.  The RT-PCR protocol (Table 3.3) 
consisted of 1 cycle at 50°C for 30 min, followed by 95°C for 15 min.  Three-step 
thermocycling was performed for 40 cycles: denaturation at 94°C for 15 s, annealing 
at 55 or 58°C for 30 s and extension at 72°C for 30 s.  Standard curves were 
constructed by serial dilution of total RNA in RNase-free water with linear mRNA 
expression ranging from 0.05-500 ng.  
 
 
Table 3.3 – General real-time RT-PCR protocol  
 
 
 
Step Time Temperature (°C) 
Reverse Transcription 30 min 50 
PCR Initial activation step 15 min 95 
 Denaturation 15 sec 94 
 Annealing 30 sec varied 
 Extension 30 sec 72 
 
 
The standard curves were generated by plotting crossing point (Ct) values (the 
PCR cycle number required for fluorescence intensity to exceed an arbitrary 
threshold in the exponential phase of the amplification) versus log of the amount of 
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total RNA added to the reaction and the amount of CYP2E1 or CYP1A2 RNA in all 
age-related liver samples were interpolated from the standard curve as arbitrary 
units.  Fold changes in mRNA expression for all ages were calculated by comparing 
the mean ratio (mRNA expression / total RNA) at eah age group to the adult ratio. 
Absence of genomic DNA contamination in the RNA samples was confirmed by the 
use of RT-negative RNA samples.  Specific PCR products were confirmed with 2% 
agarose gel stained with ethidium bromide where the amplified PCR products 
showed a single band at the expected amplicon size. 
During the optimization process, annealing temperature was selected based upon the 
highest primer efficiency (E) according to equation 3.8. 
 
Slope (= -1
log E
    (3.8) 
 
These optimization experiments also were performed to ensure that the efficiency of the 
target and the internal control gene (β-actin) was approximately equal and slopes fell 
within a range of -2.7 to -3.6.  For primer and assay optimization, the slope was 
measured from a three-point calibration curve using serial dilutions of control RNA 
(adult female Wistar rat) with final total RNA concentrations of 50 ng, 5 ng and 0.5 ng.   
Results of age-dependent changes in mRNA expression will be expressed as mean ± SD 
of the ratio CYP2E1 RNA/total RNA as a ratio to the adult value. 
 
 
3.2.9 Immunohistochemical Analyses 
 
Fresh liver tissues were carefully embedded in OCT compound (Sakura Finetek, 
Torrance, CA) in plastic mold, taking care not to trap air bubbles surrounding the tissue. 
Tissue was allowed to freeze by setting the mold on top of liquid nitrogen until 70-80% 
of the block turns white, the block was subsequently put on top of dry ice for 15-20 min 
and stored at -80°C.  Frozen blocks were allowed to equilibrate in the cryostat chamber 
for about 5 minutes before cutting the sections.  Sections (8 µm) were obtained at 
temperatures between -18 to -20°C.  The sections were fixed in buffered formalin (4% 
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formaldehyde in PBS) for 3 min at room temperature.  The sections were then incubated 
for 15 min (CYP2E1) or 30 min (CYP1A2) in PBS containing 0.9% v/v hydrogen 
peroxide to block any endogenous peroxidase activity.  All subsequent operations were 
carried out in a humidified chamber, washing the sections with PBS (1x) between each 
incubation.  For blocking nonspecific binding, sections were incubated in 5% goat serum 
and 1% bovine serum albumin in PBS for 20 min (CYP2E1) or for 3 hrs (CYP1A2).  
Sections were incubated for 4 hr with rabbit anti-human/rat CYP2E1 polyclonal 
antibody (1:250 in the blocking solution) or with sheep anti-rat CYP1A2 polyclonal 
antibody (1:100 in the blocking solution) at room temperature.  Negative control 
samples (without adding the primary antibody) were applied to test the specificity of the 
antibody used.  After washing with PBS, slides were incubated for 40 min with 
biotinylated anti-rabbit IgG (1:200 in PBS).  This was followed by incubation with 
avidin-biotinylated horseradish peroxidase H reagent (Vectastain ABC kit; Vector 
Laboratories, Burlingame, CA) for 75 min in a dark room.  After a 5 min wash with 
phosphate buffer, the reaction was detected using 3, 3’ diaminobenzidine (DAB) as a 
chromogen [0.06% w/v DAB containing 0.0034% v/v H2O2 in phosphate buffer (1x)].   
 
 
3.2.10 Oral Clearance Study with Chlorzoxazone 
 
3.2.10.1 Animals  
Four pregnant Sprague-Dawley rats were obtained from Charles River Canada (St. 
Constant, PQ).  They were allowed to give birth and one male pup from each dam was 
collected at postnatal ages 3, 7, 10, 14 and 21 days.  Male Sprague-Dawley rats at ages 8 
and 15 weeks (n = 4) were obtained from Charles River Canada and allowed an 
acclimatization period of one week.  Rat husbandry was similar to conditions indicated 
in Section 3.1.1 and the study was approved by the Animal Care and Supply Committee 
of the University of Saskatchewan. 
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3.2.10.2 Study Design 
Four neonates per age per sacrifice time were dosed by oral gavage with CZX 
dissolved in 0.1M NaOH: 0.9% saline (30:70) at a dose of 30 mg/kg body weight. 
Different CZX stock solutions were prepared so that the oral dosed volume ranged from 
0.1-0.15 ml according to the pup’s body weight.  Disposable 1.0 mL syringes with a 
suitable stainless steel feeding needles (Popper & Sons. Inc., New Hyde Park, NY) were 
used for dosing neonates, juvenile and adult animals (Table 3.4).  The concentration and 
homogeneity of the dosing solution were assessed by HPLC analysis of CZX.  
 
Table 3.4 – Sizes of feeding and blood sampling needles 
used in CZX in vivo oral clearance study 
 
 
Age Feeding Needle size Sampling Needle size 
(days) Gauge × length (inches) 
Gauge × length  
(inches) 
3 24 × 1 27 × 0.75  
7-14 22 × 1.5 27 × 0.75 
21-28 20 × 3 22 × 1  
63-112 18 × 3 Jugular cannulas 
 
 
The pups were removed from their mothers 4-5 hours before and returned 1-2 hours 
after CZX oral administration.  During that time, pups were maintained in a warm 
environment by putting them on suitable heating pads. Blood samples were collected 
from neonates at predose and 5, 10, 20, 30, 45, 60, 90, 120, 240 and 360 minutes 
postdosing.  For blood collection, a destructive sampling schedule (four 
neonates/age/sacrifice time) was employed due to the limited blood volume of the 
neonatal pups.  Neonates were anesthetized with isoflurane and blood samples were 
collected via cardiac puncture using suitable hypodermic needles (Tyco Healthcare 
Group, Mansfield, MA), (Table 3.4).  Neonates were immediately decapitated after 
blood collection. 
For the 63 and 112 days old rats, animals were allowed a one-week acclimatization 
period.  One day prior to oral dosing, the rats underwent surgical implantation of 
vascular cannulas (Silastic tubing, I.D. × O.D. (0.64 × 1.19 mm), Dow Corning 
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Corporation, Midland, MI) into the right jugular vein under isoflurane anesthesia.  For 
access, cannulas were passed under the skin and fixed between the shoulder blades.  At 
the end of the surgery, cannulas were instilled with heparinized saline (1 USP heparin 
unit/mL saline) until blood collection.  Rats were fasted for 4-5 hours prior to oral 
dosing, because fasting for a longer time could induce CYP2E1 activity137,278.  Prior to 
CZX administration, a zero time blood sample (250 µL) was collected from the jugular 
cannula, followed by infusing equal volume of sterile saline back into the jugular 
cannula.  After CZX oral administration, blood samples were collected by the same 
manner at 5, 10, 20, 30, 45, 60, 90, 120, 240, 300 and 360 minutes postdosing.  After the 
last blood sample, rats were anesthetized and euthanaized by isoflurane overdose and 
exsanguination. Blood samples were allowed to clot for 30 minutes, centrifuged at 6 000 
× g and serum was transferred to a clean 1.5 mL eppendorf microcentrifuge tube and 
stored at -20°C until HPLC analysis of CZX.   
 
3.2.10.3 HPLC Assay of CZX 
The concentration of CZX in serum samples were determined by a modification of a 
reported HPLC method279.  Briefly, a 100 µL aliquot of 0.2M acetate buffer (pH 4.7) 
and 100 µL aliquot of internal standard (UMB, 10 µM) were added to a 75 µL aliquot of 
serum sample, QC sample or CZX standard solutions in uncapped 12×75 mm glass 
culture tubes.  After manual mixing for 10 minutes, a 1.0 mL aliquot of tert-butyl methyl 
ether was added and the mixture was shaken for 10 minutes and then centrifuged at 3 
000 × g for 10 minutes.  The upper organic layer was transferred to a clean tube and 
evaporated at 37°C under nitrogen.  The residue was reconstituted in a 100 µL mobile 
phase and a 30 µL aliquot was injected into the HPLC column.  The mobile phase 
(acetonitrile and 0.25% acetic acid (20:80)), was delivered at 1.0 mL/min.  UV 
absorbance was monitored at 287 nm.  The method was validated for the determination 
of CZX in rat serum samples as described in section 3.2.4. 
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3.2.11 Kinetics and Statistical Analyses 
 
All data within the same age was reported as mean ± SD. Metabolite formation 
velocity as a function of substrate concentration was fit to a one-enzyme site Michaelis-
Menten equation.  The parameters, Vmax and KM, were estimated by an iterative 
nonlinear least squares regression analysis using GraphPad Prism 4.0 (GraphPad 
Software, San Diego, CA).  Significant differences in total microsomal protein content, 
CYP protein content, and Vmax and KM estimates, ontogeny of protein and mRNA 
expression between the different age groups were assessed with one-way Analysis of 
Variance with Tukey’s post-hoc test for pair-wise multiple comparisons using GraphPad 
Prism. For CZX KM estimates, a Wilcoxon signed rank test was used for the pooled data. 
The level of significance was set at P<0.05.  The observed ISF(t) values were fit to 
various models describing the developmental maturation of CYP enzyme with 
WinNonLin 5.1 (Pharsight Corporation, Mountain View, CA, USA).  Criteria 
determining the goodness of fit and suitability of the model included visual inspection of 
the regression line, the randomness of the residual plots, the accuracy of the predicted to 
the extrapolated estimates, the Aikaike information criterion and the coefficient of 
variation of the parameter estimates.  For the in vivo oral clearance study, PK 
parameters including area under the serum concentration-time curve (AUC∞), maximum 
serum concentration (Cmax), time to reach Cmax (tmax), terminal elimination rate constant 
(λz), apparent volume of distribution at steady-state (Vd,ss) and oral clearance (Cl/F) 
were estimated using a non-compartmental analysis (WinNonLin 5.1).  Elimination half 
life (t1/2) at each age was obtained from the ratio 0.693/ λz.  
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RESULTS 
4.1 Evaluation of the Assumptions of an Ontogeny Model of CYP Enzymes  
 
4.1.1 Age-Dependent Changes in Hepatic Scaling Factor (HSF) 
To estimate the HSF at each age, wet liver weight (g), total body weight (g) and 
hepatic microsomal protein content (mg/g liver) were determined for each animal (n=8) 
at each age group. 
 
4.1.1.1 Total Body and Liver Weights  
Table 4.1 lists total body and wet liver weights in male Sprague-Dawley rats at fetal 
(gestation day 20), neonatal, juvenile and adult ages.  
 
Table 4.1 – Age-dependent changes in mean (± SD) body and liver weights for male 
Sprague-Dawley rats (n=8). 
Total Body Weight (g) Liver Weight (g) Age (days) 
       Mean              SD     Mean             SD 
Fa 3.64b 1.3 0.34b 0.17 
1 7.09b 0.5 0.32b 0.077 
3 9.40b 0.9 0.42b 0.070 
5 12.9b 1.4 0.52b 0.119 
7 17.4b 1.4 0.63b 0.096 
10 26.2b 4.5 0.86b 0.34 
14 32.7b 3.3 1.13b 0.24 
21 59.4b 5.2 2.62b 0.24 
28 105b 6.7 4.93b 0.54 
42 203b 12.9 9.39b 0.75 
63 399b 32.7 16.2  2.6 
84  411b,c 11.0 13.8c  0.51 
112 507 29.2 15.0 1.4 
a Fetuses were collected at 20 day gestation from 3 dams and the fetal livers from 
individual dams were pooled, b Statistically significant from adult (112 days), c n=4. 
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As expected, mean total body and liver weights increased with postnatal age, with 
the most prominent increases occurring during puberty (42-63 days).  The variation in 
total body and liver weights observed within and between age groups can be attributed 
to normal interindividual variation in the rate and pattern of body and organ growths. 
Normalization of wet liver weight to total body weight revealed relatively constant 
values with postnatal maturation (Figure 4.1). 
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Figure 4.1 –Wet liver weight (g) normalized to total body weight (g) in male Sprague-
Dawley rats (n=8, except at 84 days where n=4).  Results are expressed as mean ± SD.  
Asterisks indicate statistical difference from adult (112 days), P<0.05.  F = gestation day 
20.  
 
 
4.1.1.2 Hepatic Microsomal Protein Content  
To evaluate whether microsomal protein (MP) content remains constant with 
developmental age (the first major assumption of our ontogeny model of CYP enzyme 
activity) and to calculate age-dependent HSF values, hepatic microsomal protein content 
for each age group (n = 8) was measured by the method of Lowry et al270.  The results 
shown in Figure 4.2 indicate that average MP (mg/gram liver weight) was low at birth 
(18 % of the adult value, P<0.05) and increased steadily to reach a maximum value (133 
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% of the adult value, P>0.05) at postnatal day (PD) 42, followed by gradual, but not 
statistically significant, decline towards the adult value.  The only significant difference 
from the adult MP level was observed in hepatic microsomes from fetuses and postnatal 
days younger than 7 days (Figure 4.2). 
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Figure 4.2 – Mean (± SD) hepatic microsomal protein content in male Sprague-Dawley 
rats (n=8, except for PD 84 where n=4).  Asterisks indicate statistical difference from 
adult (112 days), P<0.05.  F = gestation day 20. 
 
 
4.1.1.3 Hepatic Scaling Factor (HSF) 
 
Results of liver weights, total body weights and hepatic microsomal protein 
content at each developmental age were used to calculate age-dependent changes in 
HSF values (Figure 4.3) according to equation (3.3).  Reltive to adult, there was no 
significant difference in HSF values between 20 day gestation and 14 day age groups 
(about 50-90% of the adult value, P>0.05).  By 21 days of age, the HSF value had 
increased more than threefold and did not change further at 28 or 42 days of age 
(about 150-200 % of the adult value, P<0.05), but decreased gradually from puberty 
(PD 42-63) group to the adult age group. 
Upon close examination of the data the pattern observed in the mean HSF with age 
(Figure 4.3) mirrored the developmental pattern of microsomal protein content per 
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gram liver (Figure 4.2), since the ratio of liver weight to total body weight remained 
relatively constant with postnatal development. 
 
F 1 3 5 7 10 14 21 28 42 63 84 112
0.0
0.5
1.0
1.5
2.0
2.5
3.0
* *
*
Age (days)
H
ep
at
ic
 S
ca
lin
g 
Fa
ct
or
 (m
g/
g 
bo
dy
 w
ei
gh
t)
 
Figure 4.3 – Mean (± SD) hepatic scaling factor (mg/g body weight) in male Sprague-
Dawley rats (n=8, except for PD 84 where n=4).  HSF was calculated using Equation 
3.3.  Asterisks indicate statistical difference from adult (112 days), P<0.05.  F = 
gestation day 20.  
 
 
4.1.1.4 Age-Dependent Changes in Total CYP protein Content 
Total CYP protein content was determined in age-specific rat hepatic microsomes by 
carbon monoxide difference spectroscopy271.  As shown in Figure 4.4, total CYP content 
was fairly low in fetal microsomes (less than 25% the adult level, P<0.05) and increased 
slightly between postnatal days 1 and 28.  There was no significant difference between 
hepatic microsomal CYP content at puberty (PD63) and adult ages. 
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Figure 4.4 – Mean (± SD) total hepatic microsomal CYP content (nmol/mg microsomal 
protein) in male Sprague-Dawley rats (n=8, except for PD 84 where n=4).  CYP content 
was determined by the method of Omura and Sato271.  Asterisks indicate statistical 
difference from adult (112 days), P<0.05. F = gestation day 20.  
 
 4.1.2 Enzyme Kinetic Studies in Rat Hepatic Microsomes 
To evaluate the age-dependent changes in KM and Vmax values, enzyme kinetic 
studies in rat hepatic microsomes were conducted using probe substrates specific for 
CYP2E1 and CYP1A2 enzymes, namely chlorzoxazone (CZX) and methoxyresorufin 
(MR), respectively.  KM and Vmax values were determined by measuring metabolite 
formation velocities of CZX and MR at substrate concentrations of 0 to 1000 µM and 0 
to 1000 nM, respectively.  As well, Vmax values were estimated using a second probe 
substrate, ρ-nitrophenol (PNP) for CYP2E1 and phenacetin for CYP1A2.   
 
4.1.2.1 Assessment of the Optimum Incubation Conditions 
 Preliminary experiments using hepatic microsomes from 50-day old male Sprague-
Dawley rats were conducted to determine the optimum incubation conditions regarding 
incubation time and microsomal protein content to give linear metabolite formation 
kinetics for CYP2E1-mediated CZX and PNP hydroxylation and CYP1A2-mediatd 
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dealkylation of MR and phenacetin.  Results of these experiments are indicated in Table 
4.2. These conditions were used in subsequent enzyme kinetic experiments. 
 
Table 4.2 –Results of preliminary experiments in male rat hepatic microsomes to assess 
the optimum microsomal incubation conditions to ensure linear metabolite formation 
kinetics. 
  Optimum incubation conditions 
  Incubation time (min) Protein content (mg/mL) 
1. CZX hydroxylation 30 0.4 
2. PNP hydroxylation 30 0.4 
3. MR O-dealkylation 8 0.08 
    4. Phenacetin O-dealkylation 60 0.4 
 
4.1.2.2 Validation of the HPLC Methods 
To monitor metabolite formation rate in age-dependent hepatic microsomes, 
validated HPLC methods were used.  Validation was performed according to the FDA 
guidelines (section 3.2.4).  Table 4.3 demonstrates the basic validation parameters for all 
the HPLC methods used for evaluation of CYP2E1 and CYP1A2 enzyme kinetics and 
CZX oral clearance. 
 
Table 4.3 –Method validation parameters for the HPLC assays used to analyze 
metabolites and/or substrates in enzyme kinetic and oral clearance studies. 
 
                                Metabolites analyzed   Validation 
parameters 6-OH CZX 4 NC APAP e Resorufin CZXa 
      
1. Linearity 
range (μM)b 
0.3-40 
 
0.1-40 0.2-20 0.04-2 1-250 
2. LODb,c 0.15 0.02 0.05 0.01 0.25 
3. LOQb,d 0.30 0.10 0.20 0.04 1.0 
4. Intra-day      
Accuracy 101-113% 95-104% 96-114% 96-113 % 100-114% 
Precision < 14% < 11% < 9% < 6% <7% 
5. Inter-day      
Accuracy 101-106% 91-103% 104-111% 88-110% 91-108% 
Precision < 9% <8% <14% <8% <8% 
aThis method was used to analyze CZX in oral clearance study (section 4.4), bResorufin 
units are nM, cLimit of detection, dLimit of quantitation, eacetaminophen. 
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Figures 4.5 and 4.6 show representative HPLC chromatograms of rat hepatic 
microsomal samples after being incubated with CYP-specific substrates under optimum 
incubation conditions (Table 4.2).  
 
 
 
 
Figure 4.5 – Representative HPLC chromatograms of rat hepatic microsomes after 
incubation with CYP2E1 probe substrates, chlorzoxazone (A) and ρ-nitrophenol (B), 
under incubation conditions mentioned in Table 4.2 and explained in section 3.2.3.  
HPLC chromatographic conditions are explained in section 3.2.4. 
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Figure 4.6 – Representative HPLC chromatograms of rat hepatic microsomes after 
incubation with CYP1A2 probe substrates, methoxyresorufin (A) and phenacetin (B) 
under incubation conditions mentioned in Table 4.2 and explained in section 3.2.3.  
HPLC chromatographic conditions are explained in section 3.2.4. 
 
 
4.1.2.3 Developmental Changes in KM Value 
To investigate whether KM value remains constant with developmental age (the 
second major assumption of our ontogeny model of CYP enzyme activity), KM values 
for CYP2E1-mediated CZX hydroxylation and CYP1A2-mediated MROD activities 
were determined in age-dependent hepatic microsomes.  For CYP2E1, CZX 6-
hydroxylase activity was not detected in gestation day 20 and PD1 hepatic microsomes. 
Chlorzoxazone KM values (Figure 4.7 A) were only 35-40% of adult values at PD3 and 
PD5.  By PD10, KM values reached adult level and stayed relatively constant thereafter 
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except at PD21 where the KM value was 70% that of adult value.  The data may simply 
represent normal biological variation given the rather small sample size and pooled data.  
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Figure 4.7 – Michaelis-Menten constant (KM) estimates for CYP2E1-mediated 
chlorzoxazone hydroxylase activity (A) and CYP1A2-mediated methoxyresorufin-O-
dealkylation (MROD) activity (B) as a function of developmental age in male Sprague-
Dawley rat hepatic microsomes.  KM values for chlorzoxazone are obtained from pooled 
microsomes of four rats at each age group.  Wilcoxon signed-rank test indicated 
significance.  KM values for methooxyresorufin are expressed as mean ±SD of 4 rats 
except fetal livers, which were pooled from 3 different dams.  The asterisk refers to 
those age groups that show significant difference from adult.  MROD activity was 
detected at PD3, but the data did not allow for KM estimation. 
 77
For CYP1A2, the methoxyresorufin KM values (Figure 4.7 B) in PD5 and PD7 were 
significantly higher than adult values (~250-275% of adult values).  No significant 
differences in KM values were observed for PD age groups ≥ 10 days.  The data did not 
allow estimation of KM values in PD3 age group, although activity was detected. 
 
4.1.2.4 Developmental Changes in Vmax Value 
To evaluate the age-dependent changes in maximum enzyme activity (Vmax), both 
CYP2E1-mediated CZX hydroxylase and CYP1A2-mediated MROD activities were 
measured at saturating probe substrate concentrations in rat hepatic microsomes at 
different developmental stages.  CYP2E1 activity was not detected in fetal and PD1 
livers (Figure 4.8A).  A higher level of activity was detected in PD3 livers (70% of the 
adult value, P>0.05), which increased progressively to reach a maximum level at PD14 
(170% of the adult value, P<0.05).  The activity declined to the adult level at weaning 
(PD21) and remained similar to the adult values during puberty (Figure 4.8A).  No 
significant difference in activity levels relative to the adult value was observed at any 
age group, except at PD14.  The marked postnatal increase in Vmax values for 
chlorzoxazone preceded hepatic scaling factor values, where the predominant age-
dependent increase occurred between PD14 and PD21 and continued to increase until 
PD42 (Figure 4.3). 
 
Although rat hepatic CYP1A2-mediated MROD activity was first detected at PD3, 
the values were below the limit of quantification of the HPLC assay.   At PD5 and PD7 
hepatic microsomes demonstrated significantly lower MROD activity at 11% and 20% 
adult activity, respectively (Figure 4.8 B).  MROD activity increased significantly to 
reach 165% and 175% adult values by PD21 and PD28, respectively.  However, after 
weaning (PD28) and during puberty (PD42-63) Vmax values fell to adult values. 
Although, the marked increase in MROD activity between PD14 and PD21 
corresponded to a marked increase in age-dependent hepatic scaling factors (Figure 4.3), 
activity declined after PD28 to the adult value by PD42, unlike the hepatic scaling 
factor.   
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Figure 4.8 - Vmax estimates for CYP2E1-mediated chlorzoxazone hydroxylase activity 
(A) and CYP1A2-mediated methoxyresorufin-O-dealkylase activity (B) as a function of 
developmental age in male Sprague-Dawley rat hepatic microsomes.  The data are 
expressed as mean ±SD of 4 rats except fetal livers, which were pooled from 3 different 
dams.  The asterisks refer to those age groups that show significant difference from 
adult. 
  
4.1.2.5 Developmental Changes in Vmax Value Using a Second Probe Substrate 
To determine whether enzyme activity (Vmax) from one substrate predicts the level of 
activity for all substrates of the enzyme, developmental changes in Vmax were estimated 
using a second probe substrate, ρ-nitrophenol for CYP2E1 and phenacetin for CYP1A2. 
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Figure 4.9 shows age-dependent changes in CYP2E1-mediated ρ-nitrophenol (PNP) 
hydroxylase activity and CYP1A2-mediated phenacetin-O-dealkylase activity (POD). 
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Figure 4.9- Vmax estimates for CYP2E1-mediated PNP hydroxylase activity (A) and 
CYP1A2-mediated POD activity (B) as a function of developmental age in male 
Sprague-Dawley rat hepatic microsomes.  The data are expressed as mean ±SD of 4 rats 
except fetal livers, which were pooled from 3 different dams.  The asterisks refer to 
those age groups that show significant difference from adult. 
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To confirm whether changes in enzyme activity of one CYP substrate covaries with 
changes in the activity of a second CYP substrate (the fourth major assumption of our 
ontogeny model of CYP enzyme activity), infant scaling factors (product of HSF and 
Vmax normalized to their respective adult values) were determined at each age group 
(Table 4.4) using the two probe substrates for each CYP enzyme followed by correlation 
of the ISF values. 
 
 
Table 4.4 - Age-specific infant scaling factor estimates for CYP2E1 and CYP1A2 based 
upon age-specific relative  hepatic scaling factors (RHSF) and Vmax values normalized to 
adult Vmax values (OSF) in male Sprague-Dawley rats. 
 
                         CYP2E1    CYP1A2 
   Chlorzoxazone ρ-nitrophenol Methoxyresorufin Phenacetin 
Age 
(day) 
RHSF OSF ISF OSF ISF OSF ISF OSF ISF 
F 0.57   0.074 0.042   0.019 0.011 
1 0.47   0.10 0.049   0.13 0.063 
3 0.71 0.70 0.50 0.24 0.17   0.16 0.11 
5 0.67 0.74 0.50 0.62 0.42 0.11 0.076 0.27 0.18 
7 0.80 0.99 0.80 1.16 0.93 0.20 0.16 0.42 0.33 
10 0.76 1.25 0.95 0.94 0.71 0.71 0.54 0.47 0.36 
14 1.00 1.59 1.60 1.20 1.21 0.75 0.75 0.51 0.52 
21 1.72 1.11 1.92 0.99 1.70 1.66 2.86 0.91 1.57 
28 1.94 1.28 2.49 0.50 0.97 1.77 3.43 1.24 2.40 
42 2.09 1.04 2.17 0.77 1.60 1.01 2.11 0.85 1.78 
63 1.52 0.86 1.32 1.16 1.78 0.71 1.08 1.30 1.99 
112 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
RHSF = Relative Hepatic Scaling Factor calculated from age-specific HSF values 
normalized to adult value (Equations 3.3 and 3.4); OSF = Ontogeny Scaling Factor 
calculated from age-specific Vmax values normalized to adult Vmax value (Equation 3.5); 
ISF = Infant Scaling Factor calculated from the product of RHSF and OSF (Equation 3.6). 
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Figure 4.10 suggests a strong positive correlation between the activity of one specific 
substrate relative to a second specific substrate for both CYP2E1 and CYP1A2 (r = 0.82 
and r = 0.89, respectively). 
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Figure 4.10- Correlation between infant scaling factor estimates for (A) ρ-nitrophenol 
as a function of chlorzoxazone (r = 0.82); (B) Phenacetin as a function of 
methoxyresorufin (r = 0.89). 
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4.1.2.6 Correlation between Age-Dependent Changes in Catalytic CYP Activity and 
Immunoreactive CYP Protein level 
To investigate a proportional relationship between enzyme activity (Vmax) and 
protein level during postnatal development (the fifth major assumption of our ontogeny 
model of CYP enzyme activity), CYP2E1 and CYP1A2 enzyme activity was measured 
at saturating probe substrate concentrations in rat hepatic microsomes at different 
developmental stages.  Also CYP2E1 and CYP1A2 protein levels were determined in 
the hepatic microsomes at the same developmental stages by immunoblotting procedures 
(Section 4.6).  When the age-dependent changes in Vmax were compared with changes in 
enzyme protein levels, CYP2E1-mediated chlorzoxazone hydroxylase Vmax values did 
not correlate with changes in CYP2E1 protein levels observed at the same age group 
(Figure 4.11A).  CYP2E1 protein and activity were not detectable at < PD3.  Although 
CYP2E1 protein increased following PD3, protein levels plateaued at PD10 and began 
increasing again at PD28.  This biphasic pattern was not mirrored by CYP2E1 activity 
where a dramatic increase in activity was observed between PD3 and PD14 (Figure 4.8). 
At PD28 immunoquantifiable CYP2E1 protein levels were only ~50% of adult levels 
despite ~30% greater enzyme activity levels relative to adult.  CYP2E1 protein 
continued to increase thereafter to adult values, despite the decrease in chlorzoxazone 
Vmax to adult values.  
Similarly, CYP1A2-mediated methoxyresorufin Vmax values did not reasonably 
correlate with changes in immunoquantifiable CYP1A2 protein levels observed at the 
same age group (Figure 4.11B).  A similar biphasic pattern demonstrated by CYP2E1 
protein was observed with CYP1A2 protein ontogeny.  However, CYP1A2 activity 
increased markedly between PD5 and PD28 such that MROD Vmax values were ~175% 
adult values (Figure 4.8).  Thereafter, CYP1A2 protein continued to increase while 
MROD activity declined to adult values. 
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Figure 4.11 – Age-dependent changes in CYP enzyme activity (open circle) as a 
function of its immunoreactive protein levels (closed circle) in rat hepatic microsomes. 
(A) Average CYP2E1-mediated chlorzoxazone hydroxylase Vmax estimates as a function 
of average CYP2E1 protein levels.  (B) Average CYP1A2-mediated methoxyresorufin-
O-dealkylase Vmax estimates as a function of average CYP1A2 protein levels. 
Immunoreactivity is expressed in arbitrary units per microgram of microsomal protein. 
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4.1.2.7 Eadie-Hofstee Plots 
To investigate possible involvement of more than one CYP isoform in CZX 
hydroxylation and MROD activities, Eadie-Hofstee plots were used.  Figures 4.12 and 
4.13 show representative Eadie-Hofstee plots at selected postnatal ages.  The results may 
indicate that both CZX hydroxylation and MROD activities demonstrate at least two 
components, rather than a simple one component Michaelis-Menten kinetics. This 
possible contribution of more than one CYP pathway will have a significant impact on 
the estimated Vmax and KM parameters for these reactions. 
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Figure 4.12 – Eadie-Hofstee plots for CZX hydroxylation catalyzed by rat hepatic 
microsomes from different ages. V = rate of metabolite formation; S = substrate 
concentration; PD = postnatal day; CZX = chlorzoxazone.  
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Figure 4.13 – Eadie-Hofstee plots for MROD activity catalyzed by rat hepatic 
microsomes from different ages. V = rate of metabolite formation; S = substrate 
concentration; PD = postnatal day; MR = methoxyresorufin.  
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4.2 Development of an Ontogeny Model of CYP2E1 and CYP1A2 enzymes in Rat 
The age-dependent changes in CYP2E1 and CYP1A2 enzyme activity using specific 
probe substrates were used to develop pharmacokinetic models to describe the 
developmental maturation of these enzymes in the rat.  
 
4.2.1 Developmental Maturation of CYP Activity 
 
4.2.1.1 Age-Specific Infant Scaling Factor 
Infant scaling factors at a particular age, t, (ISF(t)) were estimated from the product 
of HSF(t) and Vmax values at the same age, t (Vmax,(t)), normalized to the product of the 
respective adult values according to Equation 3.6 and as illustrated in Table 4.4.  As 
shown in Figure 4.14, CYP2E1 ISF value is very low at birth, increases asymptotically 
during the first 2 weeks, and undergoes a burst during the third week before falling back 
to adult level after 50 days of age.  Similar observations were obtained with CYP1A2 
but its developmental changes were more delayed compared to CYP2E1.  The 
asymptotic increase in activity was observed during the third week with a burst in 
activity during the fourth week and a sharp decline in activity during the pubertal stage 
(PD42-63).  Given the fact that CYP2E1 and CYP1A2 are the dominant clearance 
pathways for CZX and MR280, respectively, pattern of age-dependent changes in ISF 
calculated using these substrates should reflect the pattern of CYP2E1 and CYP1A2 
ontogeny. 
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Figure 4.14- Infant scaling factor (ISF) as a function of age for CYP2E1 (A) and 
CYP1A2 (B) enzymes. 
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4.2.1.2 Model Development  
The observed ISF(t) values were fit to various models describing the developmental 
maturation of each CYP enzyme using pharmacokinetic modeling software (GraphPad 
Prism 4).  Modifications to the general ontogeny model (Equation 1.16) were required to 
describe the age-dependent changes in CYP function from birth to adulthood as shown 
in Equation 4.1.  
The primary modification included a parameter ( ISFBurst (e
-k2 (t - lag) -e-k3 (t - lag) ) ) that 
accounted for an apparent burst of activity (greater than the adult value) in the period 
between weaning and puberty that overlay the general exponential increase in activity to 
some asymptotic level reached at adulthood (ISFD (1 - e-kt)).  
)e(1ISFISFISF ktD(j,0)t)(j,
−−+=                                           (1.16) 
  )e(eISF)e(1ISFISFISF lag)(tklag)(tkBurst
tk
D(j,0)t)(j,
321 −−−−− −+−+=   (4.1) 
where: (t)ISF is the predicted hepatic CYP enzyme-specific infant scaling activity in vivo 
at age, t (d); (j,0)ISF  is the scaled in vivo CYP enzyme activity present at birth; DISF and 
BurstISF  are a fixed and fitted parameters associated with the slow rise and burst, 
respectively; k1 is the first order rate constant describing the slow rate of increase in 
CYP enzyme pathway efficiency (d-1) to the adult value; k2 and k3 are the first order rate 
constants describing the onset and decline in CYP enzyme pathway efficiency (d-1) 
during the burst phase; t is the age in days (d); and lag is the time delay associated with 
the appearance of the burst phase.   
 
4.2.1.3 Model Selection 
This model (Equation 4.1) was written into Prism 4 (GraphPad Software Inc.) and 
the number of exponential terms and inclusion of a t lag parameter were determined by 
nonlinear regression analyses of observed ISF values to models of increasing 
complexity.  The ISFBurst, lag, and k terms are fitted parameters and ISF(j,0) is a constant 
based upon the scaled CYP enzyme activity determined in fetal microsomes.  Upper and 
lower bounds were established for each estimated parameter and remained consistent 
between different models.  Initial parameter estimates remained consistent for each 
analysis.  Several sets of initial parameter estimates were used to ensure that the program 
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was not stopping at local minima.  Equal weighting factors or 1/observation2 weighting 
factors were given to all ISF data.  Model selection was based on several criteria which 
included the Akaike Information Criterion (AIC) values, confidence intervals (CI) of 
parameter estimates, correlation coefficient, weighted residual plots, correspondence of 
observed versus predicted parameters, and visual inspection of the fitted nonlinear 
regression line.  In general, the model equation with minimum AIC and narrowest CI 
values was considered the best representation of the time course of scaled CYP enzyme 
activity data.  Table 4.5 represents the model parameter estimates (Equation 4.1) for 
each CYP enzyme. 
 
 
Table 4.5- Parameter estimates for the predictive models of CYP2E1 and CYP1A2-
mediated hepatic clearance in rats 
 
    Clearance mechanism  
Model parameter CYP2E1 CYP1A2 
ISF(j,0) a 0 0 
ISFDa 1 1 
k1 0.00275 0.0058 
ISFBurst 32.75 34.55 
k2 0.02679 0.041 
lag 0.3875 6.46 
k3 0.03427 0.0498 
 
a  Fixed parameters 
ISF(j,0) is the scaled in vivo CYP enzyme activity present at birth. 
DISF and BurstISF  are fixed and fitted parameters associated with the slow rise and burst, 
respectively. 
k1 is the first order rate constant describing the slow rate of increase in CYP enzyme 
pathway efficiency (d-1) to the adult value. 
k2 and k3 are the first order rate constants describing the onset and decline in CYP 
enzyme pathway efficiency (d-1) during the burst phase. 
t is the age in days (d). 
lag is the time delay associated with the appearance of the burst phase.   
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The nonlinear regression fit shown in Figures 4.15A demonstrate a reasonable 
correspondence between the fitted line and the observed ISF values. 
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Figure 4.15- Plot output of calculated (line) and observed (squares) ISF data versus age 
using the model given in equation 4.1 for CYP2E1 (A) and CYP1A2 (B).  Best fits and 
model selection were obtained using unweighted regression analysis (GraphPad Prism).  
Model parameter estimates for each CYP enzyme are given in Table 4.5. 
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4.2.2 Age-Dependent Changes in Chlorzoxazone Oral Clearance in Rats 
 
To assess the ability of the general ontogeny PK model to make a priori predictions of 
the elimination capacity at different developmental ages as proof of concept, the oral 
clearance of chlorzoxazone (CZX) whose elimination is mediated by a single elimination 
mechanism (CYP2E1) was evaluated.  Plots of average CZX serum concentration following 
oral administration to male Sprague Dawley rats at early neonatal (3 days), middle neonatal 
(7 days), late neonatal (10 and 14 days), weaning (21 days), juvenile (63 days) and adult 
(112 days) are shown in Figure 4.16.  Pharmacokinetic parameter estimates for CZX 
calculated by non-compartmental analysis are shown in Table 4.6.  The oral clearance (Cl/F) 
value of CZX at 3 days was about 130% the adult value followed by a sudden increase to 
200% the adult value at 7 days and more than 230% the adult value at 10 days.  This value 
gradually declined with age to less than 80% the adult value at puberty age (63 days). 
Although significant changes in oral clearance values and Cmax values were observed, the 
elimination rate constant was almost similar at all examined postnatal ages.  As well, other 
PK parameters e.g. AUC∞ volume of distribution and elimination half life underwent age-
dependent changes.  
To test the ability of our rat CYP2E1 ontogeny model (Equation 4.1) to provide a priori 
prediction of oral clearance of chlorzoxazone (CYP2E1 substrate), age-specific ISF values 
were predicted from the model equation (Equation 4.1).  Estimation of age-specific ISF 
values allowed prediction of age-specific CZX oral clearance values using a published adult 
oral clearance values (Cl/F) of 10.5 ml/min/kg 278 and using Equation 1.15.   
 
 
ClH j,t( )
infant  = ISFH j,t( )Clsystemic
adult
                         (1.15) 
Visual demonstration of the correspondence between observed and calculated Cl/F values 
versus age (Figure 4.17A) indicates that the model underestimates the oral clearance values 
at the all examined ages except at the weaning age (21 days).  While, calculated versus 
observed Cl/F data plot (Figure 4.17B) shows a reasonable correspondence (r = 0.75), a 
distinct deviation from a straight line is also shown.  Such deviation may indicate the need 
for a more complex model or more data points. 
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Figure 4.16 – Mean ±SD serum concentration versus time curves of chlorzoxazone after 30 
mg/kg oral dose in male Sprague Dawley rats (n = 4) at different developmental ages. 
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Figure 4.17 – Age-related correspondence between calculated and observed CZX oral 
clearance (Cl/F) values (A) and plot output of calculated versus observed CZX Cl/F data 
using CYP2E1 ontogeny model (Equation 4.1) (B).  
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4.3 Characterization of the Ontogeny of CYP2E1 and CYP1A2 
 
4.3.1 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 mRNA  
To assess developmental changes in mRNA expression levels of rat hepatic CYP2E1 
and CYP1A2, real-time RT-PCR was performed using 20-residue oligonucleotide 
primers (Table 3.2) specific to rat CYP2E1 and CYP1A2, respectively.  
 
4.3.1.1 Optimization of Real-Time RT-PCR Conditions 
Table 4.7 lists the optimal annealing temperatures and corresponding primer 
efficiencies and standard curve ranges for CYP2E1 and CYP1A2 genes.  Primer 
sequences and amplicon sizes are detailed in Section 3.2.8.2.  Optimal annealing 
temperatures were selected based on primer efficiency (E) (a theoretical value of 2 is 
optimal) and lack of primer dimer formation.  For primer and assay optimization, the 
slope was measured from a three-point calibration curve using serial dilutions of control 
RNA (adult female Wistar rat). 
 
Table 4.7 – Optimal annealing temperatures and standard curve ranges for CYP2E1, 
CYP1A2 and β-actin genes for real-time RT-PCR analysis. 
 
Gene Annealing Temperature (oC) Primer E Standard Curve Range (ng) 
CYP2E1 55 1.9 0.05-500 
CYP1A2 58 2.04 0.05-500 
β-actin 55 1.93 0.05-500 
 
 
4.3.1.2 Age-Dependent Changes in mRNA Expression of Rat Hepatic CYP2E1 and 
CYP1A2 
 Results of age-dependent changes in CYP mRNA expression levels are expressed as 
mean ± SD of the ratio (CYP mRNA/total RNA) as compared to adult (Figure 4.18). 
CYP2E1 mRNA expression was low in fetal livers (approximately 0.005 fold the adult 
value) and increased after birth to reach more than 2.5- fold the adult value at PD14.   
The expression at puberty (PD42) was 2-fold the adult value with P value <0.05.  As 
well, CYP1A2 mRNA expression was very low in fetal livers (approximately 0.05 fold 
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the adult value), and increased gradually after birth until PD10.  Dramatic increases in 
CYP1A2 mRNA expression occurred after PD10 to reach more than three fold the adult 
value at 28 days.  The expression at puberty (PD42) was more than two fold the adult 
value with P <0.05. 
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Figure 4.18 – Age-related variations in rat hepatic CYP2E1 and CYP1A2 mRNA 
expression levels.  Total RNA was extracted from rat livers (n = 4) and 40 ng was 
reverse transcribed and amplified as described in materials and methods.  Data are 
expressed as mean ± SD of the ratio CYP RNA/total RNA and as ratio to adult.  Fetal 
livers were pooled from 3 different dams.  The asterisks refer to those age groups that 
show significant difference from adult. 
 
 
4.3.2 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 Protein Expression 
 
To assess changes in protein expression levels of hepatic CYP2E1 and CYP1A2 
with maturation and investigate the correlation between CYP enzyme activity and CYP 
protein level, immunoblot analyses were performed using specific polyclonal antibodies 
against rat hepatic CYP2E1 and CYP1A2.  The polyclonal antibodies used in this study 
recognized unique bands at 56 and 58 kilo Daltons (KD) which were the same sizes 
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recognized by the purified rat CYP2E1 and CYP1A2 proteins loaded with the hepatic 
microsomes, respectively (Figures 4.19 and 4.20). 
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Figure 4.19 –Immunoblots of rat hepatic microsomes and rat CYP2E1 purified protein. 
10.5 µg microsomal protein and different CYP2E1 protein amounts (20, 50 and 100 
pmol) were electrophoresed on a 10% SDS-PAGE, transferred onto a PVDF membrane, 
and probed with a polyclonal antibody to rat CYP2E1.  Lanes (1-3) are purified rat 
CYP2E1 protein (100, 50 and 20 pmol, respectively).  Lanes (4-16) are rat hepatic 
microsomes from fetal (lane 4) and postnatal days 1, 3, 5, 7, 10, 14, 21, 28, 42, 63, 84 
and 112, respectively. 
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Figure 4.20 – Immunoblots of rat hepatic microsomes and rat CYP1A2 purified protein. 
0.4 µg microsomal protein and different CYP1A2 protein amounts (20, 80, 200 and 500 
pmol) were electrophoresed on a 10% SDS-PAGE, transferred onto a PVDF membrane, 
and probed with a polyclonal antibody to rat CYP1A2.  Lanes (1-4) are purified rat 
CYP1A2 protein (500, 200, 80 and 20 pmol, respectively).  Lanes (5-16) are rat hepatic 
microsomes from fetal (lane 5) and postnatal days 1, 3, 5, 7, 10, 14, 21, 28, 42, 63 and 
112, respectively. 
 
 
The amount of protein present in hepatic microsomes and cross-reacting with the 
polyclonal antibody is shown in Figure 4.21.  The results are expressed as absorbance 
unit/amount of microsomal protein.  When examined as a function of age, expression of 
CYP2E1 and CYP1A2 proteins showed a biphasic pattern.  Proteins were not visible in 
fetal and postnatal day 1 hepatic microsomal samples.  Expression for both CYP2E1 and 
CYP1A2 proteins was detected at 3 days of age where it accounted for no more than 25 
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% of the adult content, P<0.05.  Expression increased progressively and plateaued at PD 
10 followed by gradual increase at PD28 (30% of the adult value, P<0.05).  Protein 
levels reached 75% of the adult value at the puberty age (63 days).  
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Figure 4.21 – Age-related changes in rat hepatic CYP2E1 and CYP1A2 protein 
expression.  Microsomal proteins were separated on a 10% SDS-PAGE and transferred 
to a PVDF membrane.  CYP proteins were immunochemically detected with polyclonal 
antibodies raised against rat CYPs.  The antigen-antibody complex was visualized after 
addition of a peroxidase-conjugated IgG, and quantified by scanning with an image 
analysis system.  Data are expressed as mean ±SD of 4 rats except fetal livers, which 
were pooled from 3 different dams.  The asterisks refer to those age groups that show 
significant difference from adult. 
 
 
4.3.3 Ontogeny of Rat Hepatic CYP2E1 and CYP1A2 Activity 
 
Developmental changes in CYP2E1 and CYP1A2 maximal enzyme activities (Vmax) 
were assessed by measuring the enzyme activity at saturating chlorzoxazone and 
methoxyresorufin concentrations in age-dependent rat hepatic microsomes as shown in 
Figure 4.8.  Both activities were undetected in fetal and PD1 hepatic microsomes. 
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Activities were low at early neonatal ages followed by a marked increase between PD3 
and PD21 (CYP2E1) or between PD5 and PD28 (CYP1A2).  Subsequently, activities 
declined to adult values by puberty with both enzymes (see section 4.1.2.4 for more 
detailed description for the ontogeny of CYP2E1 and CYP1A2 activity).  
 
4.3.4 Correlation between Different Ontogeny Patterns of CYP2E1 and CYP1A2 
Enzymes in Rats 
 
4.3.4.1 CYP Immunoreactive Protein and its mRNA Level 
A poor correlation was observed for CYP2E1.  Although CYP2E1 protein was not 
detected in fetal and PD1 livers, its mRNA was detected.  Postnatally, mRNA levels rose 
rapidly to achieve approximately 1-fold, 3-fold, and 2-fold the adult level at PD10, 
PD14 and PD28, respectively.  On the other hand, CYP2E1 protein levels increased 
slowly from PD3 (25% the adult value) to PD28 (30% the adult value).  After PD28, 
CYP2E1 protein increased progressively to achieve the adult level at PD42 (Figure 
4.22). 
As well, developmental changes in CYP1A2 mRNA expression did not correlate 
with the immunoquantifiable CYP protein, except for the early postnatal period where 
both CYP1A2 protein and its transcript were low and increased gradually (Figure 4.22). 
 
4.3.4.2 CYP Immunoreactive Protein and its Catalytic activity 
For both CYP enzymes, their protein and activity were not detected in fetal and PD1 
livers.  However, dramatic increase in catalytic activity was observed between PD3 and 
PD21 (CYP2E1) or between PD5 and PD28 (CYP1A2) followed by a decline to the 
adult level during puberty.  These dramatic changes in activity were not mirrored by 
changes in protein levels for both enzymes, as mentioned in section 4.2.6 and shown in 
Figure 4.11.   
 
4.3.4.3 CYP mRNA and its Catalytic Activity 
On the other hand when age-dependent changes in CYP enzymes activities were 
compared with changes in mRNA levels obtained from the real-time RT-PCR data, 
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CYP2E1-mediated CZX hydroxylase activity and CYP1A2-mediated MROD activity 
correlated reasonably well with changes in CYP2E1 and CYP1A2 mRNA levels, 
respectively (Figure 4.23). 
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Figure 4.22- Developmental changes in expression of (A) CYP2E1 and (B) CYP1A2 
mRNA, protein and activity levels in rat livers.  All data are expressed as a percentage of 
adult levels. 
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Figure 4.23– Age-dependent changes in CYP enzyme activity (open circle) as a 
function of mRNA levels (closed circle) in rat hepatic microsomes.  (A) Average 
CYP2E1-mediated chlorzoxazone hydroxylase Vmax estimates as a function of average 
CYP2E1 mRNA levels.  (B) Average CYP1A2-mediated methoxyresorufin-O-
dealkylase Vmax estimates as a function of average CYP1A2 protein levels.  mRNA data 
were expressed as (CYP RNA/total RNA) as a ratio to adult values. 
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Although activities were not detected at <PD3, mRNA expression was detected, yet 
very low levels.  Both enzyme activity and mRNA levels increased markedly following 
PD3 to reach maximum levels at PD14 (CYP2E1) or PD28 (CYP1A2) before declining 
to adult values.  While activity levels at early puberty (PD42) were similar to adult 
values, mRNA levels were about 2-fold the adult values for both CYP enzymes (Figure 
4.23). 
 
4.3.5 Ontogeny of Zonal Expression of Rat Hepatic CYP2E1 and CYP1A2  
 
To characterize the age-dependent changes in intrahepatic distribution of CYP2E1 
and CYP1A2 protein I performed an immunohistochemical analysis with polyclonal 
antibody to CYP2E1 and CYP1A2 in gestation age 20, postnatal ages 1, 5, 10, 42 and 
adult livers.  Immunoreactivity in fetal and PD1 livers was homogeneously distributed 
throughout the liver and the intensity of staining appeared similar regardless of the 
intralobular location of the hepatocyte (Figures 4.24 A-B and 4.25 A-B).  At postnatal 
days 5 (only for CYP2E1) and 10 immunostaining showed slightly greater intensity in 
the perivenous hepatocytes (Figures 4.24 C-D and 4.25 C).  A more distinct loss of 
immunoreactivity was observed in periportal hepatocytes at postnatal day 42 (Figures 
4.24 E and 4.25 D).  In adult liver, immunoreactivity is focally distributed in the 
perivenous hepatocytes with almost no staining in the periportal region (Figures 4.24 F 
and 4.25 E). 
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Figure 4.24 – Immunohistochemical localization of CYP2E1 in representative rat livers 
from (A) fetus; (B) postnatal day 1; (C) postnatal day 5; (D) postnatal day 10 (late neonatal); 
(E) postnatal day 42 (early puberty); and (F) adult.  In fetal and neonatal livers, hepatocytes 
throughout the entire hepatic acini exhibit staining.  Increasingly more intense staining is 
observed in the perivenous hepatocytes in the livers from postnatal day 42 rats with very 
intense staining in perivenous hepatocytes and almost negative staining in the periportal 
hepatocytes in the adult.  (PV = perivenous; PP =periportal.). Scale Bar, 100 μm. 
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Figure 4.25 – Immunohistochemical localization of CYP1A2 in representative rat livers 
from (A) fetus; (B) postnatal day 1; (C) postnatal day 10; (D) postnatal day 42 (early 
puberty); and (E) adult.  In fetal and neonatal livers, hepatocytes throughout the entire 
hepatic acini exhibit staining.  Increasingly more intense staining is observed in the 
perivenous hepatocytes in the livers from postnatal day 42 rats with very intense staining in 
perivenous hepatocytes and almost negative staining in the periportal hepatocytes in the 
adult.  (PV = perivenous; PP =periportal.).  Scale Bar, 100 μm. 
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4.3.6 Ontogeny of Rat Hepatic Glutathione-S-Transferase (GST) Activity  
To determine the age-dependent changes in GST activity in rat livers, cytosolic 
protein content (mg/gram liver) was determined and the cytosolic GST activity was 
assessed spectrophotometrically using a GST general probe substrate. 
 
4.3.6.1 Age-Dependent Changes in Cytosolic Protein Content  
 
Hepatic cytosolic protein content for each age group (n = 4) was measured by the 
method of Lowry et al 270.  The results shown in Figure 4.26 indicate that average 
cytosolic protein content (mg/gram liver weight) was low at birth (30 % of the adult 
value, P<0.05) and increased gradually to puberty (63 days) where it was 50 % of the 
adult value, P<0.05. 
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Figure 4.26 – Mean (± SD) hepatic cytosolic protein content in male Sprague-Dawley 
rats (n=4). Asterisks indicate statistical difference from adult (112 days), P<0.05. F= 
gestation day 20.  
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4.3.6.2 Age-Dependent Changes in Total Cytosolic GST Activity 
 
Liver cytosolic GST activity was determined using the general substrate 1-chloro-
2,4-dinitrobenzene (CDNB).  As shown in Figure 4.22, general GST activity was 
detected at gestational age 20, (10% of the adult value; P<0.05), and increased gradually 
until PD21 where activity was about ten fold the fetal value.  By PD28 general GST 
activity reached adult values. 
 
 
 
Figure 4.27 –Age-related changes in hepatic cytosolic GST activity. The activity was 
monitored by spectrophotometric analysis of glutathione conjugation of 1-chloro-2,4-
dinitrobenzene, a general GST probe substrate.  Data are expressed as mean ± SD of the 
hepatic GST activity of 4 animals.  Fetal livers were pooled from 3 different dams. The 
asterisks refer to those age groups that show significant difference from adult. 
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5. DISCUSSION 
5.1. Evaluation of the Assumptions of an Ontogeny Model of CYP Enzyme Activity 
 
5.1.1 Development and Relevance of the Model 
Breastfeeding is the most significant route of exposing the developing infant to a 
wide variety of drugs and environmental toxicants16,30,47.  Most of the commonly used 
exposure risk assessment approaches usually underestimate the toxicity risk to the 
exposed infant because these approaches consider mainly the amount of exposure dose 
in breast milk and ignore the contribution of infant pharmacokinetics in determining the 
exposure outcome on the child16,43,47-49.  Early life stages exhibit significant and dynamic 
developmental changes in the physiological and biochemical processes that govern the 
pharmacokinetics and pharmacodynamics of xenobiotics and such changes can 
significantly affect the toxicological outcome of an exposure44,221.  However, only 
recently have efforts intensified to enhance our understanding of age-related changes in 
pharmacokinetic processes.  Databases containing paediatric clinical pharmacokinetic 
data are in development to provide relevant information for more successful adult-to-
infant extrapolation of therapeutic compounds and applicable toxicants224,281.  
Furthermore, physiologically based pharmacokinetic models are improving the 
extrapolation of animal developmental toxicology data for human paediatric risk 
assessments223,282, which is particularly important for those toxicants for which no 
human data are available. 
Although the general lack of information regarding paediatric pharmacokinetics 
compels the use of toxicological information available from adult populations221,224 or 
animal developmental toxicology studies282,283, both adult-to-infant and animal-to-
human extrapolations can lead to under- or overestimations of exposure risk in 
paediatric populations222,284.  An alternative approach is to use pharmacokinetic models 
that are based upon relevant biochemical and physiological data from paediatric 
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populations.  These models offer the promise to provide more quantitative predictions of 
internal dosemetrics (i.e. steady state plasma concentration, area-under-the-plasma 
concentration vs. time-curve) and the potential for toxicity.  Such models, then, may 
provide critical information for use in risk/benefit assessments of the safety of 
breastfeeding during maternal therapy or following exposure of the nursing mother to 
environmental toxicants.  
Several modeling approaches have been proposed using either human clinical or 
animal data221,222,224,235.  In our laboratory, a general mathematical model describing the 
ontogeny of hepatic CYP enzyme-mediated elimination in the first 6 months of age was 
developed and applied to predict infant metabolic clearance77.  The model involves an in 
vitro-in vivo extrapolation of CYP enzyme activity data from age-specific human hepatic 
microsomes using CYP-specific probe substrates (see Appendix I for the theoretical 
framework of the model).  The model enables prediction of age and CYP-specific infant 
scaling factors (ISF) that correlate adult intrinsic clearance with the ability of the infant 
to eliminate drugs by CYP pathways (Equations 1.15 and 1.16).  Accordingly, this 
model could be a promising approach to provide appropriate assessments of the 
toxicological risk to infants following exposure to toxicants that undergo CYP-mediated 
bioactivation or detoxification.  
Application of this model requires an evaluation of its underlying assumptions and 
its ability to make robust predictions of infant metabolic clearance. Given the 
logistic/ethical boundaries of obtaining in vitro/in vivo metabolism data in human 
infants60,285, the rat was used as an animal model system to evaluate the model’s 
assumptions.  I used the rat because this species shows sufficient similarities to humans 
regarding developmental physiology (i.e. liver development), enzymology and 
molecular mechanisms of drug metabolism1,96,259.  As well, the rat is the most widely 
studied model in preclinical and toxicology studies when initial information regarding 
drug metabolism in humans is required1,116,261,262.  Accordingly, its shortcomings are 
highly understood and characterized. 
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5.1.2 Developmental Changes in Hepatic Scaling Factors (HSF) 
Extrapolation of the in vitro metabolism data to the in vivo situation is based on the 
use of the parameter, intrinsic clearance (Clint).  This parameter is a pure measurement of 
the enzyme activity towards a substrate without influence of the other physiological 
determinants of hepatic clearance, hepatic blood flow and drug binding within the 
blood225.  In vitro/in vivo extrapolation of intrinsic clearance (Clint) is achieved when 
appropriate hepatic scaling factors (HSF) are applied (Appendix I).  HSF (mg 
microsomal protein per g body weight) accounts for the contribution of hepatic 
microsomal protein content (MP) and liver weight (LW) normalized to body weight 
(BW) to the metabolic function of the whole liver (Equation 3.3). 
In the human CYP ontogeny model (see Appendix I), literature data of age-
dependent changes in human LW and BW were obtained and used to develop an 
empirical equation describing the developmental changes in LW and BW from birth to 
the first year of life (Equation 11, Appendix I).  However, due to the limited information 
about age-dependent changes in MP, it was assumed that microsomal protein content 
(mg/g liver) remains constant throughout postnatal maturation77.  Accordingly, an adult 
human value of 52.2 mg/g liver258 was used as MP value for all infant age groups.  By 
assuming constant MP value in building the general model of CYP ontogeny, any 
change in HSF (t) will be solely due to the developmental changes in LW normalized to 
BW (Equation 3.3).  
 
5.1.2.1 Developmental Changes in Microsomal Protein Content (MP) in Rat 
Livers 
In my attempt to evaluate this assumption, hepatic MP was determined in age-
specific rat hepatic microsomes.  Results shown in Figure 4.2 reveal that rat hepatic 
microsomal protein content was significantly lower in fetal (20% the adult value) and 
early neonatal (25-60% the adult value) livers and continued to increase until reaching 
the adult value at postnatal day 7 (PD7) with the maximum value obtained at the onset 
of puberty (PD42) (125 % the adult value).  Several studies have reported developmental 
changes in rat hepatic MP content, but these studies were conducted using a limited 
number of liver samples or age groups that do not cover all developmental stages in 
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rats95,115,286,287.  The observed MP data in my study are in agreement with the MP results 
reported in similar age groups used in these studies.  
To my knowledge, there are few data reporting developmental changes of MP 
content in human.  Most of the reported studies were conducted in adult human (35-75 
years) hepatic microsomes.  While these reports show that hepatic concentration of 
microsomal protein remained virtually unchanged, they also show significant 
interindividual variability288-290 as well as gender differences289.  Other studies reported 
adult values of 45 mg/g252, 53 mg/g258, 77 mg/g291, or 27-108 mg/g290 for MP content in 
human.  These studies determined MP content from a limited number of liver samples 
(3-20 livers) with some studies using samples from patients with liver cancer.  
Generally, this significant interindividual variability could have implications for the 
accurate extrapolation of in vitro data on drug metabolism to predict in vivo metabolic 
clearance.  However, a recent article using hepatic microsomes from 38 liver donors 
proved that microsomal scaling factor from human livers to be a robust method and 
recommended the use of a microsomal scaling value of 40 mg of microsomal protein per 
gram of liver as a generic value for predicting in vivo drug metabolic clearance from in 
vitro human hepatic microsomal data292. 
Whether such changes in rat hepatic MP content can be extrapolated to human 
development is unknown, but compared to human, rats exhibit important differences in 
biogenesis of the endoplasmic reticulum (ER) and hepatocellular differentiation during 
development293-295. Liver parenchymal cells during late gestation and early neonatal 
stages in rats contain predominantly rough ER294.  The total amount of ER per cell 
increases between 3 days before birth and birth where rough ER remains predominant294.   
Smooth ER becomes a quantitatively significant component only a few days after 
birth293,294.  Such developmental changes in hepatocellular content of smooth ER may 
explain the age-related changes in MP in rats.  
 
5.1.2.2 Developmental Changes in Rat Liver Weight (LW) and Body Weight 
(BW) 
An examination of the developmental changes in the ratio of liver weight to body 
weight reveals that this ratio remains relatively constant throughout rat postnatal 
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development (Figure 4.1).  This suggests the age-dependent changes in HSF (Figure 4.3) 
are primarily a function of developmental changes in MP content.  The similarity 
observed between the developmental profiles of MP and HSF confirms this assertion 
(Figures 4.2 and 4.3, respectively). 
 
5.1.2.3 Consequences on the Model 
While the above observations demonstrate a relatively constant (LW/BW) ratio 
throughout development, they show developmental changes in MP with significantly 
low values at early postnatal stages compared to adult.  Although these findings 
contradict one of the assumptions of the ontogeny model of CYP enzyme activity, this 
contradiction does not necessarily weaken the potential value of the model.  These 
results merely suggest the need to measure hepatic microsomal protein content in 
paediatric livers to incorporate age-dependent changes in hepatic microsomal protein 
content in the modeling process to provide predictive estimates of the ISF values. 
 
5.1.3 Developmental Changes in Metabolic Intrinsic Clearance (Clint) 
Application of the ontogeny model is limited only to low hepatic clearance drugs 
where systemic clearance is principally a function of hepatic enzyme activity and the 
unbound fraction, and not hepatic blood flow (Equation 1.10).  As well, the model 
assumes that efflux and uptake transporters do not contribute significantly to the 
intrinsic clearance (Clint) of the compound.  Transport processes can markedly influence 
Clint and act as the rate limiting process of metabolic clearance296-298.  At present, the 
model may provide predictions for a wide variety of low clearance compounds when 
their systemic clearance is not affected by transport processes.  However, the model can 
accommodate the contribution of transport processes other than passive diffusion and 
future investigations in this laboratory are planned to address this issue.   
CYP2E1 and CYP1A2 were selected to evaluate the model assumptions due to the 
following reasons: 
1. Each enzyme demonstrates markedly different ontogeny patterns44.  This will 
enable the recognition of critical model elements that are necessary to improve 
the general ontogeny model of CYP-mediated hepatic clearance. 
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2. Reasonable predictions made for these two CYP enzymes, with different 
developmental patterns, may indicate the potential ability of the model to 
describe the developmental maturation of a wide variety of CYP enzymes. 
3. Both CYP2E1 and CYP1A2 have significant toxicological relevance as they 
mediate bioactivation and/or detoxification of many commonly used 
therapeutic drugs and environmental toxicants and procarcinogens100. 
Consequently, developmental changes in the activity of these enzymes could 
have profound and age-dependent effects on the ultimate toxicological 
outcome of xenobiotic exposures. 
Considering the genetically similar complement of hepatic CYP enzymes between 
infant and adults, a basic underlying model assumption is that affinity for a substrate for 
a given CYP enzyme should not be different between infant and adults for the specific 
enzyme-substrate pair77.  Affinity, in this context, refers to the specific affinity between 
an enzyme and substrate pair in the absence of factors that may influence the apparent 
affinity of a compound, i.e. non-specific binding and contribution of other enzymes to 
the reaction pathway252.  Accordingly, the developmental differences in maturation of 
the specific CYP enzyme activity exclusively determines the age-dependent differences 
in Clint )
K
V
(
M
max
, i.e. substrate affinity (KM) for the enzyme remains constant during 
postnatal development and the developmental changes in Clint is only due to changes in 
functional enzyme activity (Vmax). 
 
5.1.3.1 Developmental Changes in Substrate Affinity (KM) 
  To evaluate the critical assumption of constant KM  values during development, 
probe substrates for CYP2E1 and CYP1A2 were selected with low hepatic extraction 
ratios and hepatic intrinsic clearances180,272,280.  Additionally, no reports are available to 
indicate that uptake or efflux transporters can affect hepatic intrinsic clearance of these 
compounds.  Upon examination of the developmental changes in KM values of CYP2E1-
mediated CZX hydroxylation and CYP1A2-mediated MROD activities, lower values for 
CYP2E1 and higher values for CYP1A2 were observed in postnatal ages < 7 days 
compared to adult (Figure 4.7).  
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Due to the limited human and rat data, it is difficult to confirm whether such 
developmental changes in KM values occur during human neonatal development.  One 
study133 reported a 50% KM value for CYP2E1-mediated CZX hydroxylation in adult 
human hepatic microsomes compared to newborns.  Also some studies reported different 
KM values in microsomes prepared from livers in neonates relative to adult liver 
microsomes for other substrates156,272,299.  Although I did not conduct further 
investigations to explain the age-dependent differences in the apparent KM values, three 
possible explanations could be suggested.  These include inefficient probe substrate 
specificity, non-specific protein binding in hepatic microsomes, and age-related changes 
in microsomal membrane composition. 
 
5.1.3.1.1 Inefficient probe substrate specificity 
 Enzyme kinetic parameters were estimated using accepted probe substrates and age-
dependent rat hepatic microsomes.  This in vitro system consists of heterogeneous 
population of CYP enzymes.  No single probe substrate is 100% specific for a particular 
CYP of interest, and the contribution of other CYP enzymes to a reaction pathway is 
very possible280,300.  Consequently, the measured KM value is in fact the apparent KM, a 
hybrid value that takes into account the contribution of all enzymes in the particular 
reaction pathway, and not the KM value for a specific CYP enzyme-substrate pair.  
Depending upon their relative contributions and affinities for the substrate and stage of 
development, other CYP enzymes could markedly impact apparent KM values301.  
Specificity for all CYP probe substrates has been established using adult hepatic 
microsomes. Studies have documented that most probe substrates can be selective for 
the enzyme of interest but are not 100% specific280,300.  Although CYP2E1 contributes 
extensively to the metabolism of both chlorzoxazone (CZX) and ρ-nitrophenol (PNP), 
CYP1A2, CYP2C11, CYP3A1 and CYP3A2 also contribute to some extent280.  
Furthermore, the CYP1A2 probe substrates, ethoxyresorufin and phenacetin, undergo 
extensive metabolism by CYP1A2, but with minor contributions from CYP2C6, 
CYP2C11, CYP2E1, CYP3A1 and CYP3A2280.  While these studies show a major 
contribution from one particular pathway (e.g. CYP2E1 or CYP1A2) and minor 
contributions from others, these results were observed in adult hepatic microsomes, a 
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situation that may be significantly different from neonatal microsomes.  Since most CYP 
enzymes undergo different rates and patterns of maturation towards adulthood114,268, the 
major elimination pathway observed in adult livers can be functionally immature in the 
developing infant.  Consequently, the minor contributing pathways seen in adult may 
contribute significantly to substrate elimination in the developing infant77.  Some of 
these CYP pathways, especially CYP3A1 and CYP3A2, are expressed during 
gestational stages in rats and increase dramatically after birth, whereas activities of 
CYP2E1 and CYP1A2 are either undetected or very low1.  Eadie-Hofstee plots (Figures 
4.12 and 4.13) gave clear evidence of a deviation from a single site Michaelis-Menten 
model for chlorzoxazone hydroxylation and MROD activity, which may indicate the 
possible contribution of other CYP enzyme(s), in addition to CYP2E1 and CYP1A2, 
respectively.  
 
5.1.3.1.2 Non-specific protein binding in hepatic microsomes 
The apparent KM value can be significantly affected by developmental changes in 
non-specific protein binding of drug substrate in the hepatic microsomal system, which 
affects the unbound, free fraction (fu,mic) that is available to interact with the enzyme of 
interest252,302.  Michaelis-Menten (MM) kinetics assumes that all substrate available in 
the system is in the unbound form, and parameter estimates are generated assuming that 
all substrate is freely available to the enzyme active site303.  Many substrates violate this 
assumption, and for some substrates, non-specific binding is extensive251,252. 
Furthermore, the extent of non-specific binding and its influence on the apparent KM 
value has never been assessed in paediatric hepatic microsomes.  
The degree to which non-specific protein binding influences the M-M parameter 
estimates depends upon the amount of protein in the system304.  At equilibrium and with 
non-saturable binding, Equation 5.1 describes the relationship between the microsomal 
free fraction (fu,mic), the dissociation constant (Kd), and the concentration of microsomal 
protein binding component [B]301,304 
         
dK[B]
dK
 mic u,f +=                               (5.1) 
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Assuming age-dependent changes in hepatic microsomal protein components 
responsible for non-specific binding and using Equation 5.1 to define the ratio of free 
fractions expected at two different developmental stages with different concentrations of 
non-specific binding components, the fraction unbound is expected to be constant only 
when the concentrations of the binding components are similar between ages or much 
less than Kd301. The apparent KM (KM, app) will be influenced by the degree of non-
specific binding in a manner shown in Equation 5.2. 
 
micu,
M
app M, f
KK =                         (5.2) 
 
Assuming different concentrations of non-specific binding components with 
development, the apparent KM value is expected to be similar between different age 
groups only when the concentration of microsomal protein binding components are 
similar or much less than Kd301.  On the other hand, if the concentrations of these 
components are much greater than Kd, a proportional relationship is expected between 
the apparent KM and concurrent changes in protein concentration301. 
In light of my own data, an age-dependent difference in the extent of non-specific 
binding is possible.  Total hepatic microsomal protein (MP), which constitutes a 
heterogeneous population of proteins to which CYP substrates can bind specifically 
and/or non-specifically, shows age-dependent changes (Figure 4.2).  Accordingly, age-
dependent differences in the extent of non-specific binding is possible.  Total CYP 
protein content constitutes a major component of the microsomal fraction and provides 
both specific and non-specific binding sites for CYP substrates100.  My results, shown in 
Figure 4.4, indicate that total CYP protein undergoes developmental changes with age. 
This observation is supported by many studies that report age-dependent changes in total 
hepatic microsomal CYP content in rats95,114,115,286 and humans93,166,108.  Such changes 
can lead to variations in the extent of non-specific binding with age and could 
significantly affect the apparent KM value during development. 
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5.1.3.1.3 Microsomal membrane composition 
One last possible reason for the observed age-dependent changes in the 
experimentally determined KM values may relate to age-related changes in the 
phospholipid composition of the microsomal membrane293,294.  The apparent viscosity of 
the microsomal membrane is much higher in fetal and newborn livers than in adult livers 
due to changes in phospholipid/cholesterol molar ratios305,306.  Endogenous 
glucocorticoids were found to play a major role in this phenomenon through their effect 
on the unstauration of microsomal fatty acids leading to increasing microsomal 
membrane fluidity in the perinatal period305,306.  This can modify the catalytic efficiency 
of CYP enzymes either directly, through changing the conformation of the CYP protein, 
or indirectly, by improving substrate accessibility to the enzyme active site or by 
increasing the rate of electron transfer from NADPH-cytochrome P450 reductase to the 
CYP enzyme active site242. 
 Such uncertainty regarding the developmental changes in KM values needs further 
investigation.  The use of cDNA-expressed CYP enzymes both singly or mixed in 
proportions similar to those of CYP enzymes in hepatic microsomes at different age 
groups may facilitate the assessment of the contribution of different CYP isoforms to the 
estimated KM value at a given age280,307.  Furthermore, the influence of non-specific 
protein binding on the experimentally estimated KM values can be assessed by 
determining the apparent KM value at different microsomal protein concentrations.  A 
proportional change in the KM value with a change in microsomal concentration 
indicates that the substrate has high protein binding capacity and non-specific binding 
may have a significant effect on the estimated KM value.   
 
5.1.3.2 Developmental Changes in Functional Enzyme Activity (Vmax) and 
Correlation to Functional CYP Protein. 
To monitor the ontogeny of the catalytically active CYP2E1 and CYP1A2 enzymes 
in rats, in vitro CZX hydroxylation and methoxyresorufin-O-delkylation (MROD) 
activities were monitored, respectively (Figure 4.8).  For both CYP enzymes, activity 
was not detected in the perinatal period.  Postnatally, enzyme activity was significantly 
lower than adult levels and steadily increased after postnatal day 5 (PD5) to reach 
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maximum levels prior to (CYP2E1) or during (CYP1A2) the weaning period (PD21-28), 
where the activity was significantly higher than the adult level.  While the obtained Vmax 
values are markedly higher than few reported studies180,182,274, the ontogeny profiles for 
CZX hydroxylation and MROD activities demonstrate similar patterns with these 
studies, even though they utilized few developmental ages1,308.  The pattern of changes 
in Vmax values is most critical since all Vmax values are normalized to adult values for the 
purpose of the model. 
The observed surge in CYP2E1 activity before the weaning period and the peak in 
CYP1A2 activity around the time of weaning is probably regulated by endogenous 
hormones (e.g. growth hormone and thyroxin) that are involved in the weaning 
process125,183.  Also this weaning-related surge in activity may be an adaptation to 
ingestion of solid food and exposure to different xenobiotics that could affect the 
endogenous hormones levels and consequently alter CYP expression125,245.  However, 
these observed developmental changes in functional enzyme activity could also be due 
to one or more of the aforementioned reasons in section 5.1.3.1.  For example, 
inefficient probe substrate specificity means that the observed activity could be a hybrid 
function of the CYP enzyme of interest (e.g. CYP2E1 or CYP1A2) in addition to one or 
more CYP enzymes that contribute to some extent in the metabolic reaction under 
investigation.  This is more prominent in hepatic microsomes from younger ages where 
the major CYP pathway is immature or underdeveloped leading to considerable 
contributions from other CYP pathways that play only a minor role in adult hepatic 
microsomes. Since these CYP enzymes have different onsets and patterns of 
development44, their influence on the observed changes in functional enzyme activity 
could be significant. 
The profiles of developmental changes in catalytic activity of each CYP enzyme 
were correlated to its specific immunoreactive protein level at each age to assess the 
proportional relationship between enzyme activity (Vmax) and its functional protein level 
(one of the major assumptions of the general ontogeny model and a basic assumption of 
the MM equation)303.  However, my results show that developmental changes in Vmax 
did not completely parallel the biphasic patterns observed with its respective CYP 
protein level (Figure 4.11).  Although some human CYP enzymes (e.g. CYP2E1, 
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CYP1A2 and CYP2D6) show a reasonable correlation between the maturation of CYP 
activity and CYP protein level133,165,242, other CYP enzymes (e.g. CYP3A and CYP2C) 
demonstrate a discordance93,241.  
Before I go further and discuss these unexpected findings, recall that the model 
assumes a proportional relationship between enzyme activity and functional protein 
level. Accordingly, evaluation of this assumption requires: 
1. Measurement of the developmental changes in CYP activity using a specific 
probe substrate for this particular CYP enzyme. 
2. Monitoring the developmental changes in the functional protein level of that 
CYP enzyme.                                                                                                               
As discussed previously, one may question the substrate specificity of the probe 
substrates (i.e. not 100% specific)280,300.  Furthermore, quantitative immunoblotting 
techniques using CYP-specific antibodies do not differentiate functional from non-
functional CYP protein.  Therefore, the observed discordance between CYP enzyme 
activity and its protein level could be attributed to two main reasons: 
1. During the early postnatal period, discordance may be due to the contribution of 
other CYP enzymes whose development precedes CYP2E1 or CYP1A2 pattern 
of development and contributes significantly to probe substrate metabolism at 
particular postnatal ages.  For example CYP3A1 is involved in the hydroxylation 
of CZX280.  This enzyme is well expressed in rat fetal livers, whereas CYP2E1 
activity is not detected1.  CZX hydroxylase activity in the early neonatal period 
may reflect CYP3A1 (and others) activity rather than solely CYP2E1. 
Consequently, a poor correlation between CZX hydroxylase activity and 
CYP2E1 protein level could be expected during early stages of development. 
2. During the neonatal, weaning and post weaning periods, discordance may be due 
to posttranslational mechanisms that markedly influence enzyme activity during 
development.  Posttranslational modification of CYP proteins may diminish or 
inactivate its catalytic activity.  For example, protein phosphorylation may 
rapidly inactivate CYP2B and CYP2E1 enzymes309,310.  The decline in CYP 
enzyme activity relative to the increase in CYP content at or after weaning may 
be due to the possible accumulation of non-functional protein.  
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Interestingly, a recent study reported a model of CYP2E1 ontogeny in human liver 
microsomes based upon evaluations of CYP2E1 protein content with immunoblotting 
techniques311.  My data questions the potential application of models that are developed 
to predict in vivo intrinsic clearance of CYP substrates based on human CYP protein 
levels311, rather than CYP probe substrate activity.  Hence, immunodetectable protein 
levels may not act as a suitable surrogate to CYP enzyme activity when specific probe 
substrates are not available.  
 
5.1.3.3 Consequences on the Model  
As mentioned in sections 5.1.3.1 and 5.1.3.2, significant changes were observed in 
KM and Vmax values during development. Although the first observation (developmental 
changes in KM values) seems inconsistent with the model’s assumption, it suggests a 
need to incorporate developmental changes in KM (j) estimates in the model building 
process (i.e. model the Vmax/KM ratio) instead of modeling only changes in Vmax (j).  The 
incorporation of a new parameter, which undergoes interindividual variability during 
development, will increase the model’s complexity and possibly result in greater 
uncertainty in its parameter estimates. 
 
5.1.4 Correlation between CYP Enzyme Activity Levels Determined Using Two 
Probe Substrates 
My findings, on the other hand, have satisfied another critical assumption of our 
CYP ontogeny model.  The developmental changes in CYP enzyme activity using one 
specific substrate was found to correlate well with changes in activity using a second, 
somewhat less specific substrate (Figures 4.9 and 4.10).  Some minor differences were 
observed, especially in the detection of enzyme activity in fetal and early neonatal stages 
using the second probe substrate.  This may suggest the contribution of other CYP 
enzymes that express relatively significant activity in the early neonatal period relative 
to CYP2E1 and CYP1A2 enzymes280.  Such similarity between different substrates for 
the same CYP enzyme indicates that the model can be applied generally to all substrates 
of the CYP enzyme of interest. 
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5.1.5 Conclusion 
The general ontogeny model of human CYP enzyme activity is a promising risk 
assessment tool for pediatric populations, particularly following exposures to 
xenobiotics in breast milk.  In my attempt to evaluate its underlying assumptions, I 
recognized potentially important discrepancies with the stated assumptions.  Microsomal 
protein (MP) content may not remain constant with development, which will require 
incorporation of age-related changes in MP content into the model building process. 
Changes in KM values during early postnatal development may reflect lack of probe 
substrate specificity or changes in non-specific binding to microsomal components 
during CYP enzyme ontogeny, rather than age-dependent changes in the inherent 
properties of substrate-CYP enzyme interactions.  Further assessments of probe substrate 
specificity and KM evaluations are required for further evaluation of the model 
assumptions.  Postnatal increases in Vmax occur for both CYP2E1 and CYP1A2, with 
maximal activity prior to or at weaning stage, respectively.  The activity of one substrate 
seems to correlate with the level of activity of a second substrate of the CYP enzyme.  
However, a poor correlation was observed between catalytic activity and protein level of 
the tested CYP enzymes during development, and further investigations are needed to 
explain this discordant development.  
Until further investigations provide appropriate explanations for these discrepancies 
that dispute the validity of the model, one can not dismiss the potential value of the CYP 
ontogeny model as a potential risk assessment tool.  As a proof of concept, Section 5.2 
discusses the ability of the model to predict in vivo oral clearance of a specific CYP2E1 
substrate, CZX, in rats. 
 
 
5.2. Development of a Pharmacokinetic Model of Rat CYP2E1 and CYP1A2 
Ontogeny  
Despite the documented similarities between rats and humans concerning the 
biochemistry and enzymology of CYP2E1 and CYP1A22,312, comparison of the 
developmental changes in ISF estimates between the rat (Figure 4.14) and human77 
reveals important differences in the onset, rate and pattern of maturation of CYP 
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activity.  These differences in developmental ISF profiles indicate species differences in 
CYP regulation with development and this information should be carefully considered 
when extrapolating rat toxicokinetic information to human paediatric populations. Due 
to their significant role in mediating bioactivation or elimination of xenobiotics, 
developmental maturation of CYP enzymes may determine the toxicological outcome 
following exposure to xenobiotics. Accordingly, different ontogeny patterns of CYP 
activity between rats and human could result in different toxicological responses to the 
same xenobiotic during development. Such differences in developmental patterns 
necessitate the development of an unique model that describes the ontogeny of CYP 
enzymes in rats.  
To develop a model describing the ontogeny of CYP enzymes in rats, the following 
scaling factors were estimated (see Appendix I and section 3.2.6 for more details): 
1. Hepatic scaling factors (HSF(t)) that account for the contribution of hepatic 
microsomal protein content (MP) and liver weight (LW) normalized to body 
weight (BW) to the metabolic function of the whole liver, Equation 3.3.  
2. Normalization of HSF of a particular developmental age to HSF in adult to 
produce age-specific relative hepatic scaling factor (RHSF(t)) that relates the 
abundance of microsomal protein content per body weight in infant to the 
adult, Equation 3.4. 
3. Ontogeny scaling factors (OSF(t)) were determined by normalizing functional 
enzyme activity (Vmax (t)) observed at a particular age (t) to that observed in the 
adult, Equation 3.5.  Accordingly, OSF represents the elimination capacity of a 
specific enzyme in the infant relative to the adult. 
4. The product of the scaling factors, RHSF(t) and OSF(t), is the age-specific 
infant scaling factor (ISF(t)) that represents the ontogeny of an individual 
functional enzyme relative to the whole body, Equation 3.6, and correlates 
adult in vivo intrinsic clearance due to an individual CYP enzyme to the 
capacity of the infant at age (t) to eliminate drugs by the same metabolic 
pathway, Equation 1.15. 
 The observed ISF(t) values were fit to various models describing the developmental 
maturation of each CYP enzyme using the modeling software GraphPad Prism 4. 
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Modifications to the general human ontogeny model (Equation 1.16) were required to 
describe the age-dependent changes in CYP function from birth to adulthood in rats as 
shown in Equation 4.1. The primary modification included a parameter 
( ISFBurst (e
-k2 (t - lag) -e-k3 (t - lag) ) ) that accounted for an apparent burst of activity (greater 
than the adult value) in the period between weaning and puberty that overlay the general 
exponential increase in activity to some asymptotic level reached at adulthood [(ISFD (1 
- e-kt))].  
 While the visual inspection of the fitted non-linear regression lines shows adequate 
fits (Figure 4.15), the parameter estimates (Table 4.5) are associated with wide 
confidence intervals around the estimates.  This may be due to the limited number of 
data points (average of 4 at 12 developmental ages) and the need for a more complex 
equation to describe the data.  
The primary importance of establishing a PK model of the ontogenesis of rat CYP 
activity is to 1) provide a proof-of-concept that a model can be established based on 
appropriate in vitro data to make reasonable predictions of CYP-mediated intrinsic 
clearance and 2) allow predictions of internal dosimetry metrics (i.e. steady-state plasma 
concentrations, AUC) at different developmental rat stages for developmental 
toxicology studies and extrapolation to humans. The model was tested for its ability to 
provide a priori predictions of chlorzoxazone (CZX) oral clearance in male Sprague-
Dawley rats.  Chlorzoxazone is a probe substrate commonly used to monitor CYP2E1 
activity in vivo3,123.  Although the original model predicts a systemic clearance, 
chlorzoxazone was administered orally for the following reasons:  
1. Oral ingestion is the most common route of exposure in infants (e.g. 
breastfeeding).  
2. In toxicology studies, test compounds are usually administered to animals orally 
in solutions or suspensions. 
3. Oral bioavailability (F) of CZX is high278,313. 
 4. Difficulty of CZX administration by IV route to rat pups.  Attempts to administer 
CZX by intracardiac administration resulted in a mortality rate > 50% following 
injection.  
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Table 4.6 shows the age-dependent changes in pharmacokinetic parameters of CZX 
in rats.  The table demonstrates similar elimination rate constant (λz) values between the 
different ages, while different values were observed for maximum serum concentration 
(Cmax) and area under serum concentration time curve (AUC).  One would expect age-
dependent changes in the λz values, since changes in Vmax (or ISF) values were observed 
with development.  The age-related changes in Cmax and AUC in conjunction with the 
similar λz values may suggest age-dependent changes in the oral bioavailability of CZX.  
Also, while the table shows similar elimination rate constants across all tested ages, 
dramatic developmental changes in ISF and oral clearance estimates were observed. 
Since the elimination rate constant is a hybrid function of systemic clearance and 
volume of distribution, these observations may be the result of developmental changes in 
body composition (e.g. water content, lipid content) and extent of tissue and protein 
binding, which can induce age-dependent changes in CZX volume of distribution. 
Comparison of the predicted and observed oral clearance (Figure 4.17) indicates that the 
model reasonably predicted CZX oral clearance values at all tested postnatal ages with 
the poorest prediction observed at juvenile and adult stages where the predicted values 
were 3- and 3.5-fold the observed values, respectively.  Predicted oral clearance values 
at other ages were within 2-fold the observed values. 
 The two most commonly used approaches to predict clearance in neonates are 
physiologically based pharmacokinetic (PBPK) modeling and allometric scaling78,235,250. 
Compared to our pharmacokinetic model of CYP ontogeny, PBPK models require 
estimation of age-dependent changes in drug absorption, elimination capacity, plasma 
protein binding, physiological characteristics of the subject and physicochemical 
parameters of the drug under investigation78.  Accordingly, generation and validation of 
a PBPK model is resource and time intensive.  However, when these data are available 
this approach can provide reasonable predictions of systemic clearance78,257.  Although 
our general ontogeny model does not account for age-related changes in body 
composition and extent of protein and tissue binding, it can be incorporated into these 
PBPK models as it provides essential information regarding the developmental changes 
in CYP activity.  
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The second approach of predicting systemic clearance is allometric scaling235,250. 
However, this is an empirical approach that does not provide physiological relevance 
and usually fails to make adequate predictions for low and intermediate hepatic 
extraction ratio drugs235.  Since CYP enzymes undergo a developmental maturation, 
many substrates are likely to exhibit low hepatic extractions during early postnatal 
development despite their possible intermediate to high extraction ratios in the adult250. 
Accordingly, allometric scaling may not be a suitable approach to predict drug clearance 
in neonatal populations. 
A principal goal of our ontogeny model of CYP enzyme activity is to provide risk-
relevant information regarding the potential for toxicity in paediatric populations 
following exposure to toxicants, especially from breast milk.  Evaluation of exposure 
risks requires knowledge of the developmental window of susceptibility (the onset of 
toxicodynamic processes that lead to toxicity), the internal biologically effective dose 
(tissue dosimetry) that occurs during that window and dose-response behavior within 
that window229.  Due to the difference in timing of birth across species in relation to the 
development of organs and physiological systems, often differences exist in the 
pharmacokinetics that occur during the relevant developmental period in each species229. 
Such differences may create difficulties in relating rodent critical developmental 
stages to human stages.  However, our ontogeny model may still make predictions of 
internal dosimetry following a given toxic dose during the exposure period (e.g. in utero 
exposure, postlactational exposure), which may help to further explain dose-response 
behavior and age-related changes in susceptibility to toxicity. 
Due to age-dependent changes in pharmacokinetic processes314, the same dose/kg 
body weight may result in different values for internal dosimetry metrics at different 
developmental stages and, therefore, different risks of toxicity.  This illustrates the 
uncertainties associated with extrapolating adult dosimetry estimates to paediatric 
populations, especially in the early neonatal ages where the physiological and 
biochemical changes are rapid and significant224.  As toxicant elimination is a major 
determinant of tissue concentration (tissue dosimetry), a PK model that provides an a 
priori prediction of elimination capacity at different developmental ages is of great 
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significance in defining age-dependent internal doses and correlating that dose to the 
response observed during the exposure period221,224.   
Calculation of the age-dependent changes in internal dosimetry in laboratory animals 
used in pre-clinical and toxicology studies can potentially improve the accuracy of 
estimating the exposure risk in humans315.  Such inter-species extrapolation requires 
estimation of exposure levels that result in a comparable effective internal dosimetric 
value in humans.  Assuming similar toxicodynamic processes between rats and humans, 
a human PBPK model based upon human parameters can be used to simulate an 
exposure level that achieves the same internal dosimetric value as observed in the rat 
(Figure 5.1).   
 
 
 
Figure 5.1- Calculation of a human equivalent exposure dose from laboratory animal 
toxicity data using dosimetry/physiologically based pharmacokinetic (PBPK) models. 
Adapted from reference 315. 
 
This approach has been recommended by Health Canada (HC) and US Environment 
Protection Agency (EPA) to determine internal dose-response relationships in 
calculating target dose levels223.  
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This general PK model of rat CYP enzyme activity ontogeny is an initial proof-of-
concept investigation to demonstrate that an ontogeny model based on a physiologically-
based (PB) ISF can be developed and applied in predicting age-dependent systemic 
clearance due to CYP-mediated metabolism if appropriate in vitro data is available. 
Future investigations with more age groups can increase the reliability of the model. 
A serious limitation of the model is its inability to accommodate those compounds 
whose concentration at the CYP enzyme is controlled by uptake or efflux membrane 
transporters.  Future investigations using primary hepatocytes are required to assess the 
potential role of membrane transport processes during development and incorporate 
them into the model building process to extend the spectrum of model application.  
 
5.3. Characterization of Rat CYP2E1 and CYP1A2 Ontogeny  
 
The lack of pharmacokinetic/toxicokinetic data in paediatric populations represents a 
critical obstacle to accurately assess the pharmacological/toxicological outcome of 
exposure to chemicals, e.g. from breast milk316.  In many cases this risk assessment is 
based upon extrapolation of toxicity data from adult populations to the infant227,234,250. 
However, due to the immature physiological and biochemical processes that determine 
the pharmacokinetics (or toxicokinetics) and pharmacodynamics (or toxicodynamics) of 
toxicants, the developing infant may respond to the toxicant exposure in a different way 
than the adult229,233.  This age-dependent difference in vulnerability to toxicants casts 
serious uncertainties to the simple adult-to-infant extrapolation approach and 
necessitates having toxicokinetic data from paediatric populations221,233.  However, 
obtaining such data from infants is usually associated with numerous ethical and logistic 
limitations60,285.  Extrapolation of developmental toxicity data from animal models to 
human may be an useful approach to elucidate the influence of developmental changes 
in toxicokinetic processes on the susceptibility to toxicity229,233.  
The CYP enzyme system, is considered one of the most critical toxicokinetic 
mechanisms that determine the pharmacological/toxicological outcome following 
exposure to xenobiotics96.  The ontogeny of these enzymes, then, could have a 
significant impact on the age-related differences in susceptibility to toxicity268.  Due to 
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the significant species differences in the rate and pattern of CYP enzymes ontogenesis, 
toxicity outcomes from animal models can not necessarily be extrapolated directly to 
humans110.  However, the limited available information regarding the ontogeny of CYP 
enzymes in human necessitates the use of animal model system for risk extrapolation 
and to identify the toxicokinetic mechanisms of age-related differences in susceptibility 
to toxicity222,283. 
Due to the above mentioned significance of studying the ontogeny of CYP enzymes 
in a relevant animal model, I have extensively characterized the ontogeny of two 
toxicologically significant CYP enzymes (CYP2E1 and CYP1A2)100 in a rat model 
system at the levels of mRNA, protein, catalytic activity and hepatic tissue expression. 
Collectively, this extensive characterization may identify an animal model system of 
human CYP ontogeny that will ultimately have the following benefits: 
1. Identifying a toxicokinetic basis responsible for age-dependent changes in 
susceptibility.  For example, an immature CYP pathway in the developing 
neonate could lead to accumulation and toxicity risk following exposure to a 
toxicant that undergoes elimination/detoxification by that CYP pathway, even 
when the exposure level is very minimal (e.g. with breastfeeding).  No adverse 
effects will be observed in adult after exposure to the same toxicant if that CYP 
pathway is well developed and mature. 
2. This characterization will enhance our understanding of CYP regulation and the 
impact of various endogenous and exogenous factors on CYP enzyme expression 
during maturation317.  Exposure of the fetus or the young neonate to certain 
chemicals can induce permanent alterations in CYP activity (metabolic 
imprinting)223,233.  
3. Comparison of the observed ontogeny patterns in rat to the available ontogeny 
data in humans will assess the appropriateness of the rat as an animal model for 
developmental toxicology studies. 
4. Characterization of the maturation profile of CYP enzymes, that determine 
bioactivation potential and the detoxification capacity of numerous xenobiotics, 
can facilitate prediction of the pharmacological/toxicological outcome of 
xenobiotic exposure during development. 
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The rat was selected because it is often used in developmental toxicology and pre-
clinical studies and demonstrates sufficient similarities to human CYP2E1 and CYP1A2 
enzymes regarding their enzymology and biochemistry2,312,318,319.  In addition to the 
significant similarities in nucleotide sequence between rats and human CYP2E1 and 
CYP1A2 genes2,263, these enzymes catalyze similar reactions and are induced or 
inhibited by similar mechanisms174 in both species.  Consequently, characterization of 
rat CYP2E1 and CYP1A2 ontogeny can facilitate the extrapolation of rat developmental 
toxicology studies using substrates for these enzymes and provide invaluable risk-
relevant information for human paediatric risk assessment316. 
Although both CYP2E1 and CYP1A2 are minimally affected by the sexually 
dimorphic effects of endogenous hormones (e.g. growth hormone)117,118, I chose to limit 
my studies to male rats to accommodate future investigations with CYP enzymes that 
may be affected by such factors.  
 
5.3.1 Ontogeny of mRNA Expression 
5.3.1.1 CYP2E1 
Sparse information is available in the literature on the ontogeny of CYP2E1 mRNA 
in the rat and my results using real-time RT-PCR (Figure 4.22) are consistent with the 
few published reports1,98,115,261.  CYP2E1 mRNA was detected at very low levels in fetal 
and early neonatal livers and elevated levels were detected few days after birth with 
peak levels at PD14 (approximately 3-fold the adult value), then declined to 2-fold the 
adult level at early puberty (PD42).  The mechanism governing this regulation is 
unknown, but changes in the methylation status of certain cytosine residues at the 5’ end 
of the CYP2E1 gene correlate with transcriptional activation of this gene98,264,320.  
Demethylation of these cytosine residues was detected within 24 hours after birth, and at 
one week and ten weeks after birth264.  Whether this demethylation is a result of 
transcriptional activation of the gene or whether demethylation itself causes gene 
expression is not presently known. 
While several studies failed to detect CYP2E1 mRNA in human fetal livers157,321, 
Vieira et al133 reported very low levels in fetal liver samples from late gestation. Similar 
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to the observed significant rise of mRNA in the preweaning period in rats, human 
CYP2E1 mRNA levels significantly rise during the first three months of age and reach 
50% of the adult value in by 3-12 months133.  Unfortunately, mRNA levels were not 
measured in children aged 1-10 years and during puberty and, therefore, it is difficult to 
know exactly when mRNA levels peak before declining to the adult value.  As in rats, 
the methylation status of the CYP2E1 gene has been correlated with transcriptional 
activation133,134. 
 
5.3.1.2 CYP1A2 
The very few literature reports regarding the ontogeny of CYP1A2 mRNA in rats 
could not detect any mRNA levels in fetal and perinatal livers115,157.  Other studies, 
consistent with my findings (Figure 4.22), detected CYP1A2 mRNA from as early as 2 
weeks of gestation or few days prior to parturition followed by a postnatal increase to 
adult levels around weaning age (PD 21-28)1,322,323.  In addition to the role of aryl 
hydrocarbon receptors (AhR) in the inducible expression of CYP1A2, members of the 
nuclear factor 1 (NF-1) family of transcription factors may play an important role in the 
hepatic constitutive expression of the CYP1A2 gene169,170. 
Few studies have reported the ontogeny of human CYP1A2 mRNA expression.  In 
contrast to rats, the available reports suggest the absence of detectable CYP1A2 mRNA 
expression in gestational age from 11 to 24 weeks and low levels were detected at early 
neonatal ages110,111,157,165.  Adult mRNA levels were attained in children aged 1-15 
years110.   
 
Comparison of the results of CYP2E1 and CYP1A2 mRNA ontogeny data in rats 
with those available in humans reveals some similarities between the two species, where 
the transcript is not detected or expressed at a very low level during gestation or early 
neonatal period and undergoes a significant rise during the preweaning (CYP2E1) or late 
weaning (CYP1A2).  The sparse information regarding mRNA ontogeny in human 
during childhood and puberty limits the comparison to rats during these developmental 
stages.   
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5.3.2 Ontogeny of Immunochemical CYP Protein Expression 
5.3.2.1 CYP2E1 
When the immunoreactive protein levels were examined as a function of age, the 
results shown in Figure 4.21 indicate that no CYP2E1 protein was detected in 
microsomes from fetal and PD1 livers.  The immunoreactive protein level in PD3 
hepatic microsomes was very low (less than 25% the adult level), but gradually rose 
with postnatal development.  The protein level did not change significantly between 
PD10 and PD28, but increased progressively thereafter.  My results are in agreement 
with the few studies that examined CYP2E1 protein expression in rats at selected 
developmental ages116,183,261.  However, and inconsistent with my findings, one study 
reported expression of CYP2E1 in rat fetal livers161 and another study reported peak 
CYP2E1 protein levels prior to weaning with adult level achieved after weaning127. 
A similar pattern of rat CYP2E1 protein development was reported in 
humans133,324,311.  As with the rat, human CYP2E1 protein was not detected in fetal liver 
microsomes, but unlike the rat, it rose immediately in the first 24 hours after birth133.  
Postnatally, human CYP2E1 protein levels rose gradually to reach about 30% the adult 
value during the first month, after which it remained almost steady until 12 months133,324. 
Thereafter, CYP2E1 increased progressively133,166,324.  
In contrast to human, rat CYP2E1 mRNA and protein expression increase 
dramatically during the early neonatal period.  Thereafter, developmental changes in 
mRNA did not correlate with the immunoquantifiable protein levels.  In humans, 
changes in CYP2E1 mRNA levels correlate reasonably with protein levels, especially 
after one month of age.  Such data suggests species-differences in CYP2E1 regulation 
during development.  Transcriptional mechanisms may regulate the initial rise in 
CYP2E1 level during the early neonatal period in rats.  However, posttranscriptional 
mechanisms may play a larger role in governing CYP2E1 levels in rats throughout 
postnatal development.  On the other hand, transcriptional mechanisms probably play a 
larger role in governing CYP2E1 level in humans after the first month of life.  Such 
species-differences in CYP2E1 regulation can lead to species-differences in 
susceptibility to toxicants and need further investigations.  
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5.3.2.2 CYP1A2 
When the immunoreactive protein levels were examined as a function of age, the 
results shown in Figure 4.21 indicates that no CYP1A2 protein was detected in 
microsomes from fetal and PD1 livers.  These findings are consistent with some 
studies115,183,322 but inconsistent with one study that reported very low levels of CYP1A2 
protein in PD1 liver, but not in fetal livers1.  The immunoreactive protein level in PD 3 
hepatic microsomes was very low (less than 20% the adult level) but gradually rose with 
postnatal development to reach the adult value at late pubertal age (PD63).  Inconsistent 
with my observations, Johnson et al.183 reported a surge in CYP1A2 protein expression 
at PD21 (5 fold the adult value) followed by a decline to reach the adult value at early 
pubertal age (PD40).  On the other hand, and consistent with my findings, Couroucli et 
al. reported a gradual increase in hepatic CYP1A2 protein levels in rats at postnatal days 
8, 15, 22, and 38323.  
This pattern of steady state increase in CYP1A2 immunoreactive protein is similar to 
my observation with CYP2E1 and to other CYP enzymes in rats1,325.  Interestingly, the 
observed pattern of rat hepatic CYP1A2 protein ontogeny is similar to the reported 
expression pattern in human, where CYP1A2 protein was not detected in fetal and early 
neonatal hepatic microsomes165,243.  During the first month after birth, the protein 
concentration was less than 5% the adult level, but rose slowly during the third month to 
reach only 10% the adult value165,158,243.  A 50% of the adult level was reported in 
infants aged more than one year165. 
Similar to the observed ontogeny patterns for rat CYP2E1 mRNA and protein, 
developmental changes in CYP1A2 mRNA did not correlate with changes in the 
immunoquantifiable CYP1A2 protein levels, except during the early postnatal period. 
This may suggest that CYP1A2 expression is principally determined by transcriptional 
mechanisms, which may be predetermined by the ontogeny pattern of nuclear hormone 
receptors326.  However, posttranscriptional mechanisms likely play a larger role in 
governing CYP1A2 expression in rats throughout postnatal development. In human, the 
very little information regarding the ontogeny of CYP1A2 mRNA makes it difficult to 
postulate the regulatory mechanisms governing the ontogeny of human CYP1A2. 
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In light of my results with rats and the available human data, a reasonable similarity 
was observed as the immunoreactive CYP protein levels showed a similar biphasic 
pattern in both species.  Such findings can support the suitability of rats as a model to 
describe the ontogeny of human CYP2E1 and CYP1A2 proteins.  The absence of 
immunoreactive CYP2E1 protein in fetal microsomes and its immediate surge after birth 
in both rats and human may suggest the implication of a physiological event that is 
directly related to parturition in the regulatory process rather than temporal maturation 
by itself.  CYP2E1 is thought to be involved in two gluconeogenesis pathways from 
acetone126,132.  This putative role in glucose metabolism may be related to the early onset 
of CYP2E1 expression when the newborn becomes independent of the mother’s glucose 
and has a high demand of glucose133,160.  While not yet clearly investigated, the delayed 
evolution of CYP1A2 in both human and rats may be regulated by a HNF-1 binding site 
in the 5’ flanking region of the gene167,169.  In addition to the contribution of this site to 
the tissue-specific expression of CYP1A2, it might be implicated in the age-specific 
expression as well169. 
 
5.3.3 Ontogeny of Catalytic CYP Enzyme Activity 
5.3.3.1 CYP2E1 
As shown in Figure 4.8, CZX, a CYP2E1 probe substrate, hydroxylase activity was 
not detected in fetal and PD1 hepatic microsomes.  High activity (70% the adult value) 
was detected at early postnatal ages with progressive increase to reach the maximum 
level (more than 150% the adult value) at PD14.  The activity declined to the adult value 
at the weaning age (PD21-28) and stayed constant thereafter.  Similar results were 
reported for the developmental changes in CYP2E1-mediated demethylation of 
dimethylnitrosamine activity in rats where activity peaked at PD14 and declined at 
PD21127.  Consistent with this pattern of CYP2E1 activity changes with age, greater 
hepatotoxicity due to carbon tetrachloride bioactivation was observed in PD15 compared 
to PD60 male rats327.  Developmental changes in rat hepatic CYP2E1 activity reasonably 
paralleled its mRNA expression levels, but not the immunoquantifiable protein.   
In humans, very low hepatic CYP2E1 activity was detected from the fetal liver 
samples at late gestation stage (less than 5% the adult value) and immediately after birth 
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(approximately 20% the adult value)133.  In the neonatal period, the activity gradually 
elevated to reach the adult value at ages 1-10 years133.  Unlike rats, the ontogeny pattern 
of CYP2E1 activity in humans parallels the increase in its protein levels during 
development.  Such data may suggest different regulatory mechanisms that control 
CYP2E1 levels between rats and human. 
Regardless of species, greater risk of hepatotoxicity is expected at weaning, puberty 
and adult periods for xenobiotics that undergo CYP2E1-mediated bioactivation.  
However, substrates which need CYP2E1 for their elimination may accumulate in early 
postnatal ages leading to toxicity3. 
 
5.3.3.2 CYP1A2 
The results shown in Figure 4.8 demonstrate undetectable methoxyresorufin-O-
dealkylase (MROD) activity, a CYP1A2 activity marker, in fetal and early postnatal 
ages.  At PD5, MROD activity was very low (less than 20% the adult value) and 
gradually increased to attain a maximum level at PD28 (more than 150% the adult 
value).  Similar to these findings, Couroucli et al reported 8-, 15- and 26-fold increase in 
rat hepatic MROD activity at PD15, PD22 and PD38, respectively, compared to PD8323. 
This compares reasonably well with the 4.5-, 9.5- and 10.5-fold increase in MROD 
activity at PD10, PD21 and PD28, respectively, compared to PD7 in my study.  Another 
recent study using deltamethrin as a CYP1A2 substrate328 reported a 4-, 9.5- and 9-fold 
change in intrinsic clearance values at PD21, PD40 and PD90, respectively, compared to 
PD10 in male rats329. 
Very limited data are available to describe the developmental maturation of CYP1A2 
in human. The existing literature reports indicate similar human CYP1A2 ontogeny 
pattern to the above characterized pattern for rats.  Human CYP1A2 activity was not 
detected in fetal and early neonatal hepatic misrosomes165,91.  Postnatally, CYP1A2 
shows delayed ontogenesis with the first significant rise in activity observed at ages 1-3 
months165.  Thereafter, the activity continued to rise following the ontogenic profile of 
CYP1A2 protein until reaching 33% the adult value at ages 1-10 years165.  
Such observed pattern of delayed CYP1A2 ontogenesis in both rats and human may 
have a great toxicological impact on both species.  Higher risk of CYP1A2-mediated 
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xenobiotic bioactivation is expected in rats at weaning and in human at adult stages. 
However, in both species risk of drug accumulation is expected at early postnatal 
periods for substrates whose elimination is principally mediated by CYP1A2. 
 
5.3.4 Correlation between the CYP Ontogeny Profiles in Rats 
 
Comparison of the ontogeny profiles of mRNA and protein of both CYP enzymes in 
rats (Figure 4.22) reveals a discordant relationship during postnatal development.  While 
mRNA levels were detected in fetal livers, proteins were not detected.  Postnatally, a 
rapid increase in mRNA levels was observed with levels exceeding 250% the adult 
levels by PD14 (CYP2E1) or PD28 (CYP1A2).  This was accompanied by slow rise in 
protein levels that did not exceed 50% of the adult levels until PD42.  Collectively, this 
could suggest that regulation of both CYP2E1 and CYP1A2 in rats occurs principally at 
the post transcriptional level.  This discordance between mRNA and protein levels is 
similar to that observed with human CYP enzymes166,241,330.   
A reasonable correlation was obtained when the developmental changes in CYP 
activity were compared to changes in corresponding mRNA levels for both CYP2E1 and 
CYP1A2 enzymes (Figure 4.23).  These findings are inconsistent with those reported in 
human where the maturation of CYP activity does not follow that of mRNA levels, 
especially during the early developmental stages for both CYP2E1 and CYP1A2133,165.  
On the other hand, and also inconsistent with human studies, the activity of rat CYP2E1 
and CYP1A2 enzymes did not follow the immunodetectable CYP protein (Figure 4.11).  
Possible reasons of this discordance are possible contribution of other CYP enzymes, 
especially at pre-weaning ages, and posttranslational mechanisms that can influence 
CYP activity, especially at post-weaning ages (section 5.1.3.2). 
 
5.3.5   Ontogeny of Zonal Expression of CYP2E1 and CYP1A2 
 
A number of studies have demonstrated the zonal expression of CYP enzymes in the 
livers of adult human and laboratory animals244-246,249.  However, few studies have 
investigated intrahepatic expression of CYP enzymes in the developing human or 
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animal. The results of my study on the hepatic zonal expression of CYP2E1 and 
CYP1A2 in rat livers show remarkable development-related differences in intrahepatic 
expression.  A homogenous distribution of the enzymes in all parenchymal cells was 
observed during fetal and early postnatal stages (Figures 4.24 and 4.25 A and B).  A 
more heterogeneous intralobular expression was observed at juvenile and adult stages 
with the enzymes preferentially distributed in the perivenous region (PV) (Figure 4.24 E 
and F and Figure 4.25 D and E). 
My results are quite comparable to that observed in human for CYP1A2, CYP3A 
and CYP2C243.  This may indicate a similar regulatory mechanism is controlling this 
age-dependent zonal expression in both species.  Many studies have reported the 
involvement of hormonal regulation in the zonal-specific expression of CYP 
enzymes7,201,249.  Hypophysectomy of rats resulted in higher expression of CYP2B and 
CYP3A in the periportal (PP) zone with complete disappearance of zonation, while 
treatment with growth hormones re-established the zonation pattern245,249.  This may 
suggest the potential role of growth hormone in down regulating the periportal 
transcription of these genes in the liver.  Oinonen and Lindros245 suggested the existence 
of regulatory factors located in the upstream region of the CYP gene.  These factors 
could be either negative response elements, activated periportally, or transcriptional 
activators acting in the perivenous region245,326. 
Age-dependent changes in the zonal expression of CYP enzymes could affect zone-
specific damage caused by many hepatotoxicants.  Focal expression of CYP2E1 and 
CYP1A2, which generally mediate generation of reactive intermediates following 
exposure to many chemicals, in the PV region could increase the vulnerability of this 
region to hepatotoxicity245,249,331.  Another factor that increases such vulnerability is the 
insufficient expression of glutathione peroxidase, an enzyme that detoxifies reactive 
peroxides, in this region247.  Although the two major groups of detoxification enzymes, 
glutathione-S-transferases and UDP-glucuronyl transferases, exhibit higher expression 
in the PV than the PP region, the gradient appears to be less steep compared to CYP 
enzymes247.  Accordingly, the regional imbalance between bioactivation and 
detoxification mechanisms can be the basis for PV-specific damage following exposure 
to chemicals that undergo CYP-mediated bioactivation to highly reactive and toxic 
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metabolites.  For example; acetaminophen-induced damage to the PV zone after a high 
dose is inhibited by isoniazide, a specific inhibitor to CYP2E1 that catalyzes 
acetaminophen bioactivation to reactive intermediate331.  In another study animals 
deficient in the expression of both CYP2E1 and CYP1A2 (double-null) were found 
highly resistant to acetaminophen-induced cellular damage compared to the wild-type 
animals154.  
In paediatric livers, where CYP expression level is usually low and zonation is 
absent, hepatocellular damage induced by CYP-mediated generation of reactive 
metabolites may be unlikely to happen.  However, several reports have documented the 
possibility of transplacental and translactional induction of CYP enzymes in the fetus or 
nursing neonates following chronic exposure of the pregnant or lactating mother to CYP 
inducers, e.g. ethanol and tobacco smoke116,127,159,161,262.  Whether the induction of CYP 
enzymes in fetal and neonatal livers is zone-specific is unclear.  
Several studies in rats and human have described zonated induction of CYP enzymes 
(CYP1A, CYP2B, CYP2E1 and CYP3A) with larger induction in the PV region and 
higher relative (fold) induction in the PP zone246,248,249.  This regional selectivity of CYP 
induction is independent of the kind of inducer.  The induction of glutathione-S-
transferases and UDP-glucuronyl transferases was found to be at least as strong in PP 
cells as in the PV cells248.  Accordingly, perivenous zone is generally characterized by 
dominance of CYP-mediated bioactiavation and lower capacity for detoxification. 
Zonation of CYP enzymes in the downstream PV zone seems somewhat unexpected.  
Considering the endogenous role of these enzymes as protectors against toxicants and 
their need for oxygen to achieve this role, a higher expression in the upstream periportal 
region is expected.  The mechanisms and toxicological impact of developmental changes 
in intrahepatic zonation of CYP enzymes need further investigation. 
 
 
5.3.6   Toxicological Relevance of Characterization of CYP Ontogeny 
 
This extensive characterization of CYP2E1 and CYP1A2 ontogeny at the levels of 
mRNA, protein and activity shed some light on possible regulation mechanisms of these 
toxicologically-significant enzymes.  Together with the pharmacokinetic models that 
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describe their ontogeny (see section 5.2), this extensive characterization will aid 
toxicological assessments and provide greater insights into the role of toxicokinetics in 
determining exposure risk. 
While these studies recognized some differences in the postnatal development of 
CYP2E1 mRNA, protein and activity between rats and human, a reasonable degree of 
similarity was observed between rat and human hepatic CYP1A2 ontogeny.  
Recognition of such species-differences could help explain species differences in 
susceptibility to toxicants and mechanisms of toxicity.  Identification of these species 
differences in toxicokinetics will facilitate extrapolation of developmental toxicity data 
from animals to human.  Furthermore, similar ontogeny pattern between rats and 
humans could suggest the suitability of rats as an animal model to investigate the 
influence of postnatal exposure to xenobiotics and endogenous compounds on CYP 
ontogeny and for identification of biomarkers of exposure. 
Finally, having the ontogeny of CYP enzymes fully characterized in this important 
developmental model will help to identify the underlying toxicokinetic basis for the 
observed age-dependent differences in susceptibility to toxicity.  
I have to mention that the observed conflicts between my results and some data 
reported in the literature regarding the ontogeny of CYP enzymes could be due to the 
influence of different animal strain, diet and bedding composition. For example, the rat 
chow used in my study contains soy protein and amino acids that were found to alter 
endogenous hormones levels (e.g. growth hormone and thyroxin332,333), which in turn 
could affect the CYP expression125,245.  Also strain associated alteration in enzyme 
expression has been reported178,200.  The interlaboratory variation for measurement of 
enzymatic activity are highly sensitive to factors that frequently vary from one 
laboratory to another (e.g. hepatic microsomal and cytosolic preparation, storage of 
hepatic microsomes and cytosolic fractions, analytical methods, probe substrate 
selection and substrate concentrations and incubation conditions for enzyme kinetics 
experiments). 
Statistical analysis of activity, protein and mRNA expression data at all 
developmental stages were compared to that at PD112 (young adult).  Comparison of 
my data at PD112 to published data at ages beyond PD112 shows close similarities 
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which may indicate values observed at this age may be considered as a stable reference 
for mature rats.   
 
 
5.4. Characterization of the Ontogeny of Cytosolic GST Enzymes  
 
In spite of the dual bioactivation / detoxification nature of both phase I and phase 
II enzymes, phase I enzymes (mainly CYP enzymes) are generally seen as 
bioactivating100 while phase II enzymes are generally considered to detoxify 
xenobiotics106.  Glutathione-S-Transferases (GST) are one of the elaborate phase II 
mechanisms evolved by the mammalian cells to protect against toxic insults due to 
electrophilic metabolites or reactive oxygen species that usually arise during CYP-
mediated drug metabolism46.  
The balance between CYP enzymes and GST enzymes can dramatically affect the 
toxicological outcome of exposure to chemicals that undergo CYP-dependent 
bioactivation.  Given the significant and dynamic changes in activities of these 
enzymes during development45,46, toxicological risk estimates developed for adults 
may not apply for paediatric populations following exposure to the same chemical, 
especially from breast milk.  Therefore, a thorough understanding of the ontogeny of 
both CYP enzymes and GST enzymes is necessary to accurately assess the age-
dependent exposure risk. 
In addition to characterizing the ontogeny of CYP2E1 and CYP1A2, two 
toxicologically significant CYP enzymes, I examined the ontogeny of cytosolic GST 
activity in a rat model using a general probe substrate.  Figure 4.27 shows detectable 
GST activity during late gestation (about 20% the adult level).  Postnatally, the activity 
increases steadily with age to achieve the adult level at weaning age (PD28).  To my 
knowledge, this is the first study to analyze the ontogeny of cytosolic GST activity in 
rats using large number of liver samples that cover a broad range of ages from late 
gestation to adulthood.  Consistent with these findings, Borlakoglu et al reported 
detectable, yet low, levels of GST activity at day 10 of gestation that increased more 
than 5-fold at day 20 of gestation115.  Following birth, and consistent with my 
observations, the activity progressively increased to attain the adult level at PD60115.   
Another study reported 1.75-, 2-, and 2-fold increase in GST activity at PD75, PD300 
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and PD690, respectively compared to PD14200.  Other studies have reported similar 
GST activity values at similar developmental stages used in my study200,210,276,334,214. 
Comparison of the ontogeny profile of GST enzymes, as detoxification enzymes, 
to the profiles of CYP2E1 and CYP1A2, as bioactivation enzymes, can provide some 
insight into the exposure outcome to xenobiotics.  Since CYP2E1 and CY1A2 
exhibited undetectable activity in the perinatal period yet moderate activity of GST 
enzymes suggests that paediatric populations would have a lower risk of CYP-
mediated cellular damage than compared with older ages, where CYP enzymes are 
well developed. However, direct exposure (e.g. drug therapy) or inadvertent exposure 
(e.g. breastfeeding) can potentially enhance (i.e. through induction ) the activity of low 
levels of CYP enzymes127,161.  These changes could significantly affect the response of 
the developing child to xenobiotic exposures, which could be further amplified if GST 
enzymes are not induced concomitantly.  Additional studies are needed to fully 
characterize the ontogeny of other phase II enzymes (e.g. UGT and sulfotransferases) 
and understand the molecular mechanisms that modulate their expression and activity. 
 
 
5.5. CONCLUSION AND GENERAL REMARKS 
 
The ethical and technical difficulties associated with conducting toxicity studies in 
children resulted in inadequate understanding of the impact of age and development on 
pharmacokinetics (or toxicokinetics) and pharmacodynamics (or toxicodynamics) of 
compounds.  Therefore, assessment of exposure risk to toxicity in neonates is largely 
dependent on toxicity information from adults.  Due to the significant and dynamic 
maturation of physiological determinants of drug pharmacokinetics (or toxicokinetics), 
especially in the early neonatal stages, infants can be more susceptible to the same 
toxicant exposure (on a body weight basis) than adults.  Accordingly, simple adult-to-
infant extrapolation can lead to inaccurate assessments of the exposure risk in the 
developing infant. 
In my attempt to improve assessment of exposure risk in paediatric populations, I 
evaluated the underlying assumptions of a general ontogeny model that was developed 
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to describe the postnatal maturation of CYP enzyme activity that mediated the 
elimination or formation of potential toxicants.  These assessments were made in the rat 
and the data recognized some discrepancies with the stated model assumptions. 
Microsomal protein (MP) content did not remain constant with development.  
Rather, MP content was significantly low at ages younger than postnatal day (PD) 7, 
compared to adult.  Liver weight normalized to body weight was relatively constant 
throughout postnatal development and age-related changes in hepatic scaling factors 
(HSF) become primarily a function of changes in MP.  This suggests the need to 
incorporate developmental changes in MP content into the model building process.   
The Michaelis-Menten constant (KM) did not remain constant with development. 
Rather, apparent KM values were significantly different from adult values at 
developmental stages younger than PD7.  The changes in apparent KM values during 
early postnatal development may indicate inadequate probe substrate specificity during 
CYP enzyme ontogeny, influence of developmental changes in non-specific binding in 
hepatic microsomes or changes in microsomal membrane composition.  Although these 
findings may suggest the need to incorporate these KM changes in the model building 
process, further investigations are required to provide more definitive information 
regarding the potential of KM changes with development.  These investigations need to 
assess the influence of non-specific protein binding and the contribution of different 
CYP isoforms to the estimated KM value at a given age.  
Consistent with the model assumptions, age-dependent changes in Vmax were 
observed with maximum enzyme activity occurring before (with CYP2E1) or after (with 
CYP1A2) weaning (PD21-PD28).  However, these changes did not correlate with the 
developmental changes in immunoquantifiable protein level for both CYP2E1 and 
CYP1A2.  Such discordance between activity and protein levels may indicate possible 
contribution from other CYP enzymes (especially during the early neonatal stages) to 
the apparent Vmax value or posttranslational mechanisms that may affect enzyme activity 
(especially during the postweaning stages).  Further investigations are needed to assess 
this discordance.  Again consistent with the model assumptions, different probe 
substrates for the examined CYP enzymes (CYP2E1 and CYP1A2) exhibited similar 
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patterns in age-dependent changes in activity.  This may indicate the potential 
applicability of the model to all substrates metabolized by the CYPs under investigation.  
An in vitro-in vivo extrapolation of rat hepatic microsomal activity data was used to 
develop a model to describe rat hepatic CYP2E1 and CYP1A2 ontogeny.  The model 
provided a reasonable prediction of the oral clearance of chlorzoxazone, a CYP2E1 
probe substrate.  This indicates that despite the above mentioned discrepancies with the 
model assumptions, the model is robust and has potential as a risk assessment tool.   
Extensive characterization (mRNA, protein, activity and hepatic tissue expression) 
of the ontogeny of rat hepatic CYP enzymes may provide a model system to identify 
toxicokinetic mechanisms underlying age-dependent differences in susceptibility to 
toxicity and to enhance our understanding the impact of exposure to exogenous or 
endogenous compounds on CYP ontogeny. The results of rat CYP ontogeny were 
compared to the available human data to determine the appropriateness of the rat for 
developmental toxicology studies. 
Unlike the ontogeny pattern in human, temporal changes in CYP catalytic activity 
correlate well with changes in transcript levels, but not with the immunoquantifiable 
protein levels. On the other, the ontogeny pattern of rat hepatic CYP protein was similar 
to those reported for human. Similar temporal and hepatic zonal expression of CYP 
enzymes between rats and human was observed where the expression was more 
homogenous in fetal and early neonatal stages then underwent heterogeneous expression 
towards the perivenous zone with maturation.  Recognizing such similarities and 
differences between rats and human regarding onset, rate and pattern of CYP ontogeny 
is critical for improving the accuracy of rat-to-human extrapolation of developmental 
toxicokinetic data.  
The activity of phase II enzymes, as a significant detoxification mechanism, plays an 
important role in determining the toxicological outcome of exposure.  Accordingly, the 
ontogeny of glutathione-S-transferases (GST), an important group of phase II enzymes, 
was determined in age-specific rat hepatic cytosolic fractions using a general probe 
substrate. GST activity was detected at low levels in late gestation and early neonatal 
ages followed by gradual increase with age.  Compared to the pattern of CYP activity 
that generally mediates xenobiotic bioactivation, infant populations are expected to be 
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under a low risk of CYP-mediated cellular damage relative to older age groups. 
However, characterization of the ontogeny of other phase II and antioxidant systems 
requires more extensive investigation. 
My dissertation research provided a critical evaluation of two potential model 
systems capable of providing risk relevant information in paediatric populations, namely 
a pharmacokinetic model that may predict an infant’s capacity to eliminate toxicants by 
CYP mechanisms and the developing rat as a model of human CYP2E1 and CYP1A2 
ontogeny.  The information obtained offers mounting and supportive evidence for the 
use of such model systems to identify whether toxicokinetic mechanisms may underlie 
age-dependent differences in susceptibility to toxicity and the impact of genetic and 
environmental factors on CYP enzyme ontogeny. 
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